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Abstract 
PSORIASIS ACTIVATION OF CELLS IMPORTANT IN 
CARDIOVASCULAR DISEASE 
Keywords: psoriasis, endothelial cell, cytokines, IL-36, macrophages, 
monocytes, atherosclerosis 
Psoriasis is an immune mediated inflammatory disease which affects 2-3% of the 
world’s population.  Over the last decade, psoriasis has been acknowledged as 
an independent risk factor for atherosclerosis.  The precise mechanism or 
mechanisms of the heightened risk is widely speculated.  Endothelial cells and 
macrophages are central players in the immunopathological development of both 
diseases.   
Interleukin-36 cytokines (IL-36) have been heavily implicated in psoriasis 
immunopathology. Significant upregulation of epidermal IL-36 is a recognised 
characteristic of psoriatic skin inflammation. IL-36 induces inflammatory 
responses in dendritic cells, fibroblasts and epithelial cells. While vascular 
alterations are a hallmark of psoriatic lesions and dermal endothelial cells are well 
known to play a critical role in dermal inflammation, the effects of IL-36 on 
endothelial cells have not been defined.  
We report that endothelial cells including dermal microvascular cells express a 
functionally active IL-36 receptor. Adhesion molecules VCAM-1 and ICAM-1 are 
upregulated following IL-36γ stimulation, and this is reversed in the presence of 
the endogenous IL-36 receptor antagonist. IL-36γ-stimulated endothelial cells 
secrete the proinflammatory chemokines IL-8, CCL2 and CCL20. Chemotaxis 
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assays showed increased migration of T-cells following IL-36γ stimulation of 
endothelial cells.  
Both resident and infiltrating inflammatory myeloid cells contribute to the 
immunopathology of psoriasis by promoting the IL-23/IL-17 axis. We show that 
IL-36γ induces the production of psoriasis-associated cytokines from 
macrophages (IL-23, TNFα) and that this response is enhanced in macrophages 
from psoriasis patients. This effect is specific for IL-36γ and could not be 
mimicked by other IL-1 family cytokines such as IL-1α. Furthermore, IL-36γ 
stimulated macrophages potently activated endothelial cells as illustrated by 
ICAM-1(CD54) upregulation, and led to increased adherence of monocytes, 
effects that were markedly more pronounced for psoriatic macrophages. 
Interestingly, regardless of stimulus, monocytes isolated from psoriasis patients 
showed increased adherence to both the stimulated and unstimulated 
endothelium when compared to monocytes from healthy individuals. 
Collectively, these findings add to the growing evidence for IL-36γ having roles in 
psoriatic responses, by enhancing endothelium directed leukocyte infiltration into 
the skin and strengthening the IL-23/IL-17 pathway. Our findings also point to a 
cellular response which could potentially support cardiovascular comorbidities in 
psoriasis. 
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1) Introduction 
 
Psoriasis is an autoimmune disease that causes plaques of red raised scaly skin.  
This condition affects around 2-3% of the world population and is a chronic 
relapsing inflammatory disease (Gelfand et al., 2005). The most common form of 
the disease is psoriasis vulgaris which is identifiable by papulosquamous plaques 
on the body (Raut et al., 2013).  However, psoriasis is not just associated with 
the skin; it is a systemic disease and it is linked to other conditions such as 
diabetes and metabolic syndrome (Sommer et al., 2006).  Overall, there is 
evidence that people with psoriasis have a reduced quality of life (de Korte et al., 
2004, Krueger et al., 2001) but are provided with a variety of treatments available 
to ease symptoms, however the underlying causes of psoriasis are yet to be fully 
deciphered.     
A wide range of treatments are available for treating psoriasis, including, topical, 
systemic and phototherapy.  Treatments are chosen based on disease severity, 
patient preference, cost, efficacy and the response of the individual patient 
(Menter and Griffiths, 2007, Feldman et al., 2003).  Patients are often grouped 
into to ‘mild to moderate’ or ‘moderate to severe’ with respect to psoriasis 
severity.  Mild to moderate psoriasis symptoms can often be manged with topical 
agents such as corticosteroids and emollients (Feldman, 2016, Freedman et al., 
1963).  However moderate to severe psoriasis often requires systemic agents. 
Systemic agents are often defined as biologic and non-biologic. 
Immunosuppressive or immunomodulatory include methotrexate and 
cyclosporine.  Biologics work by targeting a specific part of the immune system 
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(e.g. cytokines), examples of biologics used for treating moderate to severe 
psoriasis include, adalimumab, etanercept, infliximab, ustekinumab and 
secukinumab (Feldman, 2016, Menter et al., 2008, Mease et al., 2000, Reich et 
al., 2005, Papp et al., 2008, Langley et al., 2014).  Various phototherapy 
treatments are also available which can be used in combination or alone with the 
above. 
Atherosclerosis is a cardiovascular chronic inflammatory disease which results in 
plaque formation at particular points in the arteries, reducing blood flow to the 
vital tissues such as the heart and brain. These plaques can become unstable 
and rupture causing myocardial infarction or stroke. 160,000 people a year die in 
the UK alone from Cardiovascular Disease (CVD). Atherosclerosis and 
cardiovascular disease (CVD) represent a major burden on healthcare. In 
2012/13 the cost of treating CVD was 6.8 billion which accounts for 7% of NHS 
expenditure (British Heart Foundation).   
It has been over 30 years since a potential link between psoriasis and developing 
CVD was first proposed (McDonald and Calabresi, 1978). Evidence now 
suggests that psoriasis is an independent risk factor for developing CVD (Gelfand 
et al., 2006, Naik et al., 2015, Fang et al., 2016, Dey et al., 2017, Egeberg et al., 
2017, Bissonnette et al., 2017). However, psoriasis is often co-incident with other 
cardiovascular risk factors such as smoking, diabetes, obesity and hypertension, 
so identifying psoriasis as an independent risk factor has been refuted by some 
groups (Neimann et al., 2006, Dowlatshahi et al., 2013, Stern and Huibregtse, 
2011, Parisi et al., 2015).   
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Psoriasis patients do not have separate CVD screening unless they present with 
traditional risk factors (Kimball et al., 2012, Parsi et al., 2012).  If psoriasis is an 
independent risk factor for CVD, this could mean treating the traditional risk 
factors such as smoking and obesity do not go far enough.  Some researchers 
now believe that a CVD preventative regimen needs to be developed for severe 
psoriasis patients and that early CVD detection and monitoring in these patients 
must be improved (Coumbe et al., 2014). 
Another area of concern for psoriasis patients is regarding current therapies and 
their possible link to CVD.  Patients with moderate to severe psoriasis are often 
prescribed systemic therapies which may have positive or negative effects on 
CVD.  There is a lack of randomized controlled trials (RCTs) which directly relate 
psoriasis treatments to potential effects on CVD, thus meaning the true effects of 
such treatments which control psoriasis symptoms on vascular inflammation are 
unknown.  
Anti-inflammatory treatments such as tumour necrosis factor-α (TNFα) inhibitors 
may in fact lower cardiovascular risk (Dixon et al., 2007, Nguyen and Wu, 2014). 
IL-17 inhibitors used for psoriasis could also potentially exacerbate or decrease 
the atherosclerosis risk (Gong et al., 2015). Statins used to treat CVD may have 
anti-inflammatory effects that are beneficial to psoriasis (Weitz-Schmidt et al., 
2001).  However, beta-blockers which are used to treat high blood pressure have 
been shown to induce psoriasis (Abel et al., 1986).   
RCTs are currently in progress for CVD and psoriasis treatments such as 
inhibitors for TNFα, IL-17 and IL-23 (Takeshita et al., 2017).  A more detailed 
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description of these cytokines and their potential inhibitors will be given in later 
chapters.  
With psoriasis emerging as an independent risk factor for CVD, research has 
started to focus on potential common mechanisms between the two diseases at 
a molecular level.  The majority of research so far focuses on shared 
inflammatory molecules and pathways between the diseases.  This introduction 
will highlight the central role of endothelial cells (ECs) in both diseases that could 
cause dysfunction.  ECs in the vessel wall are key to atherogenesis, being the 
site at which inflammatory pathways are stimulated, chronic inflammation then 
results in continued immune cell recruitment into the subendothelium and 
remodelling (Williams and Tabas, 1995). In common with atherosclerosis, in 
psoriasis ECs also play a role as angiogenesis and vascular remodelling occurs 
at plaque sites.   Several important questions are at present unanswered but 
could have major implications to improve treatments. Are the vascular ECs from 
psoriasis patients more prone or predisposed to inflammation and thus promote 
atherosclerosis?  How do ECs respond to the systemic effects of psoriasis?  
These answers could add to the evidence that psoriasis is an independent risk 
factor to CVD and help with guidelines for future treatments for psoriasis patients 
and also identify possible therapeutic targets.  The introduction will consider the 
current literature on this topic, after providing an introduction to both diseases 
and the immunology and mechanisms behind them.     
1.1 Atherosclerosis- mechanisms and immunology 
 
Atherosclerosis is a chronic inflammatory disease that manifests in specific 
regions of low or disturbed flow within the arteries and results in plaque formation 
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and tissue remodelling. The build-up of these plaques and reduction of blood flow 
can cause adverse cardiovascular events such as stroke (Faxon et al., 2004).   
Around 30% of deaths in the USA are caused by CVD and over 50% of these 
deaths are directly linked to atherosclerosis (Roger et al., 2012).   It is now 
acknowledged that atherosclerotic lesions develop at arterial branches and sites 
that are subject to lower blood flow and thus less shear stress (Heo et al., 2014). 
Before any signs of the disease are present, the endothelial regions within 
arteries that are prone to atherosclerosis (low or disturbed flow) show functional 
changes (cellular alignment and enhanced adhesiveness to circulating blood 
cells) associated with increased activation of both the mitogen-activated protein 
kinase (MAPK) pathway and nuclear factor kappa-B (NF-κB) pathway (Passerini 
et al., 2004, Hajra et al., 2000).  This in turn increases expression of leukocyte 
adhesion molecules on the endothelial cell surface  such as E-selectin, ICAM-1 
and VCAM-1 which encourage capturing, rolling and adhesion of leukocytes 
(Blankenberg et al., 2003).   
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Figure 1: Leukocyte adhesion to the endothelium  
Inflammatory activated pathways such as NF-κB lead to increased 
adhesion molecule expression in ECs. Selectins encourage leukocyte 
capture and rolling on the vessel wall. Chemokines such as IL-8 and MCP-
1 facilitate integrin activation on leukocytes, which allows integrin-
adhesion molecule interactions to take place. The leukocytes which have 
adhered are able to transmigrate and reach the underlying tissue. Adapted 
from (Warboys et al., 2011). VCAM-1: Vascular cell adhesion molecule 1, 
ICAM-1: Intercellular Adhesion Molecule 1, MCP-1: Monocyte chemotactic 
protein 1. 
Junctions between activated ECs are leaky and blood lipids such as low-density 
lipoproteins (LDL) begin to accumulate at the tunica intima and have greater 
chance of being oxidised (Steinberg, 1997, Steinberg et al., 1989). One of the 
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first identifiable features of atherosclerotic plaques are fatty streaks; these 
contain lipid loaded macrophages and a smooth muscle layer (Stary et al., 1994).   
These lesions are caused by monocytes that travel to the tunica intima and then 
differentiate into macrophages, ingest oxidised lipids and become foam cells (fat 
laden macrophages) (Stary et al., 1994). A positive feedback loop is then created 
when foam cells secrete proinflammatory cytokines, which act further on the ECs 
and recruited monocytes to promote endothelial activation (van der Wal et al., 
1994).  The elastic lamina (separates the smooth muscle layers from the 
endothelium) is also degraded as a result of this inflammation, causing smooth 
muscle cells (SMCs) to migrate towards the sub-endothelium.  The SMCs then 
produce collagens that cover the plaque in a fibrous capsule thickening the 
arterial wall (Ang et al., 1990). Despite this outward remodelling, the plaque 
eventually begins to encroach the lumen, which limits blood flow.  Cells in the 
centre of the plaque begin necrosis at a quicker rate than they can be cleared, 
which creates a necrotic core causing further inflammation. Finally, if the fibrous 
cap ruptures, this can cause blockage and fatal cardiovascular events (Fuster et 
al., 1992). 
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Figure 2: Initiation stage of atherosclerosis 
Stages 1-2, LDL move into the sub endothelium. Monocytes move in aided 
by cytokines and adhesion molecules (4).  Macrophages ingest LDL and 
become foam cells (6-7).  SMCs and foam cells accumulate and cause the 
plaque (7-8). Taken from (Faxon et al., 2004). 
1.2 Psoriasis  
 
Psoriasis is a common skin disease that affects 2-3% of the world population.   
The most common type, psoriasis vulgaris, is easily diagnosed by its red 
erythematous plaques and silver dry scales, often found on elbows and knees 
(Figure 3). Other forms of psoriasis include guttate, inverse, pustular and 
erythrodermic. Psoriasis lesions are histologically distinct from other skin 
diseases, with epidermal hyperplasia and are heavily infiltrated by leukocytes.  In 
around 30% of patients more than 10% of the body is covered and this is classed 
as moderate to severe psoriasis.  For classing disease severity, the PASI index 
(Psoriasis activity and severity index) is used, which takes into account redness 
and thickness of plaques and area covered.  
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Figure 3: Psoriasis plaques 
Example of psoriasis vulgaris, also known as plaque psoriasis, covering 
the body. Image taken from (Zangeneh and Shooshtary, 2013). 
 
1.2.1 Features of a healthy epidermis 
The outermost layer of the skin, the epidermis is a stratified squamous layer 
epithelium.  The cell type that accounts for the majority of the epidermis is the 
keratinocyte.  Keratinocytes are further organised into four different layers (Figure 
4).  The basal layer contains epidermal stem cells which have a role in 
maintaining a constant renewal of cells.  Keratinocytes migrate through the 
different cell layers and eventually begin to differentiate. Keratinocytes lose their 
nuclei and become corneocytes and these are eventually shed. The process from 
the basal layer to the shedding of corneocytes takes around one month.  The 
dermis is located below the epidermis and this contains collagen and elastic 
tissue, but also capillaries which function to deliver nutrition and oxygen to the 
skin (Pastar et al., 2014, Takeo et al., 2015).  
  
10 
 
Figure 4: Layers of the skin 
In the basal layer, stems cell division results in a constant renewal of the 
layer. Keratinocytes migrate through both the spinous and granular layers. 
Following this, keratinocytes differentiate and lose their nuclei and are 
termed corneocytes.  
1.2.2 Vasculature of the skin 
The blood vessels within the skin comprise of both cellular and non-cellular 
elements such as EC and also a basement membrane consisting of smooth 
muscle cells and pericytes (Braverman, 1989).    The blood vessel organisation 
within the dermal compartment is comparable to other organs.  Feeder arterioles 
penetrate deep from the muscle.  These feeder arterioles serve to supply blood 
to the both the superficial and dermal papilla. The superficial arterioles then 
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further network into to feed into dermal papillary loops (Braverman, 1989).  These 
papillary loops represent the main site for exchange of oxygen and nutrients 
(Swerlick, 1997).  
 
Figure 5: The dermal vascular system 
Organistion of the vessels within the different compartments of the skin. 
Used with permission from (Hamm, 2014). 
1.2.3 Features of psoriasis epidermis 
A key feature in psoriatic skin is epidermal thickening; this is due to keratinocyte 
hyperproliferation (Bata-Csörgö and Szell, 2012, Saiag et al., 1985) (Figure 6).  
Keratinocyte differentiation occurs faster and the granular layer is severely 
reduced.  Psoriatic plaques are notable for their silvery scale appearance, caused 
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by hyperproliferation of epidermal keratinocytes, which have a quicker process of 
maturation and incomplete cornification (Bata-Csörgö and Szell, 2012).  
Parakeratosis is also seen in the psoriatic epidermis and is characterised by the 
retention of nuclei in stratum corneum and causes thinning of the granular layer 
(Cox and Watson, 1972).  The keratinocytes migration from the basal to the 
cornified layer usually takes a month, however in psoriasis this can occur in one 
week (Halprin, 1972).   Unlike the healthy epidermis, the psoriatic epidermis is 
subject to inflammation and is associated with an increase in the number of 
inflammatory cells.   The red appearance of psoriasis lesions is due to the 
increased angiogenesis of capillaries which increases the circulation in the upper 
dermis (Lowes et al., 2014, Hern et al., 2005).  
  
Figure 6: Cross section depiction of psoriatic skin 
In psoriatic skin, the epidermal thickening is caused by hyperproliferation 
of keratinocytes and subsequent silver scale development.  The upper 
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dermis of psoriatic skin contains capillaries that are both tortuous and 
leaky.  
 
1.2.4 Psoriasis genetics 
Psoriasis is a multi-factorial disease.  Various genes and environmental triggers 
interact to cause the disease.  Psoriasis is linked to strong genetic susceptibility, 
but despite this, a gene combination has never been clearly identified. Multiple 
genetic studies have identified susceptibility loci.   Twelve different chromosomal 
loci (PSORS1-12) have been identified as being linked to psoriasis. 
Histocompatibility complex antigens are associated with psoriasis of which the 
most associated is HLA-Cw6 within PSORS1 (Tiilikainen et al., 1980).  A detailed 
review of psoriasis genetics has recently been published and so is not considered 
further in this thesis (Harden et al., 2015).  
1.2.5 Inflammatory features of psoriasis and psoriatic proinflammatory 
cytokines 
Psoriasis immunology is highly complex process incorporating many different 
mechanisms involving keratinocytes, several types of leukocytes and the 
endothelium (Lowes et al., 2007). Early research suggested that the disease was  
a result of keratinocyte proliferation and differentiation (Barker, 1991). While this 
does occur, it is now clear that psoriasis is an immune mediated disease. Before 
the epidermal changes are apparent, proinflammatory infiltrates appear (Kim and 
Krueger, 2015). The constant over expression of cytokines is thought to be the 
primary cause of the initiation, maintenance and recurrence of the psoriasis 
plaques.   Initial research into psoriasis suggested that the disease was driven by 
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Th1 cells and subsequent Interferon gamma (IFNγ) secretion (Schlaak et al., 
1994).  However, a role for Th17 cells has since emerged. IL-23, a cytokine 
involved in Th17 development, as well as Th17 secretary cytokines, IL-17 and IL-
22, have all have been found to have major roles in psoriasis immunopathology 
(Meglio and Nestle, 2010, Hao, 2014, Ma et al., 2008, Lowes et al., 2008). 
 
 
Figure 7: Psoriasis immunopathology 
Trauma to the skin results in activated dendritic cells, which secrete IL-12 
and IL-23 to polarize naïve Th0 cells to Th1 and Th17 cells respectively.  
Resultant cytokine secretion results in inflammation, immune cell 
recruitment and further keratinocyte activation and plaque formation.  
A number of proinflammatory cytokines are involved in both the initiation and 
maintenance of psoriasis.  IL-6, IL-23, IL-8, IL-17, IL-1, IL-36 and TNFα have all 
been documented, and recently growing attention has focussed on IL-19, IL-37, 
IL-20, IL-19 and IL-22 (Sticherling et al., 1999, Grossman et al., 1989, Witte et 
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al., 2014, Teng et al., 2014). Biological treatment which targets both IL-23 and IL-
17 have shown greatest efficacy for treating severe psoriasis, which highlights 
the importance of the IL-23/IL-17 axis in the disease.  
 A review of cytokines and their potential role in psoriasis can be found here 
(Baliwag et al., 2015). IL-36 is becoming much more implicated in the recent 
literature.   
1.3 The IL-23/IL-17 axis in psoriasis 
 
Psoriasis development is thought to be a result of an inflammatory response in 
the skin, which can be triggered by injury, infection, allergy or stress.  Cells of the 
innate immune system such as Langerhans’ cells become activated (Xiao et al., 
2017).  Langerhans’ cells which are antigen presenting cells engulf antigens or 
pathogens and migrate to the lymph nodes.   The processed peptide antigens are 
then presented to T cells (Harden et al., 2015, Lowes et al., 2014).  Both local 
myeloid dendritic cells and Langerhans cells in the lymph node that have been 
activated secrete IL-23, a cytokine required for Th17 maintenance (Singh et al., 
2016). Naive CD4+ T (Th0) cells differentiate into Th17 cells and migrate back to 
the epidermis where they secrete IL-22 and a range of IL-17 family cytokines to 
drive psoriatic inflammation (Lowes et al., 2014) 
1.4 IL-23  
 
IL-23 is a heterodimeric cytokine produced by inflammatory myeloid cells and 
plays a central role in T helper 17 (Th17) responses (Iwakura and Ishigame, 
2006, Yen et al., 2006). As discussed previously, the IL-23/IL-17 axis plays a 
central role in psoriasis and other chronic inflammatory diseases such as Crohn’s 
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disease and rheumatoid arthritis (Siakavellas and Bamias, 2012, Lubberts, 
2015).  The pathogenicity of IL-23, is largely dependent on the resulting 
dysregulated IL-17 secretion from Th17 cells.  Antagonists to both IL-17 and IL-
17R in varying stages of phase development have shown anti-psoriatic efficacy 
(Wasilewska et al., 2016).   Similar positive results have been reported with IL-23 
antagonists. A detailed clinical discussion of current and phased antagonists that 
target these cytokines has recently been published (Campa et al., 2016). 
IL-23 consists of the IL-23p19 subunit paired with the IL-12p40 subunit, the latter 
being shared with IL-12 (Gaffen et al., 2014).  IL-23 signals through a receptor 
complex consisting of the IL-23 receptor (IL-23R) and IL-12Rβ1 (also shared with 
IL-12) (Gaffen et al., 2014) (Figure 8). IL-23 targets T cells and activates both 
JAK and STAT signalling molecules with a particular emphasis on STAT3 (Cho 
et al., 2006).  While IL-12 directly promotes T cell differentiation into Th1 cells, IL-
23’s relationship with Th17 development is more complex.  It is thought is not to 
be required in early Th17 development, but to play a role in terminal differentiation 
of Th17 cells (Bettelli et al., 2006, Mangan et al., 2006).   
The immunogenetic link between IL-23 and psoriasis has gained attention in 
recent years.  SNPs for both IL-23 subunits and also the IL-23R are associated 
with psoriasis (Nair et al., 2008, Cargill et al., 2007, Nair et al., 2009). The most 
commonly associated SNP for the IL-23R in psoriasis, encodes a R381Q amino 
acid substitution, where the rarer Q allele results in decreased IL-23 signalling 
and is thought to be thus protective against numerous autoimmune disorders 
such as psoriasis (Di Meglio et al., 2011). 
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Figure 8: IL-23 and IL-12 signalling 
IL-23 cytokine consists of IL-23p19 and IL-12p40 subunits.  IL-23 binds to 
IL-23R and IL-12Rβ1. STAT3 and STAT4 signalling results in IL-17 and IL-22 
secretion and stabilisation of the Th17 phenotype.  IL-12 consists of the IL-
12p35 and IL-12p40 subunits and binds to the IL-12R (IL-12Rβ2 and IL-
12Rβ1). STAT 4 signalling results in IFNγ secretion and Th1 development.  
A potential role for the IL-23/IL-17 axis in atherosclerosis is a growing area of 
research.  mRNA levels of both IL-23 and IL-23R are increased within human 
carotid plaques with heavy colocalisation to macrophages. Plasma levels of IL-
23 are also associated with disease progression and increased mortality (Abbas 
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et al., 2015).   Recently a mouse IL-23R KO model suggest a potential beneficial 
role for IL-23 in atherosclerosis, suggesting IL-23 regulates foam cell formation 
(Fatkhullina et al., 2016).  
However, a potential role of IL-17 in the pathogenesis of atherosclerosis is still 
heavily debated. Paradoxical findings have both been reported, with IL-17 
showing both protective and exacerbating functions.  A detailed review of the 
findings can be found here (Gong et al., 2015).  Several publications have as a 
result given warnings about the use of IL-17 inhibitors and their potential to 
aggravate atherosclerosis (Gong et al., 2015, Taleb and Tedgui, 2017). 
1.5 IL-36 in psoriasis 
 
Interleukin-36 (IL-36) cytokines are part of the wider IL-1 family and include IL-
36α, IL-36β, IL-36γ and their inhibitor, the IL-36 receptor antagonist (IL-36Ra) 
(Dinarello et al., 2010).  Both IL-36α and IL-36γ have been implicated in psoriasis 
pathology, but IL-36γ levels (lesion staining and circulating levels) positively 
correlate with psoriasis disease severity to a greater degree than IL-36α (D'Erme 
et al., 2015, Boutet et al., 2016). 
Like other IL-1 family members, IL-36γ requires post translational processing. 
Skin equivalent models have shown that this is achieved by the protease 
cathepsin S, which is a serine protease with a role in antigen presentation 
(Ainscough et al., 2017). The other IL-36 family cytokines are processed by a 
range of neutrophil proteases such as cathepsin G and neutrophil elastase 
(Henry et al., 2016). 
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IL-36 binds to the IL-36 receptor (IL-36R) which is expressed by keratinocytes, 
fibroblasts and has also been reported on immune cells (Dietrich et al., 2016).   
Receptor binding is followed by recruitment of an accessory protein (IL-RAcP), 
which is shared by other IL-1 family members (Towne et al., 2004). Downstream 
intracellular signalling is poorly characterised, compared to other cytokines but 
results in MAP kinase and NF-κB activation and the expression of 
proinflammatory mediators in susceptible cells (Figure 8).  Whilst the receptor 
antagonist is able to bind to the receptor, it does not recruit the AcP, so signalling 
does not occur and thus the Ra exerts antagonist effects (Towne et al., 2011, 
Gunther and Sundberg, 2014).  IL-36γ is thought to be mainly produced by 
keratinocytes and other epithelial cells in response to stimuli such as fungi, 
inflammatory mediators such as TNFα , IL-1, IL-36, bacteria, rhinovirus infection 
and smoke (Carrier et al., 2011, Chustz et al., 2011, Bochkov et al., 2010, Vos et 
al., 2005, Parsanejad et al., 2008). IL-36 members have stimulatory effects on a 
range of cell types including epithelial cells, fibroblasts and immune cells (Chustz 
et al., 2011, Foster et al., 2014, Mutamba et al., 2012, Johnston et al., 2011).  IL-
36 expression by epithelial cells has been documented in several tissues 
including the lung and gut; however, the majority of research has focused on the 
skin and specifically psoriasis (Chustz et al., 2011). 
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Figure 9: IL-36 and IL-36R 
Processed and fully active IL-36 binds to the IL-36R. When the AcP is 
recruited this leads the TIR domains of the two receptor chains to engage 
and induce transcription factors such as NF-κB and MAPKs. The IL-36Ra 
however does not recruit the AcP, so does not result in signalling. TIR: 
Toll/interleukin-1 receptor. Adapted from (Gabay and Towne, 2015). 
IL-36γ is highly upregulated in psoriasis lesions on both the mRNA and protein 
level (D'Erme et al., 2015).  Expression levels of IL-36γ also correlate with levels 
of other proinflammatory cytokines such as IL-17, IL-23 and TNFα in psoriasis 
lesions (Carrier et al., 2011). Transgenic mice in which keratinocytes overexpress 
IL-36α are susceptible to psoriasis-like inflammation following 12-O-
Tetradecanoylphorbol-13-acetate (TPA) treatment (Blumberg et al., 2010). Using 
the same model, mice which were deficient in the IL-36Ra showed chronic skin 
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abnormalities and enhanced psoriasis plaque development. Mice deficient in the 
IL-36R were protected from plaque development (Tortola et al., 2012). Also of 
note, generalized pustular psoriasis (GPP), a severe form of psoriasis, has been 
linked to a mutation in the IL-36Ra.  This mutation results in a less stable protein 
with resultant reduced control over IL-36 mediated responses (Marrakchi et al., 
2011). The subsequent condition has been termed DITRA (deficiency of the IL-
36 receptor antagonist) (Cowen and Goldbach-Mansky, 2012).  
A potential pathway of action for IL-36γ in psoriasis has recently been proposed 
(Gabay and Towne, 2015). IL-36γ is released by keratinocytes in response to 
environmental factors and further stimulates keratinocytes to release chemokines 
in an autocrine manner and DCs/Langerhans cells in a paracrine manner.   
DCs/Langerhans’ cells then produce IL-1, IL-6 and IL-23, which can stimulate 
Th17 responses.  Th17 responses lead the secretion of several cytokines 
important in psoriasis such as IL-22 and the typical manifestations of psoriasis 
pathology such as DC and neutrophils recruitment.  
1.6 The importance of endothelial cells in psoriasis 
 
Psoriatic plaques are caused by an imbalance of proinflammatory mediators, 
which attract leukocytes and stimulate proliferation of keratinocytes.  Vascular 
changes within psoriasis lesions have been gaining attention for many years.  
Capillaries at lesion sites are often dilated and tortuous in arrangement (Bull et 
al., 1992).  
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1.7 Angiogenesis in psoriasis 
 
Angiogenesis is the formation of new blood vessels from the pre-existing 
vasculature and is a hallmark of psoriasis lesions (Heidenreich et al., 2009). 
Microvascular changes within psoriasis lesions include pronounced dilation, 
increased permeability and endothelial cell proliferation. Immature permeable 
blood vessels may enhance dermal inflammation through immune cell 
recruitment (Braverman and Sibley, 1982, Braverman and Yen, 1977).  A recent 
study confirmed a positive correlation between hypervascularization and disease 
severity in psoriasis patients (Rosina et al., 2009).  Excessive capillary-venular 
dilatation precedes development of psoriatic inflammation, and resolution of 
these vascular changes is associated with remission of psoriasis lesions (Kulka, 
1964).  VEGF-A is thought to be the driving force behind angiogenesis observed 
in psoriatic lesions.  Mice which overexpress VEGF-A show an inflammatory 
response that histologically resembles psoriasis (Detmar et al., 1998, Xia et al., 
2003). The VEGF-A gene is located on chromosome 6 at 6p21, close to PSORS 
1, which is a known chromosomal locus for psoriasis susceptibility (Trembath et 
al., 1997, Brogan et al., 1999). The +405 CC VEGF genotype, also known as the 
“high VEGF producing genotype” is associated with early onset psoriasis, 
whereas the “low VEGF producing genotype” has no association with psoriasis 
(Diaz et al., 2000, Young et al., 2006, Detmar, 2004).  This suggests that the pro-
angiogenic potential of an individual may influence disease progression.   
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Figure 10: Histological stains of Psoriasis 
A) Psoriasis lesion showing epidermal thickening. B) Healthy skin showing 
normal epidermis.  C) Blood vessels stained in red in a psoriasis lesion. 
Images taken from (Heidenreich et al., 2009). 
   
1.8 How do endothelial cells contribute to inflammation in 
the skin? 
 
Inflammation can be either acute or chronic, as seen in psoriasis.  Acute 
inflammation usually revolves in a few days.  Vascular dilation and permeability 
is seen in acute inflammation and is associated with the activation and 
recruitment of neutrophils (Wright et al., 2010, Majno, 1964).  Chronic 
inflammation is associated with a sustained period of leukocyte recruitment and 
associated with angiogenesis (Jackson et al., 1997). The cellular infiltrate is also 
different, consisting of macrophages, monocytes and lymphocytes.  
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As previously described in section 1.1, ECs are central players in inflammation 
because of their ability to recruit leukocytes to the site of injury.  ECs express 
adhesion molecules ICAM-1, VCAM-1 and E-selection, all of which encourage 
leukocyte migration to the site of inflammation (Osborn, 1990).   
Several currently used medications for psoriasis may also work by affecting ECs 
in addition to immune cells. Methotrexate is thought to inhibit adhesion molecule 
expression (Yamasaki et al., 2003). Moreover, Efalizumab, which was efficient 
for psoriasis treatment when available, (discontinued to adverse side effects) 
works by blocking LFA-1 on leukocytes so they are unable bind to the adhesion 
molecule ICAM-1 on ECs (Lebwohl et al., 2003). A number of proinflammatory 
cytokines upregulated in psoriasis lesions including TNFα, IL-1 and IL-17 are 
capable of activating ECs (Terajima et al., 1998, Cannizzaro et al., 2014). A 
detailed description of psoriasis implicated cytokines with roles in endothelial 
activation can be found in psoriasis systemic section (1.10.1).  
1.9 Pro Angiogenic factors in psoriasis 
1.9.1 VEGF 
Vascular endothelial growth factor (VEGF) is a family of growth factors 
responsible for new vascular angiogenesis (Keck et al., 1989).  Many isoforms of 
VEGF exist due to mRNA splicing (Nowak et al., 2008). Two distinct families have 
emerged: the pro-angiogenic (VEGF-Axxx) and anti-angiogenic (VEGF-Axxb) 
(Nowak et al., 2008).  
VEGF binds to the VEGF tyrosine kinase receptor on ECs leading to signal 
transduction and resulting in proliferation. VEGF can be secreted by a range of 
cell types including keratinocytes (Bae et al., 2015). 
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Psoriasis skin, both lesional and uninvolved, contains a higher concentration of 
VEGF when compared to skin of healthy individuals (Henno et al., 2009). 
Importantly though, this VEGF is the isoform 121 (VEGF-A121). Whilst this 
isoform is not thought to be more angiogenic, it does however cause greater 
vessel dilation and leakage (Kusters et al., 2003) compared to other pro-
angiogenic isoforms. This allows greater infiltration of inflammatory cells to the 
site.     
In psoriasis, VEGF is primarily secreted by keratinocytes (Zhang et al., 2005). 
The reasons why keratinocytes from psoriasis patients secrete increased VEGF 
levels compared to those from healthy skin are not known. It could be due to 
genetic predisposition or as a result of stimulation from proinflammatory cytokines 
(Wongpiyabovorn et al., 2008).  Mouse models where keratinocytes over express 
VEGF result in an enhanced vascular network and a skin condition similar to 
psoriasis (Detmar et al., 1998). Recently anti-VEGF treatments have also been 
shown to reduce psoriasis severity (Li et al., 2014). These findings highlight the 
key role of the endothelium via the importance of angiogenesis in the pathology 
of psoriasis as well as highlighting the role of VEGF in worsening disease 
(Keshtgarpour and Dudek, 2007, Akman et al., 2009). 
The involvement of VEGF could provide a possible link to atherosclerosis.  
Angiogenesis and new vessel growth is found in atherosclerotic plaques and 
VEGF plays a similar role in promoting vessel permeability, thus enhancing 
leukocyte recruitment and inflammation, most importantly macrophages (Celletti 
et al., 2001). Indeed, angiogenesis is associated with plaque instability and 
rupture in atherosclerosis (Zhang et al., 1993). Interestingly higher VEGF serum 
levels are associated with psoriasis severity and can be used to predict adverse 
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cardiac events (Heeschen et al., 2003). The VEGF121 isoform could possibly 
have systemic effects and cause the atherosclerotic plaque vessels to be more 
‘leaky’ and thus inflamed and more prone to rupture.   
1.9.2 Angiopoietins in psoriasis 
The Angiopoietin growth factors Ang-1 and Ang-2 and their tyrosine kinase 
receptor Tie2 play a role in angiogenesis.   The Ang-Tie2 pathway is involved in 
maturation, stabilization and growth of new vessels (Maisonpierre et al., 1997).  
The Ang1-Tie2 pathway leads to vessel stabilization and maintenance during 
vascular embryogenesis (Sato et al., 1995).  The Ang2-Tie2 pathway causes 
vessel destabilization, meaning the vessels begin to sense for growth and 
survival signals, and when pro-angiogenic factors are present, this leads to 
angiogenesis (Maisonpierre et al., 1997).  Ang1 can be produced by a range of 
cells, but Ang2 seems to be limited to ECs (Kuroda et al., 2001). 
The Ang/Tie2 pathway is activated during psoriasis, predominately in the 
papillary dermis. Transgenic mouse models in which ECs and keratinocytes over 
express Tie2 results in a disease similar in appearance and pathology to psoriasis 
and reversal of Tie2 expression reduced the disease (Voskas et al., 2005). There 
is also evidence that Ang-2 may sensitize ECs to proinflammatory cytokines such 
as TNFα by influencing adhesion molecule expression (Fiedler et al., 2006).  
Whilst it is known the Ang/Tie2 pathway is upregulated in psoriasis lesions, no 
study has considered if ECs from uninvolved skin show different expression 
levels of proteins of this pathway compared to healthy patient ECs.  A potential 
genetic upregulation of this pathway would increase angiogenesis and the 
likelihood of plaque rupture in atherosclerosis. Recently, a single nucleotide 
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polymorphism (SNP) of Ang2 has been associated with psoriasis patients (He et 
al., 2015).  However, no functional significance has been attributed to this SNP.  
It should also be noted that Ang2 levels have been shown to be reduced following 
successful psoriasis treatment (Kuroda et al., 2001).  These findings hint at an 
important role of Ang2 in psoriasis disease maintenance.  
1.10  Do ECs from psoriasis patients have a genetic 
predisposition for atherosclerosis development? 
 
There is some evidence that ECs from psoriasis patients may have certain 
genetic predispositions which could aid atherosclerotic development. These are 
discussed below.  
1.10.1 Genetics  
There are many known immune-genetic pre-dispositions that are associated with 
psoriasis.  These genes have many wide-ranging functions including antigen 
presentation, T cell development/polarisation and innate immunity. An excellent 
review of the immunogenetics of psoriasis can be found here (Harden et al., 
2015).  
1.10.2 NF-κB 
NF-κB is a transcription factor which has a key role in immune responses in the 
majority of cell types (Hoesel and Schmid, 2013).  Many different genes that 
encode components of the NF-κB pathway have been found to be associated 
with psoriasis and importantly some of these are known to exist in ECs (Goldminz 
et al., 2013).  Under basal conditions, NF-κB is bound to its inhibitor, IκB within 
the cytoplasm (Perkins, 2007).  Upon activation, IκB is phosphorylated by IκB 
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kinase (IKK) targeting IκB for degradation and NF-κB is released for translocation 
to the nucleus and as a result, inflammatory genes are expressed (Perkins, 
2007).  A variety of cellular receptors involved in immune signalling can result in 
NF-κB activation. In the context of the endothelium and atherosclerosis, 
increased NF-κB activation could lead to increased adhesion molecule 
expression (VCAM-1, ICAM-1, E-selectin) and chemokine secretion, all of which 
would increase leukocyte adhesion (Osborn, 1990).  
1.10.3 CARD 14 
CARD (Caspase recruitment domain family member) proteins are scaffolding 
proteins involved in the activation of NF-κB (Blonska and Lin, 2011).  Related 
CARD family members interact with molecules involved in the recruitment and 
activation of IKK, such as MALT1 and TRAF2 (Scudiero et al., 2011, Bertin et al., 
2001). A coding SNP in CARD14 was found to be associated with psoriasis in 
genome wide studies (Jordan et al., 2012a).  The psoriasis mutation associated 
with CARD14 results in increased NF-κB activation (Jordan et al., 2012b, Harden 
et al., 2014).  Psoriasis patient dermal ECs were found to express CARD14 and 
have increased NF-κB activation which resulted in increased chemokine 
production. After transfection of psoriasis CARD14 into healthy dermal ECs, 
increased NF-κB activation occurred (Harden et al., 2014). CARD14 is known to 
be expressed in all ECs, so it is plausible that the psoriasis mutation is expressed 
in aortic ECs, which could lead to increased NF-κB activation and accelerated 
atherosclerotic plaque development.  
 
 
  
29 
1.10.4 ZC3H12C 
ZC3H12C (zinc finger DHHC-type containing 23) has been shown to significantly 
dampen EC inflammatory responses.  Both overexpression and knock down 
studies have confirmed that ZC3H12C has the ability to supress NF-κB activation 
(Liu et al., 2013).  However, little is known about the regulatory abilities of 
ZC3H12C or the exact method of NF-κB suppression.  Interestingly, ZC3H12C 
has a genetic association with psoriasis (Tsoi et al., 2012). However, no 
functional role has been attributed yet to this gene.  It could be possible that 
psoriasis patients may have a loss of function in ZC3H12C and lose its anti-
inflammatory ability, thus allowing enhanced NF-κB activation. 
 
1.11  Do the systemic effects of psoriasis contribute to 
atherosclerosis? 
 
The systemic effects of psoriasis could be causing enhanced risk of 
atherosclerosis.  There has been much debate considering whether or not 
psoriasis is a systemic disease.  However, multiple studies have found correlation 
between PASI score and CVD risk (Boehncke et al., 2007).  Also of note is that 
several markers implicated in systemic disease are higher in severe psoriasis 
patient serum such as C-reactive protein (Coimbra et al., 2010), VEGF (Detmar 
et al., 1994), P-selectin (Garbaraviciene et al., 2010), and previously mentioned 
cytokines (Roussaki-Schulze et al., 2005). 
Many ‘traditional’ cytokines such as TNFα and IL-1 have well defined roles in 
stimulating ECs and upregulating adhesion molecules and chemokine secretion 
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(Aziz and Wakefield, 1996).  TNFα inhibitors are well established treatments for 
psoriasis (Table 2) and a general consensus suggests they may also potentially 
lower CVD risk (Yang et al., 2016).  However, recently a number of ‘newer’ 
cytokines have been described as also possessing the ability to activate the 
endothelium (Table 1). 
 
Table 1:  Cytokines measured in psoriasis serum, either elevated or 
decreased, and their known actions on the endothelium 
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IL-33 
IL-33 is an IL-1 family member cytokine produced by fibroblasts, epithelial cells 
and immune cells (Schmitz et al., 2005, Akdis et al., 2016).  IL-33 binds to a 
receptor complex of Interleukin 1 receptor-like 1 (IL1RL1) and IL-1 Receptor 
Accessory Protein (IL1RAP) and activates NF-κB in susceptible cells (Chackerian 
et al., 2007, Pollheimer et al., 2013). Contrasting studies have reported it to be 
both upregulated and down regulated within psoriasis lesions, however it has 
been reported as being increased in psoriasis serum (Baliwag et al., 2015, 
Hueber et al., 2010, Mitsui et al., 2016). Little is known about its role in psoriasis 
but it could be involved in keratinocyte activation (Balato et al., 2012). Despite 
recent studies showing IL-33 can upregulate adhesion molecules alone or in 
synergy with TNFα (Pollheimer et al., 2013, Choi et al., 2012), mouse models of 
atherosclerosis have produced surprising findings.  Systemically administered IL-
33 surprisingly appeared to be atheroprotective to mice, whereas endogenously 
produced IL-33 was shown to have no effect on atherosclerosis severity (Miller 
et al., 2008, Martin et al., 2015).  
IL-17 
While IL-17 is mainly produced by T helper 17 cells (Th17 cells) other T cells are 
also capable of secreting it, such as CD8 T cells (Takatori et al., 2009, Miossec, 
2009). When bound to the IL-17 receptor (IL-17R), IL-17 induces the expression 
of inflammatory mediators in target cells such as keratinocytes and fibroblasts 
through NF-κB activation (Shen et al., 2006).  IL-17 family members A, F and C 
have all been reported as being over expressed within psoriasis lesions (Harper 
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et al., 2009, Johansen et al., 2009, Lowes et al., 2008). Elevated levels of IL-17A 
in psoriasis serum have been reported (de Oliveira et al., 2015, Michalak-Stoma 
et al., 2013).  IL-17A has been shown to induce inflammatory effects on ECs such 
as adhesion molecule and chemokine expression (Xing et al., 2013).  However, 
various atherosclerosis studies and models of IL-17 have produced paradoxical 
findings, with both pro-atherogenic and atheroprotective results, a review can be 
found here (Taleb et al., 2015).  The use of IL-17 inhibitors such as Secukinumab 
for psoriasis have thus far shown no change in CVD risk (van de Kerkhof et al., 
2016).  
IL-22 
IL-22 is a IL-10 family cytokine which is secreted by Th17 and T helper 22 cells 
(Th22 cells) (Sonnenberg et al., 2011). IL-22 signals via a class 2 cytokine 
receptor (IL-22R) and activates STAT3 (Signal transducer and activator of 
transcription 3) (Radaeva et al., 2004, Nagalakshmi et al., 2004). IL-22 is thought 
to be important in tissue repair and proliferation, however many studies have 
shown that dysregulated IL-22 action can promote pathological inflammation and 
tissue destruction, a theory linked to its potential role in psoriasis.  A naturally 
occurring soluble inhibitor, the IL-22 binding protein (IL-22BP) is thought to act 
as a endogenous regulator preventing the exaggerated effects of IL-22 and has 
shown to be secreted by dendritic cells (Martin et al., 2014). However, recent 
research in liver fibrosis showed contradictory, with the IL-22BP aggravating 
fibrosis and IL-22 protecting (Sertorio et al., 2015).  The paradoxical effects of IL-
22 and the balance between IL-22 and the IL-22BP in disease requires further 
research.  The IL-22R is known to exist on a variety of cells including ECs with.   
IL-22 promotes proliferation and angiogenesis of EC (Shang et al., 2015). With 
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the discovery of the natural inhibitor of IL-22, IL-22BP, it is possible ECs also may 
also secrete this inhibitor. IL-22 psoriasis serum levels have been reported to be 
higher when compared to healthy controls (de Oliveira et al., 2015).  A 
monoclonal antibody against IL-22 (Fezakinumab) was undergoing trials for 
psoriasis, but was discontinued (Gudjonsson et al., 2012).  
IL-23 
IL-23 is a heterodimeric cytokine and consists of the IL-23p19 subunit paired with 
the IL-12p40 subunit, the latter being shared with IL-12.  IL-23 signals through a 
receptor complex consisting of the IL-23 receptor (IL-23R) and IL-12Rβ1 (also 
shared with IL-12) (Duvallet et al., 2011).  IL-23 is secreted by inflammatory 
myeloid cells and plays a central role in Th17 responses. The IL-23/IL-17 axis 
has been implicated heavily in a range of inflammatory diseases including 
psoriasis (Iwakura and Ishigame, 2006). IL-23 has also been reported as being 
elevated within psoriasis serum (Michalak-Stoma et al., 2013).  Whilst no effects 
of IL-23 on ECs have been observed, it has recently been reported that ECs 
produce intracellular IL-23p19 and that it can influence VCAM-1 expression 
(Espigol-Frigole et al., 2016). mRNA levels of both IL-23 and IL-23R are 
increased within human carotid plaques and plasma levels of IL-23 are also 
associated with disease progression and increased mortality (Abbas et al., 2015).  
Mouse models with knockout IL-23 or IL-23R have not been explored in relation 
to atherosclerosis. However, briakinumab, a monoclonal antibody against the 
P40 subunit of IL-12 and IL-23 was terminated mid trial for psoriasis treatment 
due to concerns linking it with major adverse cardiovascular events (Traczewski 
and Rudnicka, 2012).   Another agent, Ustekinumab which targets the same 
  
34 
subunits, has been reported as having both no effect or potential reduction in 
CVD risk (Hugh et al., 2014).  
Anti-inflammatory cytokines, IL-10, IL-19 & IL-37 
IL-19  
IL-19 is another IL-10 family member cytokine secreted by both immune cells and 
epithelial cells. The exact role of IL-19 in psoriasis is unclear, but it has recently 
been shown to be the most upregulated cytokine in psoriasis lesions (Baliwag et 
al., 2015). It binds to the same receptor complex as another family member, IL-
20, and is able to induce STAT3 activation (Dumoutier et al., 2001). It has been 
shown to be produced by keratinocytes and promote keratinocyte growth factor 
in an autocrine manner. Its concentration has been reported as being both lower 
and higher in psoriasis serum (Li et al., 2005, Witte et al., 2014).  ECs are capable 
of secreting IL-19 themselves under pro-inflammatory conditions (Jain et al., 
2011). IL-19 has shown to be a chemoattractant for ECs and also to promote 
angiogenesis (Jain et al., 2011).  Perhaps most importantly, IL-19 has the ability 
to interfere with leukocyte-EC adhesion.  IL-19 has been shown to lower TNFα 
induced adhesion molecule-leukocyte interaction. The mechanism remains 
unclear, as IL-19 does not reduce TNFα induced NF-κB activity but does reduce 
adhesion molecule mRNA stability (England et al., 2013). Mouse models of 
atherosclerosis have also produced positive results.  IL-19 treated mice show 
reduced atherosclerosis development, and IL-19 KO mice have exacerbated 
atherosclerosis development (Ellison et al., 2013, Ray et al., 2015).    
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IL-10 
IL-10 is an anti-inflammatory cytokine secreted by a range of immune cells. IL-10 
is capable of reducing chemokine and adhesion molecule expression.  Upon 
binding to the IL-10 receptor (IL-10R), IL-10 is able to block NF-κB activity and 
lower adhesion molecule expression (Krakauer, 1995, Lisinski and Furie, 2002, 
Potteaux et al., 2006). Consistent with its anti-inflammatory role, mice models in 
which IL-10 is over-expressed show reduced atherosclerosis development (Han 
et al., 2010).  Its circulating levels have been reported as being lowered in 
psoriasis patients (Jacob et al., 2003).  
IL-37  
IL-37 is an anti-inflammatory cytokine and a member of the wider IL-1 family 
secreted by monocytes.  IL-37 employs the IL-18 receptor alpha (IL-18Rα) and 
IL-1R8 (SIGIRR) in a receptor complex and is able to lower NF-κB activation that 
has been induced by Toll/interleukin-1 receptor (TIR) binding (Nold-Petry et al., 
2015, Nold et al., 2010) in a range of cell types. IL-37 is able to lower NF-κB 
induced EC adhesion molecule expression (Li et al., 2011). Recent research has 
shown IL-37 may have a role in psoriasis skin, with studies showing it is down 
regulated within lesions (Keermann et al., 2015). However, no study has 
measured its circulating levels in psoriasis.  However, the cytokine has been 
found to be elevated in the serum of other inflammatory diseases such as 
rheumatoid arthritis (Keermann et al., 2015). The potential protective role of IL-
37 in preventing atherosclerosis development is a growing area of research that 
is starting to gain momentum (Chai et al., 2015, McCurdy et al., 2014, Wu et al., 
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2013). A SNP in IL-37 has been shown to confer significantly increased risk for 
coronary artery disease (Yin et al., 2017). 
Interestingly, two cytokines that may have anti-inflammatory effects, IL-10 and IL-
19 have been reported as being reduced in psoriasis serum while the serum 
status of IL-37 is unknown. 
 
Table 2: Biologics currently approved or undergoing clinical trials for the 
treatment of psoriasis 
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1.12  Chronic Inflammation in psoriasis as a contributor to 
CVD? 
 
Multiple studies have shown psoriasis and atherosclerosis involve similar T cell 
responses such as Th1 and Th17 (Armstrong et al., 2011).   Th1 cells are 
recruited to the dermis and activate keratinocytes by secreting IFNy, IL-2 and 
TNFα (Harden et al., 2014). Both TNFα and IFNy have been shown to initiate and 
progress atherosclerotic plaques (Branen et al., 2004, McLaren and Ramji, 
2009).  Th17 cells and their subsequent Th17 cascade are thought to impair the 
regulation of inflammation and potentially destabilise plaques (Ma et al., 2013).   
Animal studies have also shown that chronic skin inflammation results in 
increased aortic inflammation noted particularly for increased T cells and TNFα 
and IL-17 (Wang et al., 2012).  Monocytes are recruited to the skin lesion sites 
and also have crucial role in atherosclerosis.  CCL2/MCP-1 (monocyte 
chemoattractant protein-1) plays an important role in atherosclerosis by 
promoting smooth muscle proliferation and also the formation of foamy 
macrophages (Ziats and Robertson, 1981, Ylä-Herttuala et al., 1991).  Elevated 
MCP-1 levels also correlate with plaque instability and rupture potential (Liu et 
al., 2012).  MCP-1 serum levels are also known to be elevated in psoriasis (Mehta 
et al., 2013).  
A theory known as the ‘Psoriasis March’ hypothesises that the systemic effects 
of psoriasis may cause insulin resistance which in turn causes endothelial 
dysfunction (Boehncke et al., 2011). Insulin is a vasoactive hormone that 
increases vasodilation through the nitric oxide pathway, so thus can be viewed 
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as atheroprotective. Activation of the pathway results in eNOS phosphorylation, 
the precursor enzyme for NO synthesis (Kuboki et al., 2000). NO is essential for 
vascular homeostasis and its depletion is associated with numerous vascular 
pathological conditions such as hypertension, hypercholesterolemia and 
complications associated with diabetes mellitus (Hermann et al., 2006, Feron et 
al., 1999, Honing et al., 1998). During systemic inflammation, proinflammatory 
cytokines activate stress kinases such as JNK and P38, which then negatively 
regulate insulin receptor substrate (IRS-1) thus blocking P13-K/Akt signalling 
(Copps and White, 2012) which normally activates eNOS and leads to production 
of NO and dilatation as well as suppression of adhesion molecule expression.  
However, at the same time, the insulin dependent activation of the MAPK 
pathway remains undisturbed, which in turn results in increased adhesion 
molecule expression and decreased NO production (Muniyappa et al., 2007, Sitia 
et al., 2010). Psoriasis derived dermal ECs have recently been shown to have 
decreased activation of Akt (Schluter et al., 2016).  Also of note, a psoriasis 
relevant ‘cytokine cocktail’ could prevent Akt phosphorylation under insulin 
conditions (Schluter et al., 2016).   
IRS-1 is a protein involved with insulin receptor signalling, and is linked to NO 
production in ECs.  Insulin resistant patients are often found to have decreased 
IRS-1 levels (Jansson et al., 2003). With respect to atherosclerosis development, 
lower vascular IRS-1 levels have also been seen to be a marker for arterial 
stiffness (Sandqvist et al., 2005). Whilst no study has considered IRS-1 levels in 
psoriasis, there has been research into endothelial dysfunction in psoriasis.  
Ultrasound studies all hint that the psoriasis vessels (endothelium and SMC) may 
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have impaired functions such as dilation (Gisondi et al., 2009, Ulusoy et al., 2010, 
Karadag et al., 2010).  
 
Figure 11: The combined systemic and genetic effects of psoriasis that 
could enhance atherosclerosis development 
Inflammatory cytokines are elevated in psoriasis serum, which leads to 
increased EC activation.  The cytokine induced activity of NF-κB is 
enhanced by CARD14 mutations.  Mutations in ZC3H12C could possibly 
stop its ability to supress NF-κB, leading to further enhanced NF-κB 
activation. Anti-inflammatory cytokines such as IL-10 may be lowered in 
psoriasis serum and able to exert less of a regulatory role. Under normal 
conditions, insulin binding to ECs would activate Akt leading to nitric oxide 
production and decreased adhesion molecule expression. Inflammatory 
cytokines supress insulin-Akt activation, but P38 MAPK activation persists, 
leading to increased adhesion molecule expression.  A combination of 
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these effects lead to increased rolling tethering and adherence of 
monocytes on the endothelium and eventually transmigration.   
  
41 
1.12.1 Dyslipidemia 
By definition, dyslipidemia is an elevation in cholesterol levels, including LDL-
cholesterol, triglyceride or a reduction in HDL cholesterol levels. Dyslipidemia is 
a well-defined risk factor for atherosclerosis (Koba and Hirano, 2011).  Psoriasis’ 
link to dyslipidemia is a growing area of research.  Psoriasis patients have an 
increased concentration of LDL particles and a decrease of HDL particles and 
also overall decreased particle size for both the aforementioned (Mehta et al., 
2012). These abnormalities also show correlation to aortic inflammation when 
CVD risk factors have been adjusted for (Yu et al., 2012). 
1.13  Macrophages in Psoriasis and Atherosclerosis 
 
Numerous comorbidities are associated with psoriasis including cardiovascular 
disease (CVD).   However, one or more clear mechanisms linking psoriasis to 
CVD are yet to be found. Common theories include endothelial dysfunction, 
dyslipidaemia and systemic inflammation.     Monocytes represent a key cell type 
in the pathology of atherosclerosis, since they are the main cell type recruited into 
the intima where they differentiate into macrophages. Through their scavenger 
receptors, macrophages take up oxLDL and other lipids in a unregulated manner 
and begin to accumulate in the lesion and form foam cells (Moore et al., 2013). 
1.14  Monocyte subsets in inflammation 
 
In recent years, three distinct monocyte populations have been well defined and 
genotyped depending on their expression of glycoprotein CD14 and FcγIII 
receptor CD16 (Yang et al., 2014).  These subsets consist of the classical 
(CD14++CD16-) which accounts for 60-70% of total monocytes, the intermediate 
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monocytes (CD14++CD16+) and the non-classical (CD14+CD16++), which both 
account for the remaining 10-20% (Golden et al., 2015).  Due to their smaller 
numbers, many studies group intermediate and non-classical monocytes as a 
single group (CD16+ monocytes) (Rennert et al., 2016).  
Several publications suggest that CD16+ monocytes are key mediators of 
inflammation.  An increase in circulating CD16+ monocytes is associated with 
CVD, acute ischemic heart failure, myocardial infarction and peripheral artery 
disease (Rogacev et al., 2012, Wrigley et al., 2013).  Studies have also recently 
confirmed that CD16+ monocytes are elevated in psoriasis patients (and 
correlate with disease severity/PASI), rheumatoid arthritis and inflammatory 
bowel disease (Golden et al., 2015, Radwan et al., 2016, Koch et al., 2010). The 
exact mechanism by how CD16+ monocytes are induced or how they contribute 
to CVD is not clear.  CD14+ monocytes appear to be phagocytic while CD16+ 
appear to be capable of producing enhanced inflammatory mediators (Ziegler-
Heitbrock, 2007).  
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Figure 12: FACS analysis of monocyte subsets and relative percentage as 
reported in both healthy and psoriasis peripheral blood by Golden et al. 
Note that numbers do not add up to 100% as is primary FACS data.  
Increased CD16+ monocytes in psoriasis have been reported in multiple 
studies (Golden et al., 2015, Chiu et al., 2010). 
1.15  CX3CL1 and monocyte migration 
 
The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1 have been 
implicated in the process of transendothelial migration of immune cells (Umehara 
et al., 2001). Uniquely, CX3CL1 exists in two active forms, a membrane bound 
form which acts as an adhesion molecule, and a soluble form which acts a 
chemoattractant for immune cells.   Endothelial cells upregulate both forms during 
inflammatory events (Imaizumi et al., 2004).  Recently CX3CL1 has gained 
attention for its preferential role in monocyte subset migration.  CX3CR1 is highly 
expressed by both CD16+ subtypes (intermediate and non-classical) compared 
to the classical CD14+ (Mandl et al., 2014).   While blocking traditional EC 
adhesion molecules such as E-selectin and VCAM-1 is able to reduce classical 
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monocyte adherence and migration, blocking of CX3CXL1 is required to stop 
CD16+ monocyte migration (Rennert et al., 2016).   Recently, in an imiquimod 
induced mouse model of psoriasis, a significant reduction in skin inflammation 
occurred in CX3CR1 KO mice due to a reduced number of dermal macrophages 
(Morimura et al., 2016).   Previous work has showed psoriasis plaques show 
heavy infiltration of CD16+ monocytes and also show upregulated dermal 
CX3CL1 endothelial expression at plaques sites (Golden et al., 2015, Congjun et 
al., 2015).  Numerous studies also correlate serum CX3CL1 positively with PASI 
score (Congjun et al., 2015).   
1.16  CX3CL1-CX3CR1 in CVD 
 
CX3CL1 is recognised as being important in atherosclerosis pathogenesis 
(Apostolakis and Spandidos, 2013). As well as being a potent monocyte recruiter, 
it also promotes vascular smooth muscle cell migration, which is a feature of 
vascular remodelling in CVD (Lucas et al., 2003).  Animal studies have shown 
that blockage of the CX3CL1-CX3CR1 pathway significantly reduces 
atherosclerosis severity (Teupser et al., 2004).   Epidemiology studies have also 
confirmed a genetically-defined less active CX3CL1-CX3CR1 pathway is 
associated with a reduced risk of atherosclerosis (Moatti et al., 2001, McDermott 
et al., 2001, Apostolakis et al., 2009).  Whether CX3CL1 has value as a diagnostic 
marker is still debated, as is also the benefit of its therapeutic inhibition.  
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1.17  Resident Macrophages in Psoriasis and potential role 
of IL-36 
 
Mouse models suggest monocytes and macrophages are key players in psoriasis 
pathology (Clark and Kupper, 2006).  Tissue resident macrophages, monocytes 
and monocyte-derived dendritic cells (MoDC) and their subsequent T cell 
activating cytokines such as IL-23 have been shown to drive inflammation in 
imiquimod induced mouse models (Wang et al., 2006, Stratis et al., 2006, Zaba 
et al., 2009, Fuentes-Duculan et al., 2010).  In human psoriasis lesions, 
monocytes, M1 macrophages and dendritic cell show IL-23p19 staining 
(Yawalkar et al., 2009).  Given that dendritic cells migration is characteristic of 
chronic lesions, early activation and IL-23 secretion from resident macrophages 
may represent a key initiation phase.   A mechanistic link between IL-36 and the 
IL-23/IL-17 axis is becoming clear.  Mouse models of, psoriasis, respiratory 
bacterial infection, colitis and renal fibrosis, have all shown IL-36 to be a key 
component of the axis (Chi et al., 2017, Kovach et al., 2017, Blumberg et al., 
2010, Boutet et al., 2016). Numerous autoimmune skin diseases also show a 
correlation between IL-36 and IL-17 (Zebrowska et al., 2017).  
Whilst previous reports have shown IL-36γ induces inflammatory mediators from 
macrophages, little is known about its ability to induce psoriasis relevant 
cytokines such as TNFα and IL-23 (Foster et al., 2014).   IL-36γ’s ability to induce 
inflammatory mediators from tissue resident macrophages could escalate the 
inflammatory cascade by activating surrounding fibroblasts, endothelial cells and 
keratinocytes, and ultimately lead to further immune cell recruitment.  
Generalised pustular psoriasis patients with DITRA, who received monocyte 
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apheresis therapy, showed significant improvements in disease severity, 
highlighting the importance of a potential IL-36-macrophage pathway (Koike et 
al., 2017, Sugiura et al., 2014). 
1.18  IFNγ role in CVD, psoriasis and macrophage activation 
 
Interferons (IFN) are cytokines that mediate anti-viral responses (De Andrea et 
al., 2002).  There are two main classes of interferons. Type I, which include α,β 
and more.  Type I interferons are inducible in a range of cell types and act on 
macrophages and NK cells to promote anti-viral responses (McNab et al., 2015, 
Samuel, 1988). Interferon γ (IFNγ) is the only member of the class II interferons 
and is secreted by activated Th1 cells.  Binding to the IFNγ receptor (IFNγR) 
activates JAK1 and JAK2. As a result STAT1 is phosphorylated (Schroder et al., 
2004, Krause et al., 2006, Nathan et al., 1983) and signalling occurs.   
IFNγ has a documented importance in atherosclerosis at different stages of the 
immunopathology and has been described as a master regulator in this disease 
(McLaren and Ramji, 2009, Gupta et al., 1997).  In synergy with TNFα it promotes 
adhesion molecule expression.  IFNγ also promotes SMC proliferation (Zhang et 
al., 2011, Amento et al., 1991).  IFNγ primes and activates macrophages for 
chemokine/cytokine release and regulates lipid uptake (Li et al., 2010).   Th1 cells 
are thought to drive atherosclerosis development and in mouse models of 
atherosclerosis, administration of IFNγ increases atherosclerotic lesion size 
(Whitman et al., 2000).  IFNγ is elevated in psoriasis serum and correlates with 
PASI, giving a potential mechanistic risk for CVD (Abdallah et al., 2009).  
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2) Effect of IL-36 on endothelial cells 
 
Psoriasis is an immune mediated inflammatory disease affecting 2-3% of the 
world population (Nestle et al., 2009) and ranges from 1-5% in most developed 
countires (World Health Organization) IL-36γ is a recently discovered pro-
inflammatory cytokine which is highly upregulated in psoriasis lesions on both the 
mRNA and protein levels (D'Erme et al., 2015).  As an IL-1 family member, it 
shares signalling pathways with IL-1 but the intracellular signalling cascade is 
poorly described. Expression levels of IL-36γ correlates with levels of other 
cytokines such as IL-17, IL-23 and TNFα in psoriasis lesions (Carrier et al., 2011) 
and it is elevated in serum of psoriasis patients (D'Erme et al., 2015). Recently 
IL-36γ serum levels have been suggested as a biomarker for disease severity 
due to its correlation with PASI scores (D'Erme et al., 2015). 
The pathophysiologic contribution of ECs in psoriatic inflammation is well 
recognised (section 1.6).  The combination of endothelial activation followed by 
angiogenesis leads to enhanced and sustained leukocyte recruitment/migration 
to the lesion and thus tissue inflammation which does not resolve (Terajima et 
al., 1998, Horrocks et al., 1991). Upregulation of adhesion molecules such as 
VCAM-1 and ICAM-1 have been detected, which recruit T cells and monocytes 
and leads to extravasation (Cabrijan et al., 2009). However, to date no study has 
investigated the potential direct effects of IL-36 on EC.  Increased serum IL-36γ 
levels in psoriasis could potentially activate ECs in a systemic manner.  EC 
activation is essential in the early stages of atherogenesis (section 1.1), so 
confirming a role for IL-36 in EC activation would give strength to a potential 
mechanism for the psoriasis-CVD risk factor association.  
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2.1 Hypothesis 
 
I hypothesise that the psoriatic cytokine IL-36, which is thought to be crucial to 
psoriasis immunopathology, will have pro-inflammatory effects on ECs. This 
could provide knowledge into the possible enhanced ECs activation and CVD 
events in psoriasis patients.  
 
2.2  Aims 
• Determine if human large and small blood vessel primary ECs in culture 
respond to IL-36γ by upregulating adhesion molecules (ICAM-1 and 
VCAM-1) at protein level by FACs analysis 
• Determination if the responses of ECs to IL-36 occur through the IL-36 
receptor by determining  expression of the IL-36 receptor using RT-PCR 
and ICC and reversal by the IL-36Ra 
• Determine which transcription factors IL-36 activates in ECs 
• Determine if ECs exposed to IL-36 induce production of IL-8 by ELISA 
• Determine if IL-36 stimulated ECs develop chemoattractant ability for T 
cells 
• Determine if IL-36 induces angiogenesis in dermal endothelial cells 
2.3 Methods 
 
2.3.1 Ethics 
For current and following chapters, blood from both healthy and disease psoriasis 
patients was obtained by a study that was approved by Yorkshire & the Humber 
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– Leeds West Research Ethics Committee with written informed consent from all 
subjects (PDAR study: REC 16/YH/0086). 
2.3.2 Cell Culture 
All cell culture reagents used were cell culture grade.   Endothelial cell growth 
medium and supplement mix (C-22020) was purchased from PromoCell 
(Sickingenstrasse, Germany).  Penicillin/streptomycin (15140-122), Fungizone® 
Antimycotic (15290-026) and Trypsin- ethylenediaminetetraacetic acid (EDTA) 
(0.05%) (25300-054) all obtained from Life Technologies (Paisley, UK). Flasks 
75cm2 with phenolic cap (430725U) were supplied by Corning (New York, USA).    
Sterile 6 well plates (657160) were purchased from Greiner Bio-One (UK).  
Disposable sterile pipettes of volume 5, 10 and 25 ml were from Sarstedt 
(Sarstedtstraße, Germany).   Phosphate Buffered Saline (BE17513F) was 
purchased from Lonza (Verviers, Belgium). Hydroxyethylpiperazine-N’-2-
ethanesulphonic acid (HEPES, H3375), bovine serum albumin (A9576), gelatine 
(G1393), trypan blue (T6146), paraformaldehyde (P6148), Tween20 (P2287) 
were all from Sigma-Aldrich Chemical Company (Poole Dorset, UK).  
2.3.3 Isolation of HUVEC and HDLEC 
HUVEC (Human Umbilical Vein Endothelial Cells) cells were isolated by Ethical 
Tissue, University of Bradford as described before (Eccles et al., 2008). HDLEC 
(Human Dermal Lymphatic Endothelial Cells) pooled donor cells were provided 
by Promocell.  
Both HUVEC and HDLEC cells were cultured in PromoCell culture media (C-
22010). The media contained 2% v/v foetal calf serum, v/v 0.4% endothelial cell 
growth supplement, epidermal growth factor 0.1 ng/ml, basic fibroblast growth 
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factor 1 ng/ml, heparin 90 µg/ml and hydrocortisone 1 µg/ml,  
Penicillin/streptomycin (100U/100mg/ml) and fungizone (2.5 µg/ml). 
2.3.4 Cell counting and viability 
Cells in suspension were counted and viability assessed using a 
haemocytometer. Equal volumes of cell suspension and trypan blue were mixed 
and the total cells in each of the four corner squares were counted.  The total cell 
count per ml was determined by the following calculation.  
(Total cells/4) x 104 x 2 (dilution factor)   
Viability was calculated on the basis that trypan blue dye causes non-viable cells 
to absorb the dye.  The following calculation was thus used to determine viability. 
Viable cell count/ total cell count x 100.  
2.3.5 Cryopreserving cells 
Following cell counting, cells were centrifuged for 5 mins (1000 xg) and the 
supernatant discarded.  Cell pellet was then resuspended in freezer mix (foetal 
calf serum, 10% v/v DMSO) at a concentration of 1 x 106 cells per ml.  1 ml was 
then added to cryovials and the vials were stored at -80°C for 24 hr.  Following 
this, vials were transported to liquid nitrogen dewars until further use was 
required.  
2.3.6 Resuscitation of cells 
Frozen cells in cryovials were removed from liquid nitrogen and 1 ml of pre-
warmed PromoCell media was then added to the cryovial.  The suspension was 
then transferred to 10 ml of media and centrifuged.  The supernatant was 
discarded which removed DMSO.  Cell pellet was resuspended in 10ml of media 
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and transferred to a T75 cell culture flask pre-coated with 10% v/v gelatine 
solution for 24 hr and rinsed before adding the cells.  
2.3.7 Passaging/expansion of cultures 
Cells were allowed to grow to confluency in T75 flasks. All flasks were pre- coated 
with 10% v/v gelatine solution for 24 hr at 4°C and rinsed before addition of cells 
and media.  Cells were incubated in a humidified atmosphere of 95% air and 5% 
CO2 at 37°C. Media was changed every 48 hr.  Cells were passaged at a ratio of 
1:3. Culture media was removed and the cells were washed with PBS.  Cells 
were then treated with trypsin/EDTA (0.05%) at 37°C for 3 mins.  The trypsin was 
then removed without disrupting the cells.  The flask was then tapped gently 
detaching the cells. Cells were then resuspended in required volume of media 
and aliquoted to new T75 flasks or into plates for experiments.  
2.3.8 Immunocharacterisation of ECs 
Coverslips were placed in 6 well plates, and both coated with 10% gelatine as 
described before.  ECs were then plated onto the plates in 2 ml media per well.  
Plates were then incubated 5% CO2 at 37°C and cells were allowed to reach 90% 
confluency.  Media was then removed and ECs were fixed using 4% w/v 
formaldehyde solution in PBS for 15 mins at room temperature.  Following this, 
the fixative was removed and cells were washed with PBS. Cells were then 
blocked with 1% w/v BSA in PBS for 1 hr at room temperature.  Cells were then 
incubated with mouse anti-CD31 (FITC tagged) (Sigma, F8402) or sheep anti-
human vWF (both at a dilution of 1 in 20) and incubated overnight at 4°C. As a 
negative control, relevant FITC isotype controls were used (mouse IgG or sheep 
IgG) (Abcam, Cambridge, UK).  Following this, the cover slips were removed and 
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counterstained by adding a few drops of 5 –Diamidino-2-phenylindole (DAPI) 
which also served as mounting media (Sigma, F6057).  Cover slips were mounted 
onto slides and stored in the dark before viewing.  The Nikon eclipse 8oi (Nikon 
DS-U1, Tokyo, Japan) version 5.03 using 20 x objective was used to take images.  
The FITC channel and DAPI channels were used to visualise CD31 and nuclei 
respectively.  
2.3.9 Generation of active IL-36 proteins 
IL-36γ and IL-36Ra were obtained from collaborators from the University of 
Leeds. Generation methods for the proteins have already been published 
(Macleod et al., 2016).  
 
 
2.3.10 Stimulating ECs with IL-36 
6 well plates were pre-coated with 10% v/v gelatine solution overnight prior to 
use. Cells were seeded onto 6 well plates in supplemented media and allowed to 
reach 90% confluency.  Prior to stimulation, media was replaced.  Cells were 
stimulated with various concentrations or combinations of IL-36γ and the receptor 
antagonist for 24 or 48 hr and incubated as above.  Following stimulation, 
supernatant was removed and stored at -80°C.  Cells were harvested for FACS 
or RNA isolation (see methods below).   Experiments were conducted on healthy 
HUVEC donor cells from 5 different volunteers and a set of pooled donor HDLECs 
from PromoCell.  Relevant cells were incubated with NF-κB  inhibitor  (IMD- 0354)  
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(Merck Millipore, Billerica, USA) 1 μmol/L for 1 hr prior to stimulation to test the 
importance of this signalling pathway.  
2.3.11 Measurement of CCL20, CCL2 and IL-8 in supernatant by enzyme-
linked immunosorbent assay (ELISA) 
CCL2 and IL-8 Ready set ELISA kits (Ready-SET-Go!®- 2nd Generation) were 
purchased from eBioscience (San Diego, USA). Corning costar 96 well plates 
(9018) were used for all ELISAs. All assays were conducted at room temperature 
and kits used as per the manufacturer’s instructions.   Briefly, for both kits, the 
capture anti-human antibody was diluted 1 in 250 in coating buffer (1 x PBS).  
ELISA plate wells were incubated with 100µl capture antibody overnight.  Plates 
were then washed 5 times using 300 µl wash buffer (0.05% tween-20 in PBS).  
Plates were then blocked with 1 x assay diluent (1% BSA in PBS) for 1 hr.  Plates 
were further washed 3 times with wash buffer.  100 µl sample or standard 
(recombinant protein) was then added in duplicate.  Standard was diluted in 2-
fold serial dilution using assay diluent to produce a standard curve.  After 2 hr, 
plates were washed 3 times with wash buffer.  Detection antibody (anti-human 
biotin) was diluted 1 in 250 in assay diluent and 100 µl was added to each well 
for 1 hr.   Plates were then washed 3 times with wash buffer.  Enzyme (Avidin-
HRP) was diluted 1 in 250 in assay diluent and 100 µl added to each well for 30 
mins.   Plates were then washed 5 times with wash buffer.  100 µl of substrate 
(tetramethylbenzidine/TMB) was then added for 15 mins.  Reaction was stopped 
by adding 50 µl stop solution, 1 Molar sulphuric acid, Sigma (35276) to each well.  
The absorbance of each well was then measured at 490nm using the Tecan 
Infinite 200 plate reader using the Magellan 6 analysis software (Tecan, 
Männedorf, Switzerland).  
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CCL20 (DY360) ELISA kit was purchased from R&D systems (Minneapolis, 
USA).  Corning costar 96 well plates were used.  Capture antibody, mouse anti-
human was diluted 1 in 180 in PBS and 100 µl added to each well and left 
overnight.  Plates then washed as above and blocked, and samples/standards 
added as above.  Detection antibody goat anti-human was diluted 1 in 180 in 
assay diluent and 100 µl added to each well for 2 hr.  Assay procedure was then 
identical to above.  
2.3.12 Measurement of adhesion molecules by Fluorescence-activated cell 
sorting (FACS) 
Following cell culture stimulations on 6 well plates, supernatant was removed and 
stored at -80 °C.  Cells were then washed with PBS, harvested using a cell 
scraper and transferred to tubes. Each tube suspension then had a cell count 
performed using the previously described method. From this 100,000 cells were 
transferred from each falcon to a new tube.  Cells were then centrifuged for 10 
mins (1000 x g) and the supernatant discarded. The cell pellets were then 
resuspended in 1 ml 5% BSA in PBS for 30 mins to block.   Suspension was then 
centrifuged again as before, the supernatant discarded, and cells were 
resuspended in 300 µl PBS.  The following antibodies (BioLegend, San Diego, 
USA) were then added, all at 1 in 300 dilution, Alexa Flour 488 anti-human CD54 
(ICAM-1) (322713) and PE anti-human CD106 (VCAM-1) (305805). All were 
raised in mice. Unstimulated control cells were used for single stain, unstained 
and IgG isotype controls.  The isotype controls were Alexa Flour 488 mouse 
(400132) and PE mouse (400111).  After 1 hr incubation, cells were centrifuged 
as above and resuspended in 300 µl PBS.  Cells were then analysed by the 
Beckman Coulter CyAn™ ADP Analyser, using the Summit software version 4.1. 
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2.3.13 IL-36 Receptor confirmation on endothelial cells by RT-QPCR  
2.3.14 Isolation of RNA 
RNA was isolated from EC using Quick-RNA MiniPrep (Zymo Research, Irvine, 
USA) following manufacturer’s instructions.  Briefly, following removal of 
supernatant, cells were washed twice with PBS.  200 µl ZR RNA Buffer was then 
added to each well and cells lysed through gentle pipetting.  The lysate was then 
transferred into the Zymo-Spin column with a collection tube fitted and centrifuged 
for 1 min at 12,000 g.  The flow-through was then discarded.  Following this, 300 
µl RNA pre-wash buffer was added to the column and then centrifuged as before 
and the flow through discarded.  600 µl RNA wash buffer was then added, and 
the column spun and the flow through discarded as before.  The column was then 
spun as before to ensure complete removal of wash buffer.  The column was then 
placed in an RNase-free tube and 35 µl DNase/RNase free water was added. 
The column was then centrifuged as before and the eluted RNA was stored at -
80°C. 
2.3.15 Synthesis of cDNA 
Prior to cDNA synthesis, RNA concentration was measured using NanoDrop 
spectrophotometer and the required amount (1 µg) was used in cDNA synthesis 
reactions. Isolated RNA was converted to cDNA using RevertAid first strand 
cDNA synthesis kit (K1662) (Thermo Scientific).  11 µl template RNA was added 
to a nuclease free tube. The following was then added in order.  1 µl Oligo (dT) 
primer, 4 µl reaction buffer, 1 µl RiboLock RNase inhibitor (20U/ µl), 2 µl 10mM 
dNTP mix and 1 µl RevertAid M-MuLV RT (200U/ µl).   As a negative control to 
ensure no DNA contamination when conducting PCR, a tube with no RevertAid 
M-MuLV RT was included, which should contain no cDNA. 
  
56 
The tubes were then incubated for 5 min at 25 °C and then for 60 min at 42 °C.  
The cDNA was stored at - 80°C until use. 
2.3.16 Receptor confirmation by quantitative PCR (qPCR) 
Each reaction well contained the following:  10 µl SYBR green master mix, 6 µl 
nuclease free water, 2 µl primer (target or housekeeping control) and 2 µl cDNA 
sample.  The following cycling conditions were used:  95°C for 5mins, followed 
by 40 cycles of 10 seconds at 95 °C and 30 seconds and 60°C.  After cycle 
completion, melt curves were produced to ensure a single product had been 
amplified.  The CFX Connect™ Real-Time PCR Detection System was used for 
PCR and data analysed using BIO-RAD CFX manager software version 3.0.   
PCR plates were Bio-Rad (HSP9601).  IL-36R expression was assessed using 
the QuantiTect Primer (QT00072989).  U6snRNA (Sigma) was used as a 
housekeeping gene. The PCR assay was conducted using the Qiagen Quantifast 
SYBR green PCR kit (204054). Samples were tested in two dilutions and 
duplicates.  A four-point standard curve using HUVEC cDNA was conducted to 
test primer efficiency. cDNA from the following cell types were used, HUVEC, 
HDLEC (previously described) and primary keratinocytes and fibroblasts which 
had previously been isolated and cultured were used as positive controls (Alase 
et al., 2015).   To ensure no DNA contamination was present in the reaction, a 
water control (instead of sample) was used.  To ensure only cDNA had been 
synthesised, and that results were not from contamination, the no RT control was 
used. 
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2.3.17 IL-36 Receptor confirmation by Immunocytochemistry 
HUVEC and HDLEC were seeded onto gelatin coated coverslips overnight.  Cells 
were washed in TBS and fixed in 4% formaldehyde for 20 mins. Cells were then 
blocked for 1 hr in 5% BSA in TBS.   Cells were incubated overnight with mouse 
anti-human CD31 (1:1000) (Dako, Glostrup, Denmark) and rabbit anti-human IL-
36R (1:500) (Novus Biologicals, Littleton, USA) or Rabbit IgG isotype control 
(1:500, Abcam, Cambridge, UK). Cells were washed with TBST and secondary 
donkey anti-rabbit Alexa 594 conjugated, and donkey anti-mouse Alexa 488 
conjugated were added (both 1:1000, both Invitrogen, Carlsbad, USA).NF-kB and 
c-JUN activation by IHC and western blot. 
2.3.18 Chemotaxis Assays on Stimulated EC supernatant 
Chemotaxis plates (101-216, 8µm pore size) were purchased from Neuro Probe, 
USA.  30µl of EC supernatant was placed in the bottom chamber.  The porous 
insert was then placed on top.  Blood was obtained from 7 healthy volunteers.  
Mononuclear cells were isolated from blood by Lymphoprep density gradient 
centrifugation and resuspended in in RPMI containing 10% FCS. The suspension 
was then purified using a MACS magnetic separation column (Miltenyi Biotec) 
using microbeads for CD14 negative selection (to exclude monocytes) followed 
by CD4 positive selection.  T cell purity (>90%) was confirmed by FACS CD4/CD3 
selection. Isolated T cells were resuspended in RPMI and 5 x 104 cells in 20 µl 
were added to the top chamber. Cells were incubated in an atmosphere of 95 % 
humidity and 5% CO2 at 37°C for 2 hr.  Following incubation, the suspension in 
the bottom chamber containing migrated cells was removed and placed in 
counting slides (BIO RAD, USA, 1450011).  The cell count was performed using 
the BIO RAD TC20 automated cell counter. The percentage of cells that had 
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migrated was calculated for each treatment.  The percentage of cells that 
migrated for media only was normalised to 0 and other treatment values were 
expressed as a migration index. 
2.3.19 NF-κB and c-JUN analysis by Western blot 
Cells were stimulated as before, for 1 hr. Cells were lysed with CelLytic M lysis 
buffer (Sigma-Aldrich), containing protease an inhibitor cocktail (Roche Applied 
Bioscience, Rotkreuz, Switzerland) and phosphatase inhibitor (Thermo Scientific, 
Loughborough, UK). Protein concentration was determined by Bradford Assay, 
and 20μg of total protein was separated on any kDa mini protean gel (Bio-Rad, 
Hemel Hempstead, UK). Proteins were blotted onto 0.2 μm PVDF trans-blot pack 
(Bio-Rad). Membranes were probed with either rabbit anti-human phospho-NF-
κB (1:1000), rabbit anti-human Phospho c-JUN (both Cell signalling Technology, 
Leiden, the Netherlands), or mouse anti-human GAPDH (Santa Cruz 
Biotechnology, Dallas, USA)(Housekeeping control), in Tris-buffered saline 0.1% 
Tween-20 (TBST) containing 5% BSA overnight at 4°C. Mouse anti-rabbit or 
donkey anti-mouse, HRP conjugated secondary antibodies were used at 1:5000 
for 1 hr at room temperature. Gels were developed with the addition of ECL 
substrate (Bio-Rad) and visualised using Bio-Rad chemidoc.   
2.3.20 NF-κB and c-JUN phosphorylation by immunocytochemistry 
Gelatin-coated coverslips were placed into six-well plates, and HUVEC were 
cultured and stimulated as before. Following 1 hr of treatment, cells were washed 
in TBS and fixed in 4% formaldehyde for 20 mins. Cells were then blocked for 1 
hr in 5% BSA in TBS. Cells were then incubated overnight at 4°C with either rabbit 
antihuman phospho-NF-κB (1:1000) or rabbit anti-human phospho-c-JUN 
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(1:1000) (both Cell Signalling Technology, Leiden, the Netherlands). Cells were 
washed with TBST, and a secondary donkey anti-rabbit Alexa 594 (1:1000) 
conjugated antibody was added. Sheep anti-human Von Willebrand factor (FITC 
conjugated) (Abcam, Cambridge, UK) was used as a background stain. 
2.3.21 Angiogenesis assay 
Dermal fibroblasts (DF) were provided by the Centre for Skin Sciences, University 
of Bradford, as described previously (Alase et al., 2015).  DF were cultured in 
DMEM (10% FBS) containing penicillin/streptomycin (100 U/100 mg/mL).  DF 
were allowed to reach confluency in 24 well plates.  6500 HDLEC were then co- 
cultured with the confluent DF, and then allowed to acclimatise in 1:1 DMEM/ 
complete Promocell endothelial media overnight.  The following day, the media 
was replaced by endothelial media.  The cells were then stimulated with IL-36, 
IL-36Ra or VEGF inhibitor-sutent (Sigma).  Following 5 days, the cells were fixed 
in 4% formaldehyde for 20 mins and blocked in 5% BSA for 1 hr. Cells were then 
stained with mouse anti-human CD31 FITC conjugated (Sigma) for 1 hr. Cells 
were visualised using the EVOS XL microscope (Hatfield, PA, USA).Total tubule 
length was quantified from each photographic field using the open source 
software AngioQuant (www.cs.tut.fi/sgn/csb/angioquant) and values averaged. 
2.3.22 Statistical analysis 
Statistical significance was calculated using a one-way ANOVA with a 
Bonferroni's multiple comparisons test, unless stated.  Analysis was performed 
using GraphPad Prism software (GraphPad Software Inc, La Jolla, CA, USA).  
Error bars represent the standard error of the mean (SEM). *: p<0.05 from 
indicated controls.   
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2.4 Results 
 
2.4.1 Immunocharacterisation of EC 
For both EC types, the phenotype was confirmed using fluorescence microscopy 
as described in section 2.2.7. FITC-tagged CD31 (PECAM-1) was used on both 
cell types and clearly stained all cells.    
   
 
Figure 13: Confirmation of endothelial cell type for both HUVEC and HDLEC 
Cells were grown, fixed and then stained with FITC-tagged CD31 and 
counterstained with DAPI.   Isotype control confirms specific binding of 
conjugated antibody magnification x 40.  
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Figure 14: Confirmation of endothelial cell type for both HUVEC and 
HDLEC 
Cells were grown, fixed and then stained with FITC tagged Vwf and 
counterstained with DAPI.   Isotype control confirms specific binding of 
conjugated antibody magnification x 20.  
2.4.2 IL-36R confirmation by RT-QPCR 
Whilst no stimulatory effects of IL-36 on ECs have previously been documented, 
expression of the IL-36R first needed to be confirmed. For analysis of receptor 
expression, two human EC types were used, HUVEC (Human Umbilical Vein 
Endothelial Cells) and HDLEC (Human Dermal Lymphatic Endothelial Cells).  A 
range of cell types are known to express the IL-36R including fibroblasts and 
keratinocytes, and these were used as positive controls. Previous research has 
shown dermal fibroblasts are highly responsive to IL-36 stimulation (Magne et al., 
2006).  For both the IL-36R and U6 primers, efficiency curves were generated 
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(Figure 15).  For both primers, suitable efficiency curves were achieved.  qPCR 
analysis confirmed expression of the IL-36R on both HUVEC and HDLEC (Figure 
16). Keratinocytes and fibroblasts were used as positive controls.  
  
 
Figure 15 : Efficiency curves for primers U6, housekeeping gene 
E= 97.3% %, R2= 0.991 . B)IL-36R, E= 100%, R2= 0.991. 
 
 
 
  
63 
 
Figure 16: Expression of the IL-36 receptor on cell types 
A) Amplification graph showing IL-36R on cell types in comparison to U6 
housekeeping gene. B) Melt curves for each cell type cDNA confirm the 
presence of a single amplified product for both IL-36 and U6. 
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Figure 17: Expression of the IL36R on human endothelial cells 
A)qPCR was performed and relative mRNA expression determined.  
Keratinocyte expression was set to 1.00 and HUVEC, HDLEC and fibroblast 
expression of the receptor was quantified relative to keratinocyte 
expression. Samples: HUVEC n = 5, HDLEC n=3 (pooled donors) 3 
biological replicates, keratinocytes, fibroblasts n=2.  Standard error of 
mean depicted on graph.  B) ICC confirmation of receptor on HUVEC and 
HDLEC. Magnification x 40. 
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2.4.3 IL-8 release from ECs following IL-36γ stimulation 
To assess possible stimulatory effects of IL-36γ on ECs, IL-8 secretion was 
measured in response to stimulation.  To identify the most effective 
concentrations and stimulation times for IL-36γ, a range of concentrations and 
time points were used.  
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Figure 18: IL-8 secretion by HUVEC following IL-36 stimulation 
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IL-8 secretion following IL-36γ stimulation for both 24 and 48 hr 
stimulations. Sample size, n=4 (average taken of triplicate repetitions per 
N). ANOVA *: p<0.05 from relevant controls. 
For both time points a plateau in IL-8 secretion appeared to occur between the 
concentrations 50 ng/ml and 100 ng/ml.  From the statistical significance of the 
data it was evident the most effective time point was 48 hr and for the 
concentrations of 10 and 50 ng/ml.  No statistical significance was found at 5 
ng/ml at either time point and for 10 ng/ml at 24 hr.  
 
2.4.4 Chemokine release from ECs from 48hr IL-36γ stimulation 
Following significant IL-8 release following 48 hr simulation with IL-36γ, a range 
of chemokines known to be secreted by ECs that have pathological significance 
in psoriasis were measured in duplicate from treated ECs. In addition to IL-8, both 
types of ECs secreted CCL2 (MCP1) and CCL20 in a dose dependent manner.  
ECs are known to react very sensitively to endotoxin contamination; the IL-36γ 
preparation was boiled prior to stimulation to confirm no contamination was 
present.  Boiled controls subsequently produced similar secretion levels to 
untreated replicates.  Both 10 and 50 ng/ml IL-36γ resulted in significant 
chemokine production when compared to untreated control.   The receptor 
antagonist (IL-36Ra) lowered secretion levels in a dose dependent manner.  
Increasing concentrations of 10, 50 and 100 ng/ml of the IL-36Ra all lowered IL-
36γ mediated secretion of chemokines in comparison to IL-36γ stimulation alone.  
The effect of IL-36Ra also consolidates the presence of the IL-36R on both EC 
types. 
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Figure 19: ECs secrete chemokines following IL-36γ stimulation 
Following 48 hr stimulation with IL-36/IL-36Ra or NF-κB inhibitor(IMD), the 
EC cell supernatant was tested for CCL20, CCL2 and IL-8 by ELISA (A-C). 
Sample sizes: HUVEC n=5, HDLEC n=3 (3 biological replicates of pooled 
donors). Standard error of mean depicted.   ANOVA *: p<0.05 from relevant 
controls. 
 
2.4.5 Adhesion molecule upregulation on EC following IL-36γ stimulation 
Proinflammatory cytokines are known to upregulate adhesion molecules on ECs 
thereby facilitating leukocyte recruitment.  VCAM-1 is usually undetectable on 
basal cells, whereas ICAM-1 is detectable at low levels at basal.  Both adhesion 
molecules are upregulated on ECs following proinflammatory cytokine stimulation 
(Swerlick et al., 1992, Kim et al., 1993). 
Our results confirm that IL-36γ also has this ability.  FACS analysis confirmed 
both ICAM-1 and VCAM-1 were upregulated after stimulating ECs with IL-36γ for 
48 hr.  HUVEC and HDLEC both showed adhesion molecule upregulation in a 
dose dependent manner.   Although stimulating with 10 ng/ml, produced minimal 
upregulation of adhesion molecules on EC, 50 ng/ml IL-36γ resulted in a clear 
upregulation of surface expression of both ICAM-1 and VCAM-1.  Despite 
differences in chemokine secretion, no notable difference of adhesion molecule 
expression was seen between HDLEC and HUVEC. 
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Figure 20: Endothelial cell adhesion molecule upregulation following IL-36γ 
stimulation 
Following 48 hr stimulation with IL-36γ, ECs (HUVEC and HDLEC) were 
stained with labelled antibodies specific for ICAM-1 or VCAM-1 and 
analysed by flow cytometry for surface expression.  Relevant isotype 
controls were used as negative control. Fluorescence beyond the “isotype” 
line in the depicted histograms thus represents specific binding of antibody 
demonstrating detectable expression. A representative experiment is 
shown (sample sizes: HUVEC n=3, HDLEC n=3).    
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Figure 21: PE log (CD106, VCAM-1) vs FITC log (CD54, ICAM-1), showing 
surface expression of respective markers following IL-36у stimulation 
For both HUVEC (A) and HDLEC (B), increasing IL-36γ concentrations 
results in increased double positive cells for both markers (R6 area) when 
compared to untreated control. n=3, image represent 1 randomly selected 
experiment.  
2.4.6 Supernatant from IL-36γ stimulated ECs is a chemoattractant for T 
Cells 
Having observed chemokine secretion by ECs following IL-36γ stimulation, the 
chemotactic potency of the EC conditioned media was assessed.  CCL20 which 
was found to be secreted by ECs following IL-36γ stimulation is known to be a 
chemoattractant for T cells and has a documented role in psoriasis (Homey et al., 
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2000).  Untreated cell supernatant, media alone and IL-36γ + media were used 
as negative controls and rhCCL20 as a positive control.  Supernatant from IL-36γ 
stimulated ECs proved to be a chemoattractant for T cells when compared to 
negative controls (Figure 22). Increasing IL-36γ concentration to 50 ng/ml 
resulted in a tendency for increased T cell migration.  Chemotaxis assays could 
confirm that IL-36Ra at 100 ng/ml was sufficient to inhibit the stimulatory effects 
of IL-36γ 10 ng/ml. When stimulating with the Ra at 100 ng/ml, the migration of T 
cells was reduced and comparable to untreated supernatant.  This suggests IL-
36γ induced chemokine secretion was indeed responsible for T cell migration.  
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Figure 22: Chemokines secreted by ECs following IL-36 stimulation are a 
chemoattractant for T cells 
The supernatant from treated and untreated ECs was removed and tested 
for its chemoattractant ability using a chemotaxis assay. The supernatant 
was placed in the bottom chamber and T cells above. The number of 
migrated cells in the bottom chamber after 2 hr was then measured. Sample 
size: n=7. Standard error of mean depicted.   ANOVA *: p<0.05 from relevant 
controls. 
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2.4.7 IL-36γ stimulation activates NF-kB and c-JUN in ECs 
IL-36γ stimulation resulted in increased NF-κB and c-JUN phosphorylation in 
HUVEC (Figure 23).  Concentrations of 10 and 50 ng/ml of IL-36γ resulted in 
increased detection of the phosphorylated active versions of NF-κB and c-JUN in 
the nucleus of HUVEC and also in whole protein lysate.  The activation of both 
NF-κB and c-JUN was reduced by the addition of the RA.  NF-κB inhibitor only 
partially inhibited IL-8 secretion suggesting other transcription factors such as 
AP-1 may also play a role (Figure 19). 
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Figure 23: IL-36γ induces NF-κB and c-JUN phosphorylation in HUVEC 
Western blot (A) and ICC analysis (B) of  pNF-κB-p65 and pc-JUN. 
Phosphospecific antibodies detect active form of NF-κB or c-JUN in the 
nucleus of HUVEC. Increased detection of active form of both were also 
detected in whole cell lysate via Western blot.  Magnification x 40. 
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2.4.8 IL-36γ induces dermal endothelial tube formation 
Collaborators had previously shown that IL-36 induces tubule formation of 
endothelial cells in a co-culture model with fibroblasts, and that this tube formation 
is dependent on IL-36 induced VEGF from fibroblasts (unpublished). However, 
this work was conducted on HUVEC.  
In a co-culture model of HDLEC and dermal fibroblasts, IL-36y stimulation results 
in increased tube formation of HDLEC.   IL-36γ induced tube formation was 
blocked by the addition of IL-36Ra and by the VEGF inhibitor Sutent®.  
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Figure 24: IL-36y induces HDLEC tube formation 
HDLEC were co-cultured with DF for 5 days, and stimulated with IL-36, IL-
36Ra continuously or Sutent and subsequently stained for CD31 (green).  
Average tube length was then calculated.  One-way ANOVA *: p<0.05 from 
relevant controls. 
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2.5 Discussion 
 
Psoriasis is a common chronic inflammatory skin disorder affecting 2-3% of the 
world population.  The IL-1 family member, IL-36 has been linked to psoriasis 
pathogenesis and disease severity. In inflammatory diseases, ECs are activated 
by proinflammatory cytokines including, IL-1, TNFα and IL-17, resulting in 
enhanced leukocyte recruitment and this is well recognised in psoriasis 
(Heidenreich et al., 2009). However, so far the effects of IL-36 on ECs have been 
unexplored.  
Here, we describe expression of the IL-36 receptor by both large vessel (HUVEC) 
and microvessel (HDLEC) endothelium.  We assessed the functional activity of 
the receptor by assessing the biologic response of ECs to IL-36γ stimulation, 
including adhesion molecule upregulation and chemokine production. 
qPCR and ICC both confirmed the presence of the receptor on both HDLEC and 
HUVEC.  Interestingly EC expression appeared slightly lower than on both 
keratinocytes and fibroblasts.  Previous research has shown fibroblasts are 
responsive to IL-36γ and IL-36α resulting in IL-8 secretion (Frey et al., 2013).  
The receptor is also known to be highly expressed on keratinocytes when 
compared to other cell types such as monocytes (Foster et al., 2014). Prior to this 
study, the IL-36R had also been suggested on a range of EC types through DNA 
arrays by collaborators (Bridgewood et al., 2017). 
HUVEC were initially stimulated with IL-36γ using a range of concentrations and 
time points. Initial IL-8 secretion data (Figure 18) revealed that the optimal 
concentrations for stimulating HUVEC were 10 and 50 ng/ml.  Stimulating with 
  
78 
100 ng/ml appeared to cause IL-8 secretion to plateau in comparison to 50 ng/ml.   
Stimulating with 5 ng/ml resulted in no statistically significant increase in IL-8 
secretion when compared to untreated controls. Stimulating with 10 ng/ml only 
resulted in a statistical significance when at 48 hr. For all concentrations, IL-8 
secretion increased compared to untreated control when stimulated at 48 hr.  
Previous research with IL-36γ stimulations and dermal fibroblasts also found IL-
8 secretion to be most measurable at 48 hr (unpublished work, Wittmann, Leeds 
group).  For all following read outs of chemokine production and adhesion 
molecule expression, 48 hr stimulations were used with the concentrations of 10 
and 50 ng/ml IL-36γ.  
Adhesion molecules expressed on ECs are involved in leukocyte extravasation, 
by allowing leukocytes to bind them, and allowing migration to the site of 
inflammation.  Both adhesion molecules ICAM-1 and VCAM-1 were upregulated 
following IL-36γ stimulation.  Adhesion molecules are involved in leukocyte 
extravasation, which allows the movement of leukocytes to the site of tissue 
damage or infection. Selectins are responsible for the rolling and capture of 
leukocytes whereas ICAM-1 and VCAM-1 are involved in the adhesion and 
transmigration.  The integrins expressed on leukocytes, LFA-1 and VLA-4 bind to 
ICAM-1 and VCAM-1 respectively (Muller, 2013). In the context of psoriasis 
pathogenesis, both these adhesion molecules are required for T cell adhesion 
and migration and are upregulated in lesions (de Boer et al., 1994, Gabay and 
Towne, 2015, Blumberg et al., 2010).  
ECs also responded with chemokine production to IL-36γ stimulation.  CCL2 
(MCP1) has documented importance in psoriasis and other inflammatory 
diseases by recruiting monocytes (Lembo et al., 2014).  IL-8, which promotes 
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neutrophil recruitment, EC survival and angiogenesis, was also secreted 
following IL-36γ stimulation (Li et al., 2003).  The importance of angiogenesis in 
psoriasis is well recognised (Heidenreich et al., 2009), and local EC secretion of 
IL-8 induced by IL-36γ could be a contributing factor. CCL20 was secreted which 
binds to CCR6, which is highly expressed on IL-17 and IL-22 producing 
lymphocytes and the majority of T cells that infiltrate the skin in psoriasis are 
CCR6 positive (Homey et al., 2000). Serum levels of CCL20 have been 
suggested to correlate with psoriasis severity (Ekman et al., 2013). Although 
keratinocytes are a main source of CCL20 (Homey et al., 2000, Teraki et al., 
2004) our findings indicate that ECs could contribute to the cutaneous CCL20 as 
well as CCL2 production.   
For all chemokines analysed, the IL-36Ra was able to dampen the effect in a 
dose dependent manner.  This finding was also mirrored in the chemotaxis assay 
where T cell migration was reduced when ECs had been co-stimulated with the 
Ra.   
While the role of TNFα is well characterised in psoriasis, it is hypothesized 
environmental triggers can cause keratinocytes to secrete IL-36γ independently 
of proinflammatory cytokines such as TNFα (Gabay and Towne, 2015, Blumberg 
et al., 2010).  It is thus possible that IL-36γ could be important in the initiation of 
EC activation, but results in this study suggest its on-going secretion could 
contribute to chronic EC activation, contributing to the chronic inflammatory 
nature of the disease. 
Our presented findings could also have implications for other diseases.  Lung 
bronchial epithelial cells secrete IL-36 in response to cytokines such as TNFα 
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(Chustz et al., 2011). Cigarette smoke, the causative agent of Chronic 
Obstructive Pulmonary Disease (COPD) is also known to cause IL-36 secretion 
in bronchial epithelial cells (Parsanejad et al., 2008). However, the exact role of 
IL-36 in respiratory disease it still unknown.  In COPD, like many chronic 
inflammatory diseases, angiogenesis and EC activation occurs (Siafakas et al., 
2007). Therefore IL-36γ may also have a role in EC activation and leukocyte 
recruitment in COPD. Similarly, IL-36β has been linked to disease severity of 
periodontal inflammation (Kursunlu et al., 2015).  Murine models of liver 
damage/liver inflammation have also identified enhanced expression of IL-36γ,  
and elevated CCL20 levels, which could be from ECs (Scheiermann et al., 2015).  
Collaborators from the University of Leeds have also established that IL-36 
promotes angiogenesis by inducing VEGF secretion from surrounding fibroblasts 
in co-culture models (unpublished).  However, this study was conducted using 
HUVEC, and we report similar findings using the skin relevant HDLECs. VEGF 
and VEGFR are overexpressed in psoriasis lesions and serum levels of VEGF 
correlate with PASI (Young et al., 2004, Nofal et al., 2009, Detmar et al., 1994).  
A SNP in VEGF is also associated with severe psoriasis (+405 CC) and is thought 
to result in increased VEGF production (Diaz et al., 2000, Young et al., 2006).  
Interestingly the SNP is also associated with poor prognosis in patients with 
chronic heart failure (van der Meer et al., 2005).  Importantly, it is thought 
angiogenesis is induced before the onset of the lesion, so it could be 
hypothesised, that IL-36γ released from damaged keratinocytes would be well 
placed to induce VEGF and thus angiogenesis when compared to other cytokines 
that would have importance in a chronic lesion (Telner and Fekete, 1961).   
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Angiogenesis has even been muted as a potential therapeutic target for psoriasis 
(Heidenreich et al., 2009, Guérard and Pouliot, 2012, Weidemann et al., 2013). 
Case reports have demonstrated improvements in psoriatic disease severity 
scores (PASI) through targeting pro-angiogenic factors such as VEGF-A.  
Bevacizumab, a monoclonal antibody against VEGF-A used in the treatment for 
solid cancers, has also been shown to be effective in treating psoriasis, including 
one case of complete remission for a patient being treated for metastatic colon 
cancer (Akman et al., 2009). Case reports for tyrosine kinase inhibitors that target 
VEGFR such as sunitinib (Sutent®) and sorafenib also have produced positive 
results regarding psoriasis remission (Narayanan et al., 2010, Fournier and 
Tisman, 2010, Antoniou et al., 2016).  Of interest, G6-31, a murine antibody 
against VEGF-A has demonstrated therapeutic improvement, in a mouse model 
of psoriasis (Schonthaler et al., 2009).  VALPHA is a fusion protein that targets 
both TNFα and VEGF and has shown to be effective in treating TPA induced 
psoriasis in mouse models (Jung et al., 2011). 
IL-36γ serum levels are enhanced in psoriasis patients (D'Erme et al., 2015). In 
recent years psoriasis has been suggested as an independent risk factor for 
atherosclerosis (Gelfand et al., 2006).  In atherosclerosis, endothelial activation 
and initial inflammatory signalling represent an important stage of disease 
development (Hajra et al., 2000). Increased serum levels of IL-36γ and therefore 
possible increased endothelium activation within the arteries could accelerate 
atherosclerotic disease progression.  Also of concern, GPP is associated with a 
Ra mutation, which results in reduced control over IL-36.  However the risk factor 
of GGP on CVD is largely unexplored so far.  
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These results suggest that IL-36γ has a role in activating the endothelium further 
enhancing lymphocyte recruitment and thus enhancing psoriatic inflammation.  
These findings add to the growing importance of IL-36γ in both psoriasis initiation 
and maintenance.  Further studies will help decipher the significance of IL-36γ 
and its interactions with other EC stimulating mediators such as TNFα and IL-17 
in human psoriatic tissue. 
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3) IL-36 relationship with Psoriasis 
Macrophages 
 
As defined in the introduction, both IL-36 and macrophages play pivotal roles in 
the pathogenesis of psoriasis. However, the relationship between IL-36 and 
macrophages is yet to be fully deciphered.   
Hypothesis 
I hypothesize that macrophages will be stimulated by IL-36ү and that this will lead 
to the secretion of disease relevant cytokines important to psoriasis pathology.  It 
is also likely that macrophages from psoriasis patients may have increased 
secretions of these cytokines due to several genetic immune predispositions 
known to exist in psoriasis.  Finally, I wish to test the hypothesis that this 
macrophage activation will activate the endothelial cells and lead to increased 
leukocyte adhesion.  
3.1 Aims 
Examine the stimulatory effects of IL-36γ + IFNγ on both healthy and 
psoriasis macrophages by measuring levels of psoriasis important 
cytokine such as IL-23 and TNFα 
• Determine the significance of these inducible mediators on the 
surrounding tissues by stimulating HUVEC with macrophage supernatant 
• Determine if psoriasis monocytes show increased adhesion to a 
stimulated and resting endothelium 
• Determine possible mechanisms behind any adhesion trends such as role 
of CX3CL1 
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3.2 Methods 
3.2.1 Cell isolations and cell culture 
Psoriasis patient blood was obtained under ethical approval (PDAR study: REC 
16/YH/0086) and approved by Yorkshire and the Humber Leeds West Research 
Ethics Committee. Written informed consent was obtained from all subjects.  
Patients had a PASI score from 0-15. Patients on biologic treatment were used 
for experiments; however, patients on immunosuppressive treatment such as 
methotrexate were not.  
Blood was collected in sodium citrate tubes.  PBMCs were separated using 
Lymphoprep density gradient centrifugation. The mononuclear cells were 
collected and centrifuged at 200xg for 10 mins to remove platelets.  The cells 
were counted and resuspended in 80 µl of 1%  BSA in PBS per 1 x107 cells. 20 
µl of CD14+ microbeads (Miltenyi Biotech) were added per 1 x107 cells.  Cells 
were incubated for 15 mins and centrifuged at 300xg and resuspended in 500 µl 
1% BSA in PBS.  Monocytes were isolated from PBMCs using the Dynal MPC 
column (Invitrogen, California, USA).  Monocytes were resuspended in RPMI 
(Thermofisher Scientific, Massachusetts, USA) containing 10% FCS containing 
penicillin/streptomycin (100 U/100 mg/mL), (both Life Technologies, Carlsbad, 
USA).  
Umbilical cords were supplied by Bradford Royal Infirmary under the approval 
and processing of Ethical Tissue Bradford. HUVECs (human umbilical vein 
endothelial cells) isolated from umbilical cords in a previously described method.  
Cells were incubated in an atmosphere of 95% humidity and 5% CO2 at 37°C. 
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3.2.2 Macrophage purity and IL-36R confirmation 
Macrophages isolated as previously described, by seeding isolated monocytes 
onto coverslips overnight. Cells were washed in PBST and fixed in 4% 
formaldehyde for 20 mins. Cells were then blocked for 1 hr in 5% BSA in PBS.  
Cells were incubated overnight with rabbit anti-human IL-36R 1:500 (Novus 
Biologics, Littleton, USA) or Rabbit IgG isotype control (1:500) (Abcam, 
Cambridge, UK).  Cells were then washed with PBST and incubated with donkey 
anti-rabbit Alexa 594 conjugated and mouse anti-human CD14 FITC conjugated 
or mouse IgG isotype control (both 1:100) (both ImmunoTools, Gladiolenweg, 
Germany).  Cells were visualised using the EVOS XL microscope (Hatfield, PA, 
USA).  
3.2.3 Macrophage cytokine stimulation 
Monocytes were seeded at 1x105 in 96 well plates (Greiner Bio-One, 
Stonehouse,UK) in RPMI overnight to generate day 1 macrophages.   
Macrophages were stimulated with  either IL-36γ protein which was generated as 
previously described (Ainscough et al., 2017), IL-17, TNFα, IL-1α w/wo IFNγ 
(PeproTech, Rocky Hill, NJ, USA).  Following 48 hr stimulation, supernatant was 
stored at -80 °C.  Concentrations of IL-23 and TNFα were measured using ELISA 
kits from eBioscience/Thermofisher (Waltham, MA, USA).  ELISAs were carried 
out according to the manufacturer’s protocols.  Reproducibility of the 
supernatants results was confirmed by triplicate testing, with <10% error. 
3.2.4 Macrophage supernatant stimulation of EC ICAM-1 expression 
Following 48 hr stimulation of macrophages, supernatant was removed and 
centrifuged and stored at -80°C.   HUVEC were cultured on black TC grade 
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fluorescence plates (PerkinElmer, Waltham, MA, USA), in complete Promocell 
endothelial cell media containing penicillin/streptomycin  (100 U/100 mg/mL). 
Supernatant diluted 1:10 with media and used to stimulate HUVEC  for 24 hr.   
Recombinant IL-36 was added to HUVEC to serve as control wells/blank.  After 
24 hr, the cells were fixed for 15 min with 4% formaldehyde in PBS.   Mouse anti-
human ICAM-1 FITC or mouse IgG isotype control was added (1:500) 
(BioLegend, San Diego, USA).  The fluorescence intensity of each well was 
measured using the Promega GloMax plate reader (Madison, WI, USA).  For 
immunocytochemistry, the cells were visualised using the EVOS XL microscope.  
3.2.5 Monocyte/HUVEC adherence assays 
Monolayers of HUVEC were grown to confluence in 24 well plates (Greiner Bio-
One). EC were stimulated with macrophage supernatant as above, or with TNFα 
(10 ng/ml)( positive control) for 24 hr and then suspended in fresh media prior to 
experiments.  Where relevant, a blocking antibody against CX3CL1 (R&D 
system, Abingdon, UK) was added at 100 ng/ml for 1 hr prior to experiment before 
the replacement of media.   1x 105 monocytes were added per chamber for 30 
mins.  After 30 mins, non-adherent cells were washed away and the cells were 
fixed using 4% formaldehyde in PBS and blocked in 5% BSA in PBS for 1 hr. The 
cells were the stained with mouse anti-human CD14 FITC conjugated or mouse 
IgG isotype control (both 1:100) (both ImmunoTools). The cells were visualised 
using the EVOS XL microscope and the number of adhered monocytes counted 
using ImageJ software plugin. 
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Figure 25: Depiction of methods 
IL-36 stimulated macrophage supernatant (48 hr) is harvested and 
subsequnetly used to stimulated EC monolayer (24hr). Following this, 
ICAM-1 expression is measured or monocytes are allowed to adhere.   
3.2.6 Statistical analysis 
Statistical significance was calculated using a one-way ANOVA with a 
Bonferroni's multiple comparisons test, unless otherwise stated.  Analysis was 
performed using GraphPad Prism software (GraphPad Software Inc, La Jolla, 
CA, USA).  Error bars represent the standard error of the mean (SEM). *: p<0.05 
from indicated controls. 
3.3 Results 
 
3.3.1 Macrophages express IL-36R 
Whilst IL-36R had been confirmed at mRNA level on macrophages and by 
psoriasis tissue histology, it had never been previously confirmed on isolated 
macrophages and at the protein level (Boutet et al., 2016).  Contaminating 
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lymphocytes may influence downstream readouts, such as cytokine secretion, so 
therefore CD14+ staining confirms the purity of the cell population.  
 
Figure 26: Macrophages express IL-36R 
Isolated macrophages were stained for either IL-36R (RED) or also CD14+ 
(Green) to confirm cell purity. Isotype controls confirm specific binding of 
antibodies.  Magnificent X 20. 
3.3.2 IL-36 has proinflammatory effects on macrophages 
Whilst previous research has suggested monocytes respond to IL-36 by secreting 
inflammatory mediators, little is known about IL-36γ kinetics of macrophage 
stimulation. Healthy patient macrophages were stimulated with a range of 
concentrations of IL-36γ and time points, to identify the most effective stimulation 
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for TNFα secretion.  Statistical significance compared to untreated was achieved 
by IL-36γ concentrations of 10 and 50 ng/ml for 48 hr but not 24 hr as seen in 
figure 27. No statistical significance was achieved for IL-36γ 1 ng/ml at either 24 
or 48 hr time point. Concentrations of over 100 ng/ml may lead to increased 
secretions, but raises questions over physiological relevance.  
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Figure 27: IL-36γ induced TNFα secretion from healthy macrophages 
TNFα secretion from healthy macrophages stimulated with IL-36γ 1-100 
ng/ml at both 24 and 48 hr. Sample size, n=4. ANOVA *: p<0.05 from relevant 
controls. 
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3.3.3 IFNγ activates macrophages and enhances IL-36γ induced TNFα 
secretion. 
IFN-γ has a documented importance in macrophage activation (Hu and Ivashkiv, 
2009), however its ability to enhance IL-36γ induced secretions is presently 
unknown.  Macrophages were primed with increasing concentrations of IFNγ for 
24 hr before being stimulated with IL-36γ at 10 ng/ml. TNFα secretion into the 
media was measured at both 24 and 48 hr.  Statistical significance was achieved 
when IL-36γ (10 ng/ml) at 48 hr was primed with IFNγ 20 ng/ml which appeared 
to plateau when increasing to IFNγ 100 ng/ml.  Following preliminary stimulation 
data, it was thus decided that macrophages would be stimulated with both IL-36γ 
10 and 50 ng/ml and with and without IFNγ 20 ng/ml.  
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Figure 28: IL-36γ induced TNFα secretion from healthy macrophages is 
enhanced by IFNγ 
TNFα secretion from healthy macrophages stimulated with IL-36γ 10 ng/ml 
and primed with increasing concentrations of IFNγ. Sample size, n=3. 
ANOVA *: p<0.05 from relevant controls. 
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3.3.4 IL-36 induces increased IL-23 and TNFα from psoriasis macrophages 
when compared to healthy macrophages 
To assess the functional significance of IL-36γ stimulation of macrophages in the 
context of a psoriasis lesion, macrophages were stimulated with IL-36γ for 48 hr 
and the levels of TNFα and IL-23 measured by ELISA.  Macrophages are known 
to be sensitive to LPS stimulation so to confirm no contamination was present, 
boiled IL-36γ was included.  Both 10 and 50 ng/ml IL-36γ were able to induce a 
significant increase in IL-23 secretion when compared to unstimulated (Figure 
29), which was further amplified when the macrophages were primed with IFNγ 
20 ng/ml.   For both IL-36γ 10 and 50 ng/ml, psoriasis macrophages secreted 
significantly more IL-23. Treatment with macrophages with other cytokines with 
a known presence within psoriasis lesions such as IL-17, TNFα and IL-1 were 
unable to induce a significant increase in IL-23 secretion, regardless of IFNγ 
priming. IL-36y also induced significant TNFα secretion from macrophages, as 
did both IL-1 and IL-17 when compared to untreated controls.   However following 
IFNγ priming, IL-36γ induced secretion exceeded both IL-1 and IL-17. 
  
93 
p
g
/m
l
U
N
T
R
E
A
T
E
D
IL
-1
7
 1
0
 n
g
/m
l
IL
-3
6
1
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l 
(B
O
IL
E
D
)
IL
-1

 1
0
 n
g
/m
l
U
N
T
R
E
A
T
E
D
IL
-1
7
 1
0
 n
g
/m
l
IL
-3
6
1
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l 
(B
O
IL
E
D
)
IL
-1

 1
0
 n
g
/m
l
0
5 0 0
1 0 0 0
1 5 0 0
**
* *
**
*
*
*
*
IF N   P r im e
T N F 
 
  
94 
p
g
/m
l
U
N
T
R
E
A
T
E
D
IL
-1
7
 1
0
 n
g
/m
l
T
N
F

 1
0
 n
g
/m
l
IL
-3
6
1
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l 
(B
O
IL
E
D
)
IL
-1

 1
0
 n
g
/m
l
U
N
T
R
E
A
T
E
D
IL
-1
7
 1
0
 n
g
/m
l
T
N
F

 1
0
 n
g
/m
l
IL
-3
6
  
1
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l
IL
-3
6
  
5
0
 n
g
/m
l 
(B
O
IL
E
D
)
IL
-1

 1
0
 n
g
/m
l
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
*
*
*
*
IL -23
IF N   P r im e
 
 
Figure 29: IL-36γ induced TNFα and IL-23 secretion from psoriasis and 
healthy macrophages 
Macrophages were primed w/wo IFNγ and stimulated with various 
cytokines (IL-17, TNFα, IL-36γ and IL-1) and subsequent IL-23 and TNFα 
secretion was measured following 48 hr. Unpaired t test*: p<0.05 from 
relevant controls. 
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3.3.5 IL-36γ induced macrophage supernatant is inflammatory to 
endothelial cells 
To assess the functional significance of IL-36 induced macrophage cytokines on 
surrounding tissues, we stimulated HUVEC with macrophage supernatant.  To 
identify the most sensitive concentration to stimulate HUVEC with, both untreated 
and IL-36 50 ng/ml induced supernatant (treated) was diluted in media from 
concentrations ranging from neat to 1:1000.   To assess the proinflammatory 
effects of macrophage supernatant on HUVEC, ICAM-1 upregulation was 
measured by fluorescence intensity.  For both 1:1000 and 1:100 dilutions, no 
significant change in ICAM-1 expression was seen for untreated versus treated.  
For 1:10, treated ICAM-1 expression was significantly higher than untreated.   For 
neat, no statistical significance was seen between treated and untreated.   
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Figure 30: Macrophage supernatant is proinflammatory to HUVEC 
HUVEC were stimulated with various concentrations of healthy 
macrophage supernatant and ICAM-1 intensity of measured. n=3.  Unpaired 
t test *: p<0.05 from relevant controls. 
3.3.6 Psoriasis macrophage derived supernatant shows greater propensity 
to upregulate ICAM-1 
After this optimisation where healthy macrophage supernatant was used to 
determine activation of HUVEC as measured by ICAM-1 expression, HUVEC 
were stimulated with both psoriasis and healthy macrophage derived supernatant 
(both IL-36 treated and untreated macrophages). For both IL-36 10 and 50 ng/ml 
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induced supernatant, psoriasis derived macrophage supernatant showed 
increased activation of ICAM-1 on HUVEC (Figure 31).  Isotype control was 
included to ensure ICAM-1 binding was specific.  ICAM-1 staining also confirms 
increased upregulation when stimulated with with psoriasis macrophage derived 
supernatant (Figure 32). IL-36 may itself upregulate ICAM-1, recombinant IL-36 
10 and 50 ng/ml were used to zero expression (not shown). 
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Figure 31: Psoriasis derived macrophage supernatant significantly 
upregulates ICAM-1 compared to healthy 
HUVEC were stimulated with supernatant from both healthy and psoriasis 
macrophages treated with IL-36 for 24 hr and ICAM-1 intensity measured. 
(Psoriasis n=8, Healthy n=8).  Unpaired t test *: p<0.05 from relevant 
controls. 
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Figure 32: Psoriasis derived macrophage supernatant significantly 
upregulates ICAM-1 compared to healthy 
HUVEC stimulated with either psoriasis or healthy derived macrophage 
supernatant for 24 hr and ICAM-1 expression visualised by ICC.  
Magnification x 40. 
After finding that psoriasis-derived macrophage supernatant had greater 
inflammatory potential than healthy macrophage supernatant, we next assessed 
the functional significance of this in the context of immune cell recruitment. 
Monocytes from both healthy and psoriasis patients were isolated and allowed to 
adhere to stimulated HUVEC.  HUVEC were either stimulated with macrophage 
supernatant (untreated and IL-36-induced) or TNFα 10 ng/ml (positive control), 
for 24 hr.  For all treatments, psoriasis monocytes showed increased adherence 
compared to healthy monocytes. In agreement with psoriasis macrophage 
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supernatant showing increased endothelial activation ability, monocytes showed 
increased adherence to this treated endothelium.  
 
Figure 33: Psoriasis monocytes show increased adherence propensity 
Both psoriasis and healthy monocytes were allowed to adhere to both 
treated (healthy and psoriasis macrophage supernatant, 24 hr) or TNFα (24 
hr) treated HUVEC.  After 30 mins, the number of adhered monocytes were 
counted. A) Number of adhered psoriasis and healthy monocytes per 
treatment.  B) ICC showing adhered monocytes stained with anti-human 
CD14+ FITC. Magnification x 40. B) Psoriasis n=8 Healthy n=8. Unpaired t 
test *: p<0.05 from relevant controls. 
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3.3.7 CX3CL1 blocking has a greater effect on psoriasis monocyte adhesion 
CX3CL1 selectively mediates CD16+ monocyte adhesion as opposed to CD14+.  
Psoriasis patients have elevated peripheral CD16+ monocytes and because 
psoriasis lesions show CD16+ migration, we proposed that blocking CX3CL1 
would have greater effect on psoriasis monocyte adhesion when compared to 
healthy monocyte adhesion.  HUVEC were stimulated with TNFα with and w/o an 
antibody blocking CX3CL1.  Blocking CX3CL1 had a greater effect on psoriasis 
monocyte adhesion as proposed.   
 
 
 
Figure 34: Blocking CX3CL1 has greater effect on psoriasis monocyte 
adherence 
Psoriasis and heathy monocytes were allowed to adhere to TNFα 
stimulated HUVEC with and without CX3CL1 blocking.  A) The number of 
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adhered monocytes were then counted and expressed as a percent 
reduction in adherence when compared to positive control (TNFα 
stimulated). Unpaired t test *: p<0.05. B) The number of adhered monocytes 
following CX3CL1 blocking was visualised for psoriasis and healthy 
monocytes.  
3.4  Discussion 
IL-36γ is an IL-1 family member cytokine with a growing importance in the 
pathology of psoriasis (D'Erme et al., 2015). Various myeloid cells are thought to 
contribute to the pathology of psoriasis, including resident macrophages (Clark 
and Kupper, 2006).   
As IL-36γ stimulation of macrophages had not been fully characterised, we first 
established to confirm the presence of the IL-36R on macrophages (Figure 26).  
Once identified, the functional significance of the IL-36R was then confirmed by 
performing dose response curves to quantify TNFα secretion driven by IL-36 
treatment of the macrophages. Following 48 hr stimulation, both 10 and 50 ng/ml 
of IL-36γ induced significant TNFα secretion from healthy macrophages, so these 
concentrations were chosen for future stimulations (Figure 27).  IFNγ is known to 
activate macrophages, so this was investigated as a potential priming agent for 
IL-36γ 10ng/ml.  Greatest statistical significance in TNFα induction by the 
macrophages was found when priming with IFNγ 20 ng/ml.  
Myeloid cells, both infiltrating and resident are capable of secreting IL-23 and thus 
contributing to the IL-23/IL-17 axis, prominent in driving psoriasis (Zaba et al., 
2009).  Within psoriasis lesions, monocytes, M1 macrophages and dendritic cells 
all show positive staining for IL-23 (Yawalkar et al., 2009).   
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With IL-36γ being secreted by damaged keratinocytes, its downstream actions 
on resident myeloid cells such as macrophages could represent a key step in 
both early and chronic lesion pathology. While IL-36 has been shown to induce 
IL-23 secretion from dendritic cells, we report similar findings in macrophages 
(Vigne et al., 2011).  Interestingly, other prominent inflammatory cytokines within 
the lesion, TNFα, IL-17 and IL-1, had little or no ability to induce IL-23 when 
compared to IL-36γ (Figure 29).   
Psoriasis macrophages secreted significantly more IL-23 following IL-36γ 
stimulation than healthy patient macrophages.  Our findings also compliment a 
recent mouse model of skin inflammation showing that overproduction of IL-36 
by keratinocytes induces IL-23 secretion from macrophages, and that this is the 
driving force behind the pathology to a greater extent than IL-36 actions on 
dendritic cells (Ogawa et al., 2016). Moreover, the imiquimod induced mouse 
psoriasis model, is dependent on MyD88 signalling in macrophages and 
monocytes, hinting that TIR signalling as that which can be induced by IL-1 
members is key (Costa et al., 2017).  
IL-36γ-induced secretion of IL-23 was enhanced when macrophages were 
primed and activated with IFNγ. IFNγ enhancement of IL-23 secretion from 
macrophages has previously also been shown with other TIR agonists (van de 
Wetering et al., 2009, Butchar et al., 2008).  IFNγ has also been shown to induce 
an inflammatory phenotype characteristic of psoriasis when injected into the skin 
and serum levels correlate with disease severity (Abdallah et al., 2009, Johnson-
Huang et al., 2012).  Within lesions this could also hypothetically be an IL-36 
mediated effect given that IL-36 has been shown to induce IFNγ from CD4+ T 
cells (Vigne et al., 2012).  Synergy with IFNγ was a prominent feature for IL-36 
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induced responses but not for IL-17, TNFα, or the similar IL-1 family member and 
TIR agonist IL-1.   Previous reports have also shown that IL-1-induced TNFα 
secretion from macrophages is not enhanced by IFNγ (Ikejima et al., 1990).  
TNFα was prominently induced in macrophages by IL-36γ (Figure 29), which is 
in line with a recent paper, showing IL-36γ upregulating TNFα gene expression 
in microglial macrophages (Bozoyan et al., 2015).   Similar to the data on IL-23 
production, psoriasis macrophages secreted significantly more TNFα when 
stimulated with IL-36γ and when untreated. IL-36γ induced TNFα from resident 
macrophages would be then well placed to potently stimulate the surrounding 
tissues to further orchestrate the immune response. Endothelial activation and 
thus increased leukocyte migration is central to lesion development.  TNFα has 
a documented role within psoriasis immunology and several biologic treatments 
targeting TNFα have proved successful (Yost and Gudjonsson, 2009). 
TNFα is known to be an inflammatory activator of the endothelium and we show 
that IL-36 induced macrophage supernatant is a potent activator of the 
endothelium, with the adhesion molecule ICAM-1 showing upregulation (Meekins 
et al., 1994) (Figures 30-32). In accordance with enhanced cytokine secretion 
seen from psoriasis macrophages, their supernatant was able to achieve 
increased endothelial activation when compared to healthy supernatant (Figures 
31-32).  Whilst, TNFα is a known activator of the endothelium, IL-36γ is likely to 
induce other cytokines from macrophages which could induce similar effects, so 
deciphering the most important activator of the endothelium within the 
supernatant requires future study.  
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Enhanced cytokine secretion from psoriasis macrophages is characteristic of the 
exaggerated immune response associated with psoriasis (Harden et al., 2015). 
Previous studies have also shown psoriasis macrophages secreting increased 
IL-8, IL-1α/β and TNFα at baseline, in agreement with our secretion findings 
(Okubo and Koga, 1998, Nishibu et al., 1999).  Numerous mutations are thought 
to exist in psoriasis cells which lead to dysregulated immune responses (Harden 
et al., 2015).  IL-36γ signals through NF-κB, and various mutations are thought 
to exist within psoriasis cells that lead increased activity of NF-κB such as 
CARD14 (Harden et al., 2015, Sun et al., 2013).   Whilst damaged keratinocytes 
may be a potential source of IL-36γ, macrophages within lesions also show 
positive IL-36 staining, and lung macrophages are known to secrete IL-36γ in 
microparticles following LPS stimulation (Boutet et al., 2016, Kovach et al., 2016).  
Potential autocrine actions of IL-36 with macrophages thus require further study.  
We report that following stimulation of HUVEC with IL-36-induced macrophage 
supernatant, monocytes show significantly increased adherence.  Supernatant 
from psoriasis macrophages had increased ability to stimulate the endothelium, 
as quantified by ICAM-1 upregulation, and monocytes showed increased 
adhesion when compared to EC stimulated with healthy macrophage supernatant 
(Figures 31-33).  Interestingly, regardless of the stimulus, psoriasis monocytes 
showed increased adhesion to both unstimulated and stimulated EC (Figure 33).  
Circulating monocytes in psoriasis patients are known to form aggregates with 
activated platelets which increases adhesion propensity of the monocytes to 
endothelial cells (Pamuk et al., 2009, Golden et al., 2015).   Platelet binding also 
induces monocyte polarization to the inflammatory CD16+ subtype (Passacquale 
et al., 2011).  Interestingly, platelet binding also enhances IL-23 secretion from 
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monocytes, while CD16+ monocytes have also shown to secrete increased levels 
of IL-23 (Scull et al., 2010, Rossol et al., 2012).  
CX3CL1(fractalkine) is a chemokine that exists in both soluble and in a 
membrane bound forms and  specifically mediates CD16+ monocyte 
transendothelial migration, as opposed to CD14+ (Ancuta et al., 2003).  In 
psoriasis and other chronic inflammatory diseases such as rheumatoid arthritis 
and Crohn’s disease, there is an elevation in peripheral CD16+ monocytes 
(Golden et al., 2015, Koch et al., 2010, Radwan et al., 2016).  Thus, it could be 
hypothesised that blocking CX3CL1 would have greater efficacy on psoriasis 
monocytes due their increased numbers of CD16+.   CX3CL1 is upregulated 
within psoriasis lesion endothelial cells and soluble CX3CL1 correlates with PASI 
(Congjun et al., 2015, Echigo et al., 2004).  Psoriasis lesions also show heavy 
staining for CD16+ monocytes, indicating their transmigration to the tissues is key 
(Golden et al., 2015).  In a recent imiquimod mouse model of psoriasis, mice with 
KO CX3CLR1 showed decreased dermal inflammation and this was attributed to 
a decreased in M1 macrophages (Morimura et al., 2016). An allele in CX3CR1 
which results in leukocytes having less affinity for CX3CL1 is associated with a 
protective function in CVD (McDermott et al., 2003).  This allele is statistically 
lower in psoriasis patients when compared to healthy controls, suggesting a 
possible reason for decreased CX3CL1-CX3CR1 interactions seen in healthy 
monocytes when compared to psoriasis (Plant et al., 2006).  A monoclonal 
antibody targeting CX3CL1,KANAb001 (E6011), has shown positive results for 
treating RA and is currently at Phase II (Imai and Yasuda, 2016). 
The findings presented here also may have implications for a host of other 
diseases. Crohn’s disease shares many similar immunological aspects with 
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psoriasis, namely the IL-23/IL-17 axis, but also, a potential role for IL-36 in 
Crohn’s disease is becoming apparent (Siakavellas and Bamias, 2012, Boutet et 
al., 2016).  Interestingly, angiogenesis is also a feature of Crohn’s disease (Alkim 
et al., 2015).  Similarly, IL-36 has been implicated in mouse models of respiratory 
infection and again linked to the IL-23/IL-17 axis, and furthermore, angiogenesis 
is associated with chronic lung inflammation (Kovach et al., 2015, Kovach et al., 
2017, Matarese and Santulli, 2012).  Whilst IL-36 is yet to be fully implicated in 
COPD, cigarette smoke, the causative agent of COPD, induces IL-36 from 
bronchial epithelial cells (Parsanejad et al., 2008).  COPD is heavily associated 
with Th17 cell driven inflammation (Alcorn et al., 2010).  Psoriasis is emerging as 
a risk factor for COPD, and furthermore, mouse models of psoriasis show 
enhanced airway inflammation attributed to IL-23 signalling (Dreiher et al., 2008, 
Li et al., 2015, Nadeem et al., 2017).  IL-36γ has recently been implicated in 
periodontitis, another disease in which the IL-23/IL-17 axis has gained 
momentum in recent years (Kurşunlu et al., 2015, Huynh et al., 2016, Ohyama et 
al., 2009). 
Psoriasis is an independent risk factor for atherosclerosis (Miller et al., 2013, 
Ogdie et al., 2014). While the role of IL-36 in atherosclerosis development is 
presently unknown, potential effects based on our findings could be 
hypothesized.  Macrophages and TNFα have an established role in 
atherosclerosis (Tam et al., 2014, Kleinbongard et al., 2010, Moore et al., 2013). 
In the vasculature, TNFα alters both the vascular smith muscle and endothelial 
function (Kleinbongard et al., 2010).  
Recently, IL-23 has independently been associated with atherosclerosis disease 
progression with increased plasma levels correlating with mortality (Abbas et al., 
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2015). The role of IL-17 in atherosclerosis remains controversial (Gong et al., 
2015).    
 
 
Figure 35: Proposed mechanism of IL-36 actions on monocytes in the 
dermal compartment 
Injury in the skin leads to IL-36 secretion.  IL-36 stimulates tissue resident 
macrophages.  IL-36 induces TNFα from monocytes and macrophages. A 
combination of IL-36 and TNFα activate the endothelium and results in 
adhesion molecule/chemokine expression and angiogenesis.  Circulating 
monocytes and T cells are recruited to the dermis and IL-36 induces IL-23 
secretion from monocytes.  IL-23 helps maintain the Th17 T cell phenotype 
typically found in psoriasis. 
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4) Endothelial progenitor cells as a source of 
psoriasis EC 
 
Hypothesis  
I hypothesise that similar to endothelial cells from psoriasis patients, endothelial 
cells derived from progenitor cells will have exaggerated immune responses, 
which could lead to enhanced atherosclerosis risk or development. 
 
The vasculature is of central importance with respect to delivery, exchange, 
removal of gases, nutrients and regulatory cells to tissues and organs (Vanhoutte 
and Scott-Burden, 1994).   Endothelial progenitor cells (EPC) have a role in 
regeneration of the endothelial lining of the blood vessels (Yoder, 2012). Since 
the discovery of novel endothelial progenitor cells populations 20 years ago, 
researchers have become interested in the therapeutic potential of these novel 
cells with respect to repair and regeneration of the systemic vasculature (Yoder, 
2012).  
EPCs can be isolated from both bone marrow and blood.  Due to the difficulties 
in isolating mature ECs from within the blood vessels (patient subsets, lack of 
tissue, cost), the use of EPC from blood to study the function of ECs in certain 
disease subsets have become popular. Due to difficulties in acquiring psoriasis 
biopsies encountered within this research project, we attempted to isolate EPCs 
from consented psoriasis patients’ blood samples.  
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However, the isolation of EPCs from blood has been met with numerous 
controversies over methodology and phenotype (Yoder, 2012).  A definitive 
marker for EPCs is yet to be identified, and it is now thought previous studies 
which described EPC isolation from blood, may have described similar cells 
characteristically to EPCs, which will be described next, including the method we 
attempted. 
 
 
4.1 Common methods to isolate EPC 
 
4.1.1 Fibronectin coating 
We decided to isolate EPCs using the fibronectin coating method, which has been 
previously described (Hill et al., 2003). Briefly, 15ml of blood was collected in 
heparin tubes. Blood was diluted 1:1 with PBS and layered over Lymphoprep 
density gradient medium by centrifuging at 800 x g for 20 mins. The mononuclear 
layer was subsequently isolated and PBMCs resuspended at concentration of 1 
x 106 cells/ml in complete Promocell endothelial media described previously.  
Flasks were coated in fibronectin (Sigma) 1 µg/cm2 and allowed to air dry 
overnight.  PMBCs were then left to adhere for 48 hr and non-adherent cells were 
subsequently removed. Cells were then left for up to 30 days/ until EPC appeared 
with media being changed every 3 days.  
Between 10-30 days, cells did not appear endothelial-like but more like 
macrophages in appearance.  These cells had no proliferative capacity following 
passaging.  
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Figure 36: Isolated mononuclear cells plated on fibronectin 
Isolated cells, with a macrophage-like appearance following 20 days of 
culture.  Magnification x 20.  
 
Figure 37: Example of macrophage morphology in long term culture, taken 
from (Anzinger et al., 2010). 
 
Despite others having claimed to have grown EPC from the fibronectin method 
there have been numerous controversies surrounding this method. Circulating 
  
112 
platelets are known to contaminate isolated PBMCs and release membrane 
particles that bind to the ‘alleged’ EPC. Platelet membranes and ECs have many 
surface proteins in common. It is thus possible that all adhered cells, including 
those of myeloid lineage could express EC proteins on their cell surface (Prokopi 
et al., 2009).  Monocytes from PBMCs are also isolated from blood by binding to 
fibronectin. Monocytes cultured with endothelial growth factors such as VEGF 
express numerous EC surface proteins such as CD31 and vWF, and show eNOS 
upregulation (Schmeisser et al., 2003).  It is now thought that EPCs isolated using 
the fibronectin method, resemble monocytes treated with VEGF and are now 
defined as ‘circulating angiogenic cells’ (CACs) (Rehman et al., 2003). 
4.1.2 EPC isolation using FACS 
Several surface markers have been proposed for circulating EPC.  CD34 and 
CD133 have been used to isolate EPC, but the expression of these proteins is 
not restricted to EPC and are expressed by all hematopoietic stem and progenitor 
cells (Peichev et al., 2000).  A number of hematopoietic stem and progenitor cell 
subsets have been described as displaying pro-angiognenic activity (Wara et al., 
2011). Thus, cells isolated using cell sorting may also not be ‘true’ EPC.  
4.1.3 Collagen method 
A similar method to the previously described fibronectin method, substitutes type 
1 collagen for fibronectin (Ingram et al., 2004).  After 2-3 weeks, colonies of EPC 
begin to appear.  These colonies have great proliferative capacity when 
compared to the other two methods (Yoder et al., 2007).  EPC isolated using this 
method display all EC surface markers and have other EC characteristics such 
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as being able to form capillary-like structures when on Matrigel (Cheng et al., 
2011, Melero-Martin et al., 2007). 
4.2 Conclusion 
 
The isolating and culture of EPC remains controversial, due to differing results in 
the literature over methodology.  With respect to using EPC as a model to 
represent EC from diseased patients, this should thus be treated with caution.   
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5) Conclusions and future work 
 
Endothelial cells play an essential role in tissue inflammation in diseases such as 
psoriasis.  Endothelial cells and their activation is also crucial to the pathology of 
atherosclerosis. With psoriasis being an independent risk factor for 
atherosclerosis, research into endothelial function in psoriasis patients is of great 
importance as it could provide mechanistic information with beneficial therapeutic 
potential.  The exact mechanisms of why psoriasis is a risk factor for 
atherosclerosis are still hotly debated.  A combination of both systemic and 
genetic factors is likely to contribute to the increased risk. The data presented in 
this thesis and associated publications suggest that the novel cytokine IL-36 has 
a role in endothelial function and may contribute to psoriatic endothelial activation 
both directly and indirectly.  
Conclusions: 
• The psoriasis relevant cytokine IL-36γ is an activator of both the 
macrovascular and microvascular human endothelium 
This finding potentially could enhance psoriatic skin inflammation by 
enhancing immune cell recruitment.  IL-36 activation of the vascular 
endothelium within vessels could also have importance in promoting 
atherosclerosis development and progression. 
• IL-36γ stimulated EC secrete CCL20 which recruits T cells 
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CCL20 is a chemoattractant for T cells with a known function in psoriasis 
pathology.  Endothelial cell expression of this chemokine may aid this 
chemotactic gradient.  
• IL-36γ is an activator of macrophages and induces inflammatory 
cytokine secretion such as IL-23 and TNFα, both of which are of 
pathological importance in psoriasis 
Both IL-23 and TNFα have been shown to have pathological importance 
within psoriasis lesions and biological blockage of these molecules has 
proved successful for treating psoriasis symptoms.  IL-36 is known to 
induce IL-23 from dendritic cells, but I am the first to report similar findings 
in macrophages.  In accordance with this, macrophages within psoriasis 
lesions shown IL-23 staining.  The IL-23/Th17 pathway is also starting to 
gain attention in atherosclerosis, which is of interest given the psoriasis-
atherosclerosis link.  
• Other cytokines with known importance in psoriasis such as IL-17, 
TNF and IL-1 were unable to induce IL-23 from macrophages to the 
same degree as IL-36γ 
TIR agonists such as LPS have a known function of upregulating IL-23 
secretion, and TIR cytokine agonists such as IL-36 are known to 
upregulate IL-23 in dendritic cells. We report that other cytokines that are 
not TIR agonists, such as IL-17 and TNFα have no ability to induce IL-23, 
while similar family member and fellow TIR agonist IL-1 had reduced ability 
compared to IL-36γ. This highlights the potential role of IL-36 in regulating 
the IL-23/IL-17 axis.  
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• Psoriasis macrophages show enhanced secretion of IL-23 and TNFα 
cytokines when compared to healthy 
Many genetic predispositions that effect immune function are known to 
exist in psoriasis cells.  We report that psoriasis macrophages secrete 
enhanced levels of inflammatory mediators when compared to healthy 
macrophages.  Overexpression of these mediators is in line and 
characteristic of the over exaggerated immune response associated with 
psoriasis.  Functionally, increased secretion of IL-23 could lead to 
increased maintenance of the Th17 pathway. As stated above, Th17 
pathway is well documented in psoriasis, but also is a growing area of 
interest in atherosclerosis.  
• Psoriasis monocytes show increased adherence to both a stimulated 
and resting endothelium 
Previous research has shown psoriasis patients’ monocytes are activated 
and often form aggregates with other cells such as platelets, which primes 
them for activation. We report that psoriasis monocytes show increased 
adhesions to both resting and stimulated endothelium.  This finding could 
have implications for both psoriasis in the form of the immune cell 
recruitment to the skin, but also atherosclerosis.  
• CX3CL1 blocking has a greater effect on psoriasis monocyte 
adhesion then healthy monocyte adhesion 
Psoriasis patients have an elevation in CD16+ monocytes.  CX3CL1 is a 
selective chemokine for CD16+ monocyte adhesion.  Psoriasis plaques 
also show staining for CD16+ monocytes. We report blocking CX3CL1 
reduces psoriasis adhesion significantly more than healthy monocyte 
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adhesion in line with the increased CD16+ population associated with 
psoriasis.  
 
5.1 Future work 
 
IL-36 in murine models of atherosclerosis 
We have presented several possible potential mechanisms of how IL-36 may 
contribute to atherosclerosis. Both endothelial and macrophage activation 
represent key pathological components of the disease.  A monoclonal antibody 
targeting IL-36 has long been suggested for treating psoriasis (Wolf and Ferris, 
2014). It is thus crucial to explore the role of IL-36 in atherosclerosis murine 
models to determine its role if any in atherosclerosis. At present, links between 
IL-36 and other key components of atherosclerosis such as smooth muscle cells 
and foam cells are unknown. 
Both IL-23 and IL-17 are starting to gain attention in regards to atherosclerosis, 
with paradoxical findings reported, given IL-36’s relation with this axis, this 
research must receive attention.  Despite both IL-17 and IL-23 having paradoxical 
findings reported in atherosclerosis, psoriasis patients on both inhibitors for these 
cytokines have had no abnormalities in cardiovascular events.  
IL-36R ‘knockout humans’ and atherosclerosis 
 ‘Born in Bradford’ is a community based initiative to exome sequence 2162 
British Pakistani individuals. A recent study identified 6 individuals with a biallelic 
missense changes in the IL1RL1 (gene which encodes the IL-36R). Further 
studies confirmed this missense change to be deleterious (Mahil et al., 2017).   
  
118 
However, the 6 individuals had no history of abnormalities with respect to immune 
function.  This suggests blockade of IL-36 could be a therapeutic target.  It would 
be thus interesting to identify further individuals with non-functioning IL-36R and 
study epidemiology with respect to atherosclerosis.  
DITRA and atherosclerosis 
Whilst epidemiological research into psoriasis and atherosclerosis is well 
recognised, the CVD for specific psoriasis subtypes is under-researched.  It is 
presently not known if GPP patients and more specifically DITRA have an 
elevated risk for CVD risk.  This again would add to the knowledge regarding IL-
36 and atherosclerosis. 
Potential role of platelets and IL-36 
Platelet activation and subsequent monocyte/platelet aggregates are known to 
exist in psoriasis peripheral blood (Golden et al., 2015). Platelets also have a 
documented role in atherosclerosis (Lievens and von Hundelshausen, 2011). 
Interestingly it is not known if platelets express the IL-36R of if platelets secrete 
IL-36.  Platelets are known to express the similar IL-1 receptor and IL-1β has 
agonistic activating properties to platelets. Platelets also are a potential source of 
IL-1β (Brown et al., 2013).  Thus, the potential relationship between IL-36 and 
platelets could be multifaceted.   
Functional significance of psoriasis patients’ endothelial cells 
Numerous genetic predispositions that are linked to immune function are 
associated with psoriasis, and importantly, these are thought to lead to 
exaggerated inflammatory responses with psoriasis cells.  Future work should 
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attempt to isolate endothelial cells from psoriasis patients and subject them to 
various models linked to atherosclerosis to put the CVD risk into context.   
IL-36, DITRA and diabetes 
Diabetes is as a result of endothelial dysfunction (Tabit et al., 2010).  Systemic 
cytokine stimulation is thought to cause endothelial dysfunction. With psoriasis 
being associated with diabetes, there would be also great value in study 
mechanisms behind IL-36 and diabetes and also the epidemiology of DITRA and 
diabetes.  
  
  
120 
 
6) References 
 
ABBAS, A., GREGERSEN, I., HOLM, S., DAISSORMONT, I., BJERKELI, V., 
KROHG-SORENSEN, K., SKAGEN, K. R., DAHL, T. B., RUSSELL, D., 
ALMAS, T., BUNDGAARD, D., ALTEHELD, L. H., RASHIDI, A., DAHL, C. 
P., MICHELSEN, A. E., BIESSEN, E. A., AUKRUST, P., HALVORSEN, B. 
& SKJELLAND, M. 2015. Interleukin 23 levels are increased in carotid 
atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. 
Stroke, 46, 793-9. 
ABDALLAH, M. A., ABDEL-HAMID, M. F., KOTB, A. M. & MABROUK, E. A. 2009. 
Serum interferon-gamma is a psoriasis severity and prognostic marker. 
Cutis, 84, 163-8. 
ABEL, E. A., DICICCO, L. M., ORENBERG, E. K., FRAKI, J. E. & FARBER, E. 
M. 1986. Drugs in exacerbation of psoriasis. J Am Acad Dermatol, 15, 
1007-22. 
AINSCOUGH, J. S., MACLEOD, T., MCGONAGLE, D., BRAKEFIELD, R., 
BARON, J. M., ALASE, A., WITTMANN, M. & STACEY, M. 2017. 
Cathepsin S is the major activator of the psoriasis-associated 
proinflammatory cytokine IL-36γ. Proceedings of the National Academy of 
Sciences, 114, E2748-E2757. 
AKDIS, M., AAB, A., ALTUNBULAKLI, C., AZKUR, K., COSTA, R. A., CRAMERI, 
R., DUAN, S., EIWEGGER, T., ELJASZEWICZ, A., FERSTL, R., FREI, R., 
GARBANI, M., GLOBINSKA, A., HESS, L., HUITEMA, C., KUBO, T., 
KOMLOSI, Z., KONIECZNA, P., KOVACS, N., KUCUKSEZER, U. C., 
MEYER, N., MORITA, H., OLZHAUSEN, J., O'MAHONY, L., PEZER, M., 
PRATI, M., REBANE, A., RHYNER, C., RINALDI, A., SOKOLOWSKA, M., 
STANIC, B., SUGITA, K., TREIS, A., VAN DE VEEN, W., WANKE, K., 
WAWRZYNIAK, M., WAWRZYNIAK, P., WIRZ, O. F., ZAKZUK, J. S. & 
AKDIS, C. A. 2016. Interleukins (from IL-1 to IL-38), interferons, 
transforming growth factor β, and TNF-α: Receptors, functions, and roles 
in diseases. Journal of Allergy and Clinical Immunology, 138, 984-1010. 
  
121 
AKMAN, A., YILMAZ, E., MUTLU, H. & OZDOGAN, M. 2009. Complete remission 
of psoriasis following bevacizumab therapy for colon cancer. Clin Exp 
Dermatol, 34, e202-4. 
ALASE, A. A., EL-SHERBINY, Y. M., VITAL, E. M., TOBIN, D. J., TURNER, N. 
A. & WITTMANN, M. 2015. IFNλ Stimulates MxA Production in Human 
Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent 
Mechanism. Journal of Investigative Dermatology, 135, 2935-2943. 
ALCORN, J. F., CROWE, C. R. & KOLLS, J. K. 2010. TH17 cells in asthma and 
COPD. Annu Rev Physiol, 72, 495-516. 
ALKIM, C., ALKIM, H., KOKSAL, A. R., BOGA, S. & SEN, I. 2015. Angiogenesis 
in Inflammatory Bowel Disease. International Journal of Inflammation, 
2015, 970890. 
AMENTO, E. P., EHSANI, N., PALMER, H. & LIBBY, P. 1991. Cytokines and 
growth factors positively and negatively regulate interstitial collagen gene 
expression in human vascular smooth muscle cells. Arterioscler Thromb, 
11, 1223-30. 
ANCUTA, P., RAO, R., MOSES, A., MEHLE, A., SHAW, S. K., LUSCINSKAS, F. 
W. & GABUZDA, D. 2003. Fractalkine Preferentially Mediates Arrest and 
Migration of CD16(+) Monocytes. The Journal of Experimental Medicine, 
197, 1701-1707. 
ANG, A. H., TACHAS, G., CAMPBELL, J. H., BATEMAN, J. F. & CAMPBELL, G. 
R. 1990. Collagen synthesis by cultured rabbit aortic smooth-muscle cells. 
Alteration with phenotype. Biochemical Journal, 265, 461-469. 
ANTONIOU, E. A., KOUTSOUNAS, I., DAMASKOS, C. & KOUTSOUNAS, S. 
2016. Remission of Psoriasis in a Patient with Hepatocellular Carcinoma 
Treated with Sorafenib. In Vivo, 30, 677-80. 
ANZINGER, J. J., CHANG, J., XU, Q., BUONO, C., LI, Y., LEYVA, F. J., PARK, 
B. C., GREENE, L. E. & KRUTH, H. S. 2010. Native low-density lipoprotein 
uptake by macrophage colony-stimulating factor-differentiated human 
macrophages is mediated by macropinocytosis and micropinocytosis. 
Arterioscler Thromb Vasc Biol, 30, 2022-31. 
APOSTOLAKIS, S., AMANATIDOU, V., PAPADAKIS, E. G. & SPANDIDOS, D. 
A. 2009. Genetic diversity of CX3CR1 gene and coronary artery disease: 
new insights through a meta-analysis. Atherosclerosis, 207, 8-15. 
  
122 
APOSTOLAKIS, S. & SPANDIDOS, D. 2013. Chemokines and atherosclerosis: 
focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin, 34, 1251-
1256. 
ARMSTRONG, A. W., VOYLES, S. V., ARMSTRONG, E. J., FULLER, E. N. & 
RUTLEDGE, J. C. 2011. A tale of two plaques: convergent mechanisms 
of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp 
Dermatol, 20, 544-9. 
AZIZ, K. E. & WAKEFIELD, D. 1996. Modulation of Endothelial Cell Expression 
of ICAM-1, E-Selectin, and VCAM-1 by β-Estradiol, Progesterone, and 
Dexamethasone. Cellular Immunology, 167, 79-85. 
BAE, O.-N., NOH, M., CHUN, Y.-J. & JEONG, T. C. 2015. Keratinocytic Vascular 
Endothelial Growth Factor as a Novel Biomarker for Pathological Skin 
Condition. Biomolecules & Therapeutics, 23, 12-18. 
BALATO, A., LEMBO, S., MATTII, M., SCHIATTARELLA, M., MARINO, R., DE 
PAULIS, A., BALATO, N. & AYALA, F. 2012. IL-33 is secreted by psoriatic 
keratinocytes and induces pro-inflammatory cytokines via keratinocyte 
and mast cell activation. Exp Dermatol, 21, 892-4. 
BALIWAG, J., BARNES, D. H. & JOHNSTON, A. 2015. Cytokines in psoriasis. 
Cytokine, 73, 342-50. 
BARKER, J. N. 1991. The pathophysiology of psoriasis. The Lancet, 338, 227-
230. 
BATA-CSÖRGÖ, Z. & SZELL, M. 2012. The psoriatic keratinocytes. Expert 
Review of Dermatology, 7, 473-481. 
BERTIN, J., WANG, L., GUO, Y., JACOBSON, M. D., POYET, J. L., 
SRINIVASULA, S. M., MERRIAM, S., DISTEFANO, P. S. & ALNEMRI, E. 
S. 2001. CARD11 and CARD14 are novel caspase recruitment domain 
(CARD)/membrane-associated guanylate kinase (MAGUK) family 
members that interact with BCL10 and activate NF-kappa B. J Biol Chem, 
276, 11877-82. 
BETTELLI, E., CARRIER, Y., GAO, W., KORN, T., STROM, T. B., OUKKA, M., 
WEINER, H. L. & KUCHROO, V. K. 2006. Reciprocal developmental 
pathways for the generation of pathogenic effector TH17 and regulatory T 
cells. Nature, 441, 235-8. 
  
123 
BISSONNETTE, R., CADEMARTITI, F., MAFFEI, E. & TARDIF, J. C. 2017. 
Increase in coronary atherosclerosis severity and the prevalence of 
coronary artery mixed plaques in patients with psoriasis. British Journal of 
Dermatology, 176, 800-802. 
BLANKENBERG, S., BARBAUX, S. & TIRET, L. 2003. Adhesion molecules and 
atherosclerosis. Atherosclerosis, 170, 191-203. 
BLONSKA, M. & LIN, X. 2011. NF-kappaB signaling pathways regulated by 
CARMA family of scaffold proteins. Cell Res, 21, 55-70. 
BLUMBERG, H., DINH, H., DEAN, C., JR., TRUEBLOOD, E. S., BAILEY, K., 
SHOWS, D., BHAGAVATHULA, N., ASLAM, M. N., VARANI, J., TOWNE, 
J. E. & SIMS, J. E. 2010. IL-1RL2 and its ligands contribute to the cytokine 
network in psoriasis. J Immunol, 185, 4354-62. 
BOCHKOV, Y. A., HANSON, K. M., KELES, S., BROCKMAN-SCHNEIDER, R. 
A., JARJOUR, N. N. & GERN, J. E. 2010. Rhinovirus-induced modulation 
of gene expression in bronchial epithelial cells from subjects with asthma. 
Mucosal Immunol, 3, 69-80. 
BOEHNCKE, S., THACI, D., BESCHMANN, H., LUDWIG, R. J., ACKERMANN, 
H., BADENHOOP, K. & BOEHNCKE, W. H. 2007. Psoriasis patients show 
signs of insulin resistance. British Journal of Dermatology, 157, 1249-
1251. 
BOEHNCKE, W.-H., BOEHNCKE, S., TOBIN, A.-M. & KIRBY, B. 2011. The 
‘psoriatic march’: a concept of how severe psoriasis may drive 
cardiovascular comorbidity. Experimental Dermatology, 20, 303-307. 
BOUTET, M. A., BART, G., PENHOAT, M., AMIAUD, J., BRULIN, B., 
CHARRIER, C., MOREL, F., LECRON, J. C., ROLLI-DERKINDEREN, M., 
BOURREILLE, A., VIGNE, S., GABAY, C., PALMER, G., LE GOFF, B. & 
BLANCHARD, F. 2016. Distinct expression of interleukin (IL)-36alpha, 
beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, 
rheumatoid arthritis and Crohn's disease. Clin Exp Immunol, 184, 159-73. 
BOZOYAN, L., DUMAS, A., PATENAUDE, A. & VALLIÈRES, L. 2015. 
Interleukin-36γ is expressed by neutrophils and can activate microglia, but 
has no role in experimental autoimmune encephalomyelitis. Journal of 
neuroinflammation, 12, 173. 
  
124 
BRANEN, L., HOVGAARD, L., NITULESCU, M., BENGTSSON, E., NILSSON, J. 
& JOVINGE, S. 2004. Inhibition of tumor necrosis factor-alpha reduces 
atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb 
Vasc Biol, 24, 2137-42. 
BRAVERMAN, I. M. 1989. Ultrastructure and organization of the cutaneous 
microvasculature in normal and pathologic states. J Invest Dermatol, 93, 
2s-9s. 
BRAVERMAN, I. M. & SIBLEY, J. 1982. Role of the microcirculation in the 
treatment and pathogenesis of psoriasis. J Invest Dermatol, 78, 12-7. 
BRAVERMAN, I. M. & YEN, A. 1977. Ultrastructure of the capillary loops in the 
dermal papillae of psoriasis. J Invest Dermatol, 68, 53-60. 
BRIDGEWOOD, C., STACEY, M., ALASE, A., LAGOS, D., GRAHAM, A. & 
WITTMANN, M. 2017. IL-36gamma has proinflammatory effects on 
human endothelial cells. Exp Dermatol, 26, 402-408. 
BROGAN, I. J., KHAN, N., ISAAC, K., HUTCHINSON, J. A., PRAVICA, V. & 
HUTCHINSON, I. V. 1999. Novel polymorphisms in the promoter and 5' 
UTR regions of the human vascular endothelial growth factor gene. Hum 
Immunol, 60, 1245-9. 
BROWN, G. T., NARAYANAN, P., LI, W., SILVERSTEIN, R. L. & MCINTYRE, T. 
M. 2013. Lipopolysaccharide stimulates platelets through an IL-1β 
autocrine loop. Journal of immunology (Baltimore, Md. : 1950), 191, 
10.4049/jimmunol.1300354. 
BULL, R. H., BATES, D. O. & MORTIMER, P. S. 1992. Intravital video-
capillaroscopy for the study of the microcirculation in psoriasis. Br J 
Dermatol, 126, 436-45. 
BUTCHAR, J. P., PARSA, K. V. L., MARSH, C. B. & TRIDANDAPANI, S. 2008. 
IFNγ enhances IL-23 production during Francisella infection of human 
monocytes. FEBS letters, 582, 1044-1048. 
CABRIJAN, L., BATINAC, T., LENKOVIC, M. & GRUBER, F. 2009. The 
distinction between lesional and non-lesional skin in psoriasis vulgaris 
through expression of adhesion molecules ICAM-1 and VCAM-1. Med 
Hypotheses, 72, 327-9. 
  
125 
CAMPA, M., MANSOURI, B., WARREN, R. & MENTER, A. 2016. A Review of 
Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-
Severe Plaque Psoriasis. Dermatology and Therapy, 6, 1-12. 
CANNIZZARO, M., MITSUI, H., GONZALEZ, J., FUENTES-DUCULAN, J., 
SUAREZ-FARINAS, M. & KRUEGER, J. TNF-alpha and IL-17 can induce 
inflammatory changes in human aortic endothelial cells, potentially 
promoting early stages of atherogenesis in psoriasis.  JOURNAL OF 
INVESTIGATIVE DERMATOLOGY, 2014. S15-S15. 
CARGILL, M., SCHRODI, S. J., CHANG, M., GARCIA, V. E., BRANDON, R., 
CALLIS, K. P., MATSUNAMI, N., ARDLIE, K. G., CIVELLO, D., 
CATANESE, J. J., LEONG, D. U., PANKO, J. M., MCALLISTER, L. B., 
HANSEN, C. B., PAPENFUSS, J., PRESCOTT, S. M., WHITE, T. J., 
LEPPERT, M. F., KRUEGER, G. G. & BEGOVICH, A. B. 2007. A large-
scale genetic association study confirms IL12B and leads to the 
identification of IL23R as psoriasis-risk genes. Am J Hum Genet, 80, 273-
90. 
CARRIER, Y., MA, H. L., RAMON, H. E., NAPIERATA, L., SMALL, C., O'TOOLE, 
M., YOUNG, D. A., FOUSER, L. A., NICKERSON-NUTTER, C., COLLINS, 
M., DUNUSSI-JOANNOPOULOS, K. & MEDLEY, Q. G. 2011. Inter-
regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: 
implications in psoriasis pathogenesis. J Invest Dermatol, 131, 2428-37. 
CELLETTI, F. L., WAUGH, J. M., AMABILE, P. G., BRENDOLAN, A., HILFIKER, 
P. R. & DAKE, M. D. 2001. Vascular endothelial growth factor enhances 
atherosclerotic plaque progression. Nat Med, 7, 425-9. 
CHACKERIAN, A. A., OLDHAM, E. R., MURPHY, E. E., SCHMITZ, J., PFLANZ, 
S. & KASTELEIN, R. A. 2007. IL-1 receptor accessory protein and ST2 
comprise the IL-33 receptor complex. J Immunol, 179, 2551-5. 
CHAI, M., JI, Q., ZHANG, H., ZHOU, Y., YANG, Q., ZHOU, Y., GUO, G., LIU, W., 
HAN, W., YANG, L., ZHANG, L., LIANG, J., LIU, Y., SHI, D. & ZHAO, Y. 
2015. The Protective Effect of Interleukin-37 on Vascular Calcification and 
Atherosclerosis in Apolipoprotein E-Deficient Mice with Diabetes. J 
Interferon Cytokine Res, 35, 530-9. 
CHENG, G., LIAO, S., KIT WONG, H., LACORRE, D. A., DI TOMASO, E., AU, 
P., FUKUMURA, D., JAIN, R. K. & MUNN, L. L. 2011. Engineered blood 
  
126 
vessel networks connect to host vasculature via wrapping-and-tapping 
anastomosis. Blood, 118, 4740-9. 
CHI, H.-H., HUA, K.-F., LIN, Y.-C., CHU, C.-L., HSIEH, C.-Y., HSU, Y.-J., KA, S.-
M., TSAI, Y.-L., LIU, F.-C. & CHEN, A. 2017. IL-36 signaling facilitates 
activation of the NLRP3 inflammasome and IL-23/IL-17 axis in renal 
inflammation and fibrosis. Journal of the American Society of Nephrology, 
28, 2022-2037. 
CHIU, Y. G., SHAO, T., FENG, C., MENSAH, K. A., THULLEN, M., SCHWARZ, 
E. M. & RITCHLIN, C. T. 2010. CD16 (FcRgammaIII) as a potential marker 
of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther, 12, R14. 
CHO, M. L., KANG, J. W., MOON, Y. M., NAM, H. J., JHUN, J. Y., HEO, S. B., 
JIN, H. T., MIN, S. Y., JU, J. H., PARK, K. S., CHO, Y. G., YOON, C. H., 
PARK, S. H., SUNG, Y. C. & KIM, H. Y. 2006. STAT3 and NF-kappaB 
signal pathway is required for IL-23-mediated IL-17 production in 
spontaneous arthritis animal model IL-1 receptor antagonist-deficient 
mice. J Immunol, 176, 5652-61. 
CHOI, Y. S., PARK, J. A., KIM, J., RHO, S. S., PARK, H., KIM, Y. M. & KWON, 
Y. G. 2012. Nuclear IL-33 is a transcriptional regulator of NF-kappaB p65 
and induces endothelial cell activation. Biochem Biophys Res Commun, 
421, 305-11. 
CHUSTZ, R. T., NAGARKAR, D. R., POPOSKI, J. A., FAVORETO, S., JR., 
AVILA, P. C., SCHLEIMER, R. P. & KATO, A. 2011. Regulation and 
function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial 
cells. Am J Respir Cell Mol Biol, 45, 145-53. 
CLARK, R. A. & KUPPER, T. S. 2006. Misbehaving macrophages in the 
pathogenesis of psoriasis. J Clin Invest, 116, 2084-7. 
COIMBRA, S., OLIVEIRA, H., REIS, F., BELO, L., ROCHA, S., QUINTANILHA, 
A., FIGUEIREDO, A., TEIXEIRA, F., CASTRO, E., ROCHA-PEREIRA, P. 
& SANTOS-SILVA, A. 2010. Circulating adipokine levels in Portuguese 
patients with psoriasis vulgaris according to body mass index, severity and 
therapy. Journal of the European Academy of Dermatology and 
Venereology, 24, 1386-1394. 
CONGJUN, J., YANMEI, Z., HUILING, J., ZHEN, Y. & SHUO, L. 2015. Elevated 
Local and Serum CX3CL1(Fractalkine) Expression and Its Association 
  
127 
with Disease Severity in Patients with Psoriasis. Ann Clin Lab Sci, 45, 556-
61. 
COPPS, K. D. & WHITE, M. F. 2012. Regulation of insulin sensitivity by 
serine/threonine phosphorylation of insulin receptor substrate proteins 
IRS1 and IRS2. Diabetologia, 55, 2565-82. 
COSTA, S., MARINI, O., BEVILACQUA, D., DEFRANCO, A. L., HOU, B., 
LONARDI, S., VERMI, W., RODEGHER, P., PANATO, A., TAGLIARO, F., 
LOWELL, C. A., CASSATELLA, M. A., GIROLOMONI, G. & SCAPINI, P. 
2017. Role of MyD88 signaling in the imiquimod-induced mouse model of 
psoriasis: focus on innate myeloid cells. J Leukoc Biol, 102, 791-803. 
COUMBE, A. G., PRITZKER, M. R. & DUPREZ, D. A. 2014. Cardiovascular Risk 
and Psoriasis: Beyond the Traditional Risk Factors. The American Journal 
of Medicine, 127, 12-18. 
COWEN, E. W. & GOLDBACH-MANSKY, R. 2012. DIRA, DITRA, and New 
Insights Into Pathways of Skin Inflammation: What’s in a Name? Archives 
of dermatology, 148, 381-384. 
COX, A. J. & WATSON, W. 1972. Histological variations in lesions of psoriasis. 
Archives of dermatology, 106, 503-506. 
D'ERME, A. M., WILSMANN-THEIS, D., WAGENPFEIL, J., HOLZEL, M., 
FERRING-SCHMITT, S., STERNBERG, S., WITTMANN, M., PETERS, 
B., BOSIO, A., BIEBER, T. & WENZEL, J. 2015. IL-36[gamma] (IL-1F9) Is 
a Biomarker for Psoriasis Skin Lesions. J Invest Dermatol, 135, 1025-
1032. 
DE ANDREA, M., RAVERA, R., GIOIA, D., GARIGLIO, M. & LANDOLFO, S. 
2002. The interferon system: an overview. Eur J Paediatr Neurol, 6 Suppl 
A, A41-6; discussion A55-8. 
DE BOER, O. J., WAKELKAMP, I. M. M. J., PALS, S. T., CLAESSEN, N., BOS, 
J. D. & DAS, P. K. 1994. Increased expression of adhesion receptors in 
both lesional and non-lesional psoriatic skin. Archives of Dermatological 
Research, 286, 304-311. 
DE KORTE, J., SPRANGERS, M. A., MOMBERS, F. M. & BOS, J. D. 2004. 
Quality of life in patients with psoriasis: a systematic literature review. J 
Investig Dermatol Symp Proc, 9, 140-7. 
  
128 
DE OLIVEIRA, P. S. S., CARDOSO, P. R. G., LIMA, E. V. D. A., PEREIRA, M. 
C., DUARTE, A. L. B. P., PITTA, I. D. R., RÊGO, M. J. B. D. M. & PITTA, 
M. G. D. R. 2015. IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-
Type Psoriasis in Brazilian Patients. Mediators of Inflammation, 2015, 
819149. 
DETMAR, M. 2004. Evidence for vascular endothelial growth factor (VEGF) as a 
modifier gene in psoriasis. J Invest Dermatol, 122, xiv-xv. 
DETMAR, M., BROWN, L. F., CLAFFEY, K. P., YEO, K. T., KOCHER, O., 
JACKMAN, R. W., BERSE, B. & DVORAK, H. F. 1994. Overexpression of 
vascular permeability factor/vascular endothelial growth factor and its 
receptors in psoriasis. J Exp Med, 180, 1141-6. 
DETMAR, M., BROWN, L. F., SCHON, M. P., ELICKER, B. M., VELASCO, P., 
RICHARD, L., FUKUMURA, D., MONSKY, W., CLAFFEY, K. P. & JAIN, 
R. K. 1998. Increased microvascular density and enhanced leukocyte 
rolling and adhesion in the skin of VEGF transgenic mice. J Invest 
Dermatol, 111, 1-6. 
DEY, A. K., JOSHI, A. A., CHATURVEDI, A., LERMAN, J. B., ABERRA, T. M., 
RODANTE, J. A., TEAGUE, H. L., HARRINGTON, C. L., RIVERS, J. P., 
CHUNG, J. H., KABBANY, M. T., NATARAJAN, B., SILVERMAN, J. I., 
NG, Q., SANDA, G. E., SOROKIN, A. V., BAUMER, Y., GERSON, E., 
PRUSSICK, R. B., EHRLICH, A., GREEN, L. J., LOCKSHIN, B. N., 
AHLMAN, M. A., PLAYFORD, M. P., GELFAND, J. M. & MEHTA, N. N. 
2017. Association Between Skin and Aortic Vascular Inflammation in 
Patients With Psoriasis: A Case-Cohort Study Using Positron Emission 
Tomography/Computed Tomography. JAMA Cardiol, 2, 1013-1018. 
DI MEGLIO, P., DI CESARE, A., LAGGNER, U., CHU, C. C., NAPOLITANO, L., 
VILLANOVA, F., TOSI, I., CAPON, F., TREMBATH, R. C., PERIS, K. & 
NESTLE, F. O. 2011. The IL23R R381Q gene variant protects against 
immune-mediated diseases by impairing IL-23-induced Th17 effector 
response in humans. PLoS One, 6, e17160. 
DIAZ, B. V., LENOIR, M. C., LADOUX, A., FRELIN, C., DEMARCHEZ, M. & 
MICHEL, S. 2000. Regulation of vascular endothelial growth factor 
expression in human keratinocytes by retinoids. J Biol Chem, 275, 642-
50. 
  
129 
DIETRICH, D., MARTIN, P., FLACHER, V., SUN, Y., JARROSSAY, D., 
BREMBILLA, N., MUELLER, C., ARNETT, H. A., PALMER, G., TOWNE, 
J. & GABAY, C. 2016. Interleukin-36 potently stimulates human M2 
macrophages, Langerhans cells and keratinocytes to produce pro-
inflammatory cytokines. Cytokine, 84, 88-98. 
DINARELLO, C., AREND, W., SIMS, J., SMITH, D., BLUMBERG, H., O'NEILL, 
L., GOLDBACH-MANSKY, R., PIZARRO, T., HOFFMAN, H., BUFLER, P., 
NOLD, M., GHEZZI, P., MANTOVANI, A., GARLANDA, C., BORASCHI, 
D., RUBARTELLI, A., NETEA, M., VAN DER MEER, J., JOOSTEN, L., 
MANDRUP-POULSEN, T., DONATH, M., LEWIS, E., PFEILSCHIFTER, 
J., MARTIN, M., KRACHT, M., MUEHL, H., NOVICK, D., LUKIC, M., 
CONTI, B., SOLINGER, A., PEYMAN, K., VAN DE VEERDONK, F. & 
GABEL, C. 2010. IL-1 family nomenclature. Nat Immunol, 11, 973-973. 
DIXON, W. G., WATSON, K. D., LUNT, M., HYRICH, K. L., SILMAN, A. J. & 
SYMMONS, D. P. 2007. Reduction in the incidence of myocardial 
infarction in patients with rheumatoid arthritis who respond to anti-tumor 
necrosis factor alpha therapy: results from the British Society for 
Rheumatology Biologics Register. Arthritis Rheum, 56, 2905-12. 
DOWLATSHAHI, E. A., KAVOUSI, M., NIJSTEN, T., IKRAM, M. A., HOFMAN, 
A., FRANCO, O. H. & WAKKEE, M. 2013. Psoriasis Is Not Associated with 
Atherosclerosis and Incident Cardiovascular Events: The Rotterdam 
Study. J Invest Dermatol, 133, 2347-2354. 
DREIHER, J., WEITZMAN, D., SHAPIRO, J., DAVIDOVICI, B. & COHEN, A. D. 
2008. Psoriasis and chronic obstructive pulmonary disease: a case-control 
study. Br J Dermatol, 159, 956-60. 
DUMOUTIER, L., LEEMANS, C., LEJEUNE, D., KOTENKO, S. V. & RENAULD, 
J. C. 2001. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 
through IL-20 receptor complexes of two types. J Immunol, 167, 3545-9. 
DUVALLET, E., SEMERANO, L., ASSIER, E., FALGARONE, G. & BOISSIER, 
M. C. 2011. Interleukin-23: a key cytokine in inflammatory diseases. Ann 
Med, 43, 503-11. 
ECCLES, K. A., SOWDEN, H., PORTER, K. E., PARKIN, S. M., HOMER-
VANNIASINKAM, S. & GRAHAM, A. M. 2008. Simvastatin alters human 
  
130 
endothelial cell adhesion molecule expression and inhibits leukocyte 
adhesion under flow. Atherosclerosis, 200, 69-79. 
ECHIGO, T., HASEGAWA, M., SHIMADA, Y., TAKEHARA, K. & SATO, S. 2004. 
Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: 
possible contribution to skin inflammation. J Allergy Clin Immunol, 113, 
940-8. 
EGEBERG, A., SKOV, L., JOSHI, A. A., MALLBRIS, L., GISLASON, G. H., WU, 
J. J., RODANTE, J., LERMAN, J. B., AHLMAN, M. A., GELFAND, J. M. & 
MEHTA, N. N. 2017. The relationship between duration of psoriasis, 
vascular inflammation, and cardiovascular events. J Am Acad Dermatol, 
77, 650-656. 
EKMAN, A. K., SIGURDARDOTTIR, G., CARLSTROM, M., KARTUL, N., 
JENMALM, M. C. & ENERBACK, C. 2013. Systemically elevated Th1-, 
Th2- and Th17-associated chemokines in psoriasis vulgaris before and 
after ultraviolet B treatment. Acta Derm Venereol, 93, 527-31. 
ELLISON, S., GABUNIA, K., KELEMEN, S. E., ENGLAND, R. N., SCALIA, R., 
RICHARDS, J. M., ORR, A. W., TRAYLOR, J. G., JR., ROGERS, T., 
CORNWELL, W., BERGLUND, L. M., GONCALVES, I., GOMEZ, M. F. & 
AUTIERI, M. V. 2013. Attenuation of experimental atherosclerosis by 
interleukin-19. Arterioscler Thromb Vasc Biol, 33, 2316-24. 
ENGLAND, R. N., PRESTON, K. J., SCALIA, R. & AUTIERI, M. V. 2013. 
Interleukin-19 decreases leukocyte-endothelial cell interactions by 
reduction in endothelial cell adhesion molecule mRNA stability. Am J 
Physiol Cell Physiol, 305, C255-65. 
ESPIGOL-FRIGOLE, G., PLANAS-RIGOL, E., OHNUKI, H., SALVUCCI, O., 
KWAK, H., RAVICHANDRAN, S., LUKE, B., CID, M. C. & TOSATO, G. 
2016. Identification of IL-23p19 as an endothelial proinflammatory peptide 
that promotes gp130-STAT3 signaling. Sci Signal, 9, ra28. 
FANG, N., JIANG, M. & FAN, Y. 2016. Association Between Psoriasis and 
Subclinical Atherosclerosis: A Meta-Analysis. Medicine (Baltimore), 95, 
e3576. 
FATKHULLINA, A., PESHKOVA, I. & KOLTSOVA, E. 2016. Abstract 641: The 
Role of Interleukin-23 in the Development of Atherosclerosis. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 36, A641-A641. 
  
131 
FAXON, D. P., FUSTER, V., LIBBY, P., BECKMAN, J. A., HIATT, W. R., 
THOMPSON, R. W., TOPPER, J. N., ANNEX, B. H., RUNDBACK, J. H., 
FABUNMI, R. P., ROBERTSON, R. M. & LOSCALZO, J. 2004. 
Atherosclerotic Vascular Disease Conference: Writing Group III: 
pathophysiology. Circulation, 109, 2617-25. 
FELDMAN, S. 2016. Treatment of psoriasis. UpToDate. 
FELDMAN, S. R., GARTON, R., AVERETT, W., BALKRISHNAN, R. & VALLEE, 
J. 2003. Strategy to manage the treatment of severe psoriasis: 
considerations of efficacy, safety and cost. Expert opinion on 
pharmacotherapy, 4, 1525-1533. 
FERON, O., DESSY, C., MONIOTTE, S., DESAGER, J. P. & BALLIGAND, J. L. 
1999. Hypercholesterolemia decreases nitric oxide production by 
promoting the interaction of caveolin and endothelial nitric oxide synthase. 
J Clin Invest, 103, 897-905. 
FIEDLER, U., REISS, Y., SCHARPFENECKER, M., GRUNOW, V., KOIDL, S., 
THURSTON, G., GALE, N. W., WITZENRATH, M., ROSSEAU, S., 
SUTTORP, N., SOBKE, A., HERRMANN, M., PREISSNER, K. T., 
VAJKOCZY, P. & AUGUSTIN, H. G. 2006. Angiopoietin-2 sensitizes 
endothelial cells to TNF-alpha and has a crucial role in the induction of 
inflammation. Nat Med, 12, 235-9. 
FOSTER, A. M., BALIWAG, J., CHEN, C. S., GUZMAN, A. M., STOLL, S. W., 
GUDJONSSON, J. E., WARD, N. L. & JOHNSTON, A. 2014. IL-36 
promotes myeloid cell infiltration, activation, and inflammatory activity in 
skin. J Immunol, 192, 6053-61. 
FOURNIER, C. & TISMAN, G. 2010. Sorafenib-associated remission of psoriasis 
in hypernephroma: case report. Dermatol Online J, 16, 17. 
FREEDMAN, R. I., REED, W. & BECKER, S. 1963. Effect of local corticosteroids 
on psoriasis. Arch. Derm, 87, 701-705. 
FREY, S., DERER, A., MESSBACHER, M. E., BAETEN, D. L., BUGATTI, S., 
MONTECUCCO, C., SCHETT, G. & HUEBER, A. J. 2013. The novel 
cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid 
arthritis synovium. Ann Rheum Dis, 72, 1569-74. 
FUENTES-DUCULAN, J., SUAREZ-FARINAS, M., ZABA, L. C., NOGRALES, K. 
E., PIERSON, K. C., MITSUI, H., PENSABENE, C. A., KZHYSHKOWSKA, 
  
132 
J., KRUEGER, J. G. & LOWES, M. A. 2010. A subpopulation of CD163-
positive macrophages is classically activated in psoriasis. J Invest 
Dermatol, 130, 2412-22. 
FUSTER, V., BADIMON, L., BADIMON, J. J. & CHESEBRO, J. H. 1992. The 
pathogenesis of coronary artery disease and the acute coronary 
syndromes (2). N Engl J Med, 326, 310-8. 
GABAY, C. & TOWNE, J. E. 2015. Regulation and function of interleukin-36 
cytokines in homeostasis and pathological conditions. J Leukoc Biol, 97, 
645-652. 
GAFFEN, S. L., JAIN, R., GARG, A. V. & CUA, D. J. 2014. The IL-23-IL-17 
immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol, 
14, 585-600. 
GARBARAVICIENE, J., DIEHL, S., VARWIG, D., BYLAITE, M., ACKERMANN, 
H., LUDWIG, R. J. & BOEHNCKE, W.-H. 2010. Platelet P-selectin reflects 
a state of cutaneous inflammation: possible application to monitor 
treatment efficacy in psoriasis. Experimental Dermatology, 19, 736-741. 
GELFAND, J. M., NEIMANN, A. L., SHIN, D. B., WANG, X., MARGOLIS, D. J. & 
TROXEL, A. B. 2006. RIsk of myocardial infarction in patients with 
psoriasis. JAMA, 296, 1735-1741. 
GELFAND, J. M., WEINSTEIN, R., PORTER, S. B., NEIMANN, A. L., BERLIN, 
J. A. & MARGOLIS, D. J. 2005. Prevalence and treatment of psoriasis in 
the United Kingdom: a population-based study. Arch Dermatol, 141, 1537-
41. 
GISONDI, P., FANTIN, F., DEL GIGLIO, M., VALBUSA, F., MARINO, F., 
ZAMBONI, M. & GIROLOMONI, G. 2009. Chronic plaque psoriasis is 
associated with increased arterial stiffness. Dermatology, 218, 110-3. 
GOLDEN, J. B., GROFT, S. G., SQUERI, M. V., DEBANNE, S. M., WARD, N. L., 
MCCORMICK, T. S. & COOPER, K. D. 2015. Chronic Psoriatic Skin 
Inflammation Leads to Increased Monocyte Adhesion and Aggregation. J 
Immunol, 195, 2006-18. 
GOLDMINZ, A. M., AU, S. C., KIM, N., GOTTLIEB, A. B. & LIZZUL, P. F. 2013. 
NF-κB: An essential transcription factor in psoriasis. Journal of 
Dermatological Science, 69, 89-94. 
  
133 
GONG, F., LIU, Z., LIU, J., ZHOU, P., LIU, Y. & LU, X. 2015. The paradoxical 
role of IL-17 in atherosclerosis. Cellular Immunology, 297, 33-39. 
GROSSMAN, R. M., KRUEGER, J., YOURISH, D., GRANELLI-PIPERNO, A., 
MURPHY, D. P., MAY, L. T., KUPPER, T. S., SEHGAL, P. B. & 
GOTTLIEB, A. B. 1989. Interleukin 6 is expressed in high levels in psoriatic 
skin and stimulates proliferation of cultured human keratinocytes. Proc 
Natl Acad Sci U S A, 86, 6367-71. 
GUDJONSSON, J. E., JOHNSTON, A. & ELLIS, C. N. 2012. Novel systemic 
drugs under investigation for the treatment of psoriasis. Journal of the 
American Academy of Dermatology, 67, 139-147. 
GUÉRARD, S. & POULIOT, R. 2012. The role of angiogenesis in the 
pathogenesis of psoriasis: mechanisms and clinical implications. J Clin 
Exp Dermatol Res S, 2, 2. 
GUNTHER, S. & SUNDBERG, E. J. 2014. Molecular determinants of agonist and 
antagonist signaling through the IL-36 receptor. J Immunol, 193, 921-30. 
GUPTA, S., PABLO, A. M., C JIANG, X., WANG, N., TALL, A. R. & SCHINDLER, 
C. 1997. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. 
The Journal of clinical investigation, 99, 2752-2761. 
HAJRA, L., EVANS, A. I., CHEN, M., HYDUK, S. J., COLLINS, T. & CYBULSKY, 
M. I. 2000. The NF-kappa B signal transduction pathway in aortic 
endothelial cells is primed for activation in regions predisposed to 
atherosclerotic lesion formation. Proc Natl Acad Sci U S A, 97, 9052-7. 
HALPRIN, K. M. 1972. Epidermal "turnover time"--a re-examination. Br J 
Dermatol, 86, 14-9. 
HAMM, R. 2014. Text and Atlas of Wound Diagnosis and Treatment, McGraw Hill 
Professional. 
HAN, X., KITAMOTO, S., WANG, H. & BOISVERT, W. A. 2010. Interleukin-10 
overexpression in macrophages suppresses atherosclerosis in 
hyperlipidemic mice. Faseb j, 24, 2869-80. 
HAO, J. Q. 2014. Targeting interleukin-22 in psoriasis. Inflammation, 37, 94-9. 
HARDEN, J. L., KRUEGER, J. G. & BOWCOCK, A. M. 2015. The 
immunogenetics of Psoriasis: A comprehensive review. J Autoimmun, 64, 
66-73. 
  
134 
HARDEN, J. L., LEWIS, S. M., PIERSON, K. C., SUAREZ-FARINAS, M., 
LENTINI, T., ORTENZIO, F. S., ZABA, L. C., GOLDBACH-MANSKY, R., 
BOWCOCK, A. M. & LOWES, M. A. 2014. CARD14 expression in dermal 
endothelial cells in psoriasis. PLoS One, 9, e111255. 
HARPER, E. G., GUO, C., RIZZO, H., LILLIS, J. V., KURTZ, S. E., SKORCHEVA, 
I., PURDY, D., FITCH, E., IORDANOV, M. & BLAUVELT, A. 2009. Th17 
Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In 
Vivo: Implications for Psoriasis Pathogenesis. J Invest Dermatol, 129, 
2175-2183. 
HE, L., DANG, L., ZHOU, J., BAI, J. & LI, Y. Z. 2015. Association of angiopoietin-
1, angiopoietin-2 and caspase-5 polymorphisms with psoriasis vulgaris. 
Clinical and Experimental Dermatology, n/a-n/a. 
HEESCHEN, C., DIMMELER, S., HAMM, C. W., BOERSMA, E., ZEIHER, A. M. 
& SIMOONS, M. L. 2003. Prognostic significance of angiogenic growth 
factor serum levels in patients with acute coronary syndromes. Circulation, 
107, 524-30. 
HEIDENREICH, R., RÖCKEN, M. & GHORESCHI, K. 2009. Angiogenesis drives 
psoriasis pathogenesis. International Journal of Experimental Pathology, 
90, 232-248. 
HENNO, A., BLACHER, S., LAMBERT, C., COLIGE, A., SEIDEL, L., NOEL, A., 
LAPIERE, C., DE LA BRASSINNE, M. & NUSGENS, B. V. 2009. Altered 
expression of angiogenesis and lymphangiogenesis markers in the 
uninvolved skin of plaque-type psoriasis. Br J Dermatol, 160, 581-90. 
HENRY, C. M., SULLIVAN, G. P., CLANCY, D. M., AFONINA, I. S., KULMS, D. 
& MARTIN, S. J. 2016. Neutrophil-Derived Proteases Escalate 
Inflammation through Activation of IL-36 Family Cytokines. Cell Rep, 14, 
708-22. 
HEO, K.-S., FUJIWARA, K. & ABE, J.-I. 2014. Shear Stress and Atherosclerosis. 
Molecules and Cells, 37, 435-440. 
HERMANN, M., FLAMMER, A. & LUSCHER, T. F. 2006. Nitric oxide in 
hypertension. J Clin Hypertens (Greenwich), 8, 17-29. 
HERN, S., STANTON, A. W., MELLOR, R. H., HARLAND, C. C., LEVICK, J. R. 
& MORTIMER, P. S. 2005. Blood flow in psoriatic plaques before and after 
selective treatment of the superficial capillaries. Br J Dermatol, 152, 60-5. 
  
135 
HILL, J. M., ZALOS, G., HALCOX, J. P., SCHENKE, W. H., WACLAWIW, M. A., 
QUYYUMI, A. A. & FINKEL, T. 2003. Circulating endothelial progenitor 
cells, vascular function, and cardiovascular risk. N Engl J Med, 348, 593-
600. 
HOESEL, B. & SCHMID, J. A. 2013. The complexity of NF-κB signaling in 
inflammation and cancer. Molecular Cancer, 12, 1-15. 
HOMEY, B., DIEU-NOSJEAN, M. C., WIESENBORN, A., MASSACRIER, C., 
PIN, J. J., OLDHAM, E., CATRON, D., BUCHANAN, M. E., MULLER, A., 
DEWAAL MALEFYT, R., DENG, G., OROZCO, R., RUZICKA, T., 
LEHMANN, P., LEBECQUE, S., CAUX, C. & ZLOTNIK, A. 2000. Up-
regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC 
chemokine receptor 6 in psoriasis. J Immunol, 164, 6621-32. 
HONING, M. L., MORRISON, P. J., BANGA, J. D., STROES, E. S. & RABELINK, 
T. J. 1998. Nitric oxide availability in diabetes mellitus. Diabetes Metab 
Rev, 14, 241-9. 
HORROCKS, C., DUNCAN, J. I., OLIVER, A. M. & THOMSON, A. W. 1991. 
Adhesion molecule expression in psoriatic skin lesions and the influence 
of cyclosporin A. Clinical and Experimental Immunology, 84, 157-162. 
HU, X. & IVASHKIV, L. B. 2009. Cross-regulation of signaling pathways by 
interferon-gamma: implications for immune responses and autoimmune 
diseases. Immunity, 31, 539-50. 
HUEBER, A. J., MILLER, A. M., ASQUITH, D. L., MILLAR, N. L., GILCHRIST, 
D., GRACIE, A. & MCINNES, I. B. 2010. Alarmin interleukin 33 is 
overexpressed in psoriasis and induces ST2-dependent psoriasis-like 
dermatitis. Annals of the Rheumatic Diseases, 69, A40-A41. 
HUGH, J., VAN VOORHEES, A. S., NIJHAWAN, R. I., BAGEL, J., LEBWOHL, 
M., BLAUVELT, A., HSU, S. & WEINBERG, J. M. 2014. From the Medical 
Board of the National Psoriasis Foundation: The risk of cardiovascular 
disease in individuals with psoriasis and the potential impact of current 
therapies. Journal of the American Academy of Dermatology, 70, 168-177. 
HUYNH, J., SCHOLZ, G. M., AW, J., KWA, M. Q., ACHUTHAN, A., HAMILTON, 
J. A. & REYNOLDS, E. C. 2016. IRF6 Regulates the Expression of IL-36γ 
by Human Oral Epithelial Cells in Response to Porphyromonas gingivalis. 
The Journal of Immunology, 196, 2230-2238. 
  
136 
IKEJIMA, T., OKUSAWA, S., GHEZZI, P., VAN DER MEER, J. W. & 
DINARELLO, C. A. 1990. Interleukin-1 induces tumor necrosis factor 
(TNF) in human peripheral blood mononuclear cells in vitro and a 
circulating TNF-like activity in rabbits. J Infect Dis, 162, 215-23. 
IMAI, T. & YASUDA, N. 2016. Therapeutic intervention of inflammatory/immune 
diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway. 
Inflamm Regen, 36, 9. 
IMAIZUMI, T., YOSHIDA, H. & SATOH, K. 2004. Regulation of 
CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb, 
11, 15-21. 
INGRAM, D. A., MEAD, L. E., TANAKA, H., MEADE, V., FENOGLIO, A., 
MORTELL, K., POLLOK, K., FERKOWICZ, M. J., GILLEY, D. & YODER, 
M. C. 2004. Identification of a novel hierarchy of endothelial progenitor 
cells using human peripheral and umbilical cord blood. Blood, 104, 2752-
60. 
IWAKURA, Y. & ISHIGAME, H. 2006. The IL-23/IL-17 axis in inflammation. J Clin 
Invest, 116, 1218-22. 
JACKSON, J. R., SEED, M., KIRCHER, C., WILLOUGHBY, D. & WINKLER, J. 
1997. The codependence of angiogenesis and chronic inflammation. The 
FASEB Journal, 11, 457-465. 
JACOB, S. E., NASSIRI, M., KERDEL, F. A. & VINCEK, V. 2003. Simultaneous 
measurement of multiple Th1 and Th2 serum cytokines in psoriasis and 
correlation with disease severity. Mediators of Inflammation, 12, 309-313. 
JAIN, S., GABUNIA, K., KELEMEN, S. E., PANETTI, T. S. & AUTIERI, M. V. 
2011. The Anti-Inflammatory Cytokine Interleukin-19 Is Expressed in and 
Angiogenic for Human Endothelial Cells. Arteriosclerosis, thrombosis, and 
vascular biology, 31, 167-175. 
JANSSON, P. A., PELLME, F., HAMMARSTEDT, A., SANDQVIST, M., 
BREKKE, H., CAIDAHL, K., FORSBERG, M., VOLKMANN, R., 
CARVALHO, E., FUNAHASHI, T., MATSUZAWA, Y., WIKLUND, O., 
YANG, X., TASKINEN, M. R. & SMITH, U. 2003. A novel cellular marker 
of insulin resistance and early atherosclerosis in humans is related to 
impaired fat cell differentiation and low adiponectin. Faseb j, 17, 1434-40. 
  
137 
JOHANSEN, C., USHER, P. A., KJELLERUP, R. B., LUNDSGAARD, D., 
IVERSEN, L. & KRAGBALLE, K. 2009. Characterization of the interleukin-
17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol, 160, 
319-24. 
JOHNSON-HUANG, L. M., SUÁREZ-FARIÑAS, M., PIERSON, K. C., FUENTES-
DUCULAN, J., CUETO, I., LENTINI, T., SULLIVAN-WHALEN, M., 
GILLEAUDEAU, P., KRUEGER, J. G., HAIDER, A. S. & LOWES, M. A. 
2012. A single intradermal injection of IFN-γ induces an inflammatory state 
in both non-lesional psoriatic and healthy skin. The Journal of investigative 
dermatology, 132, 1177-1187. 
JOHNSTON, A., XING, X., GUZMAN, A. M., RIBLETT, M., LOYD, C. M., WARD, 
N. L., WOHN, C., PRENS, E. P., WANG, F., MAIER, L. E., KANG, S., 
VOORHEES, J. J., ELDER, J. T. & GUDJONSSON, J. E. 2011. IL-1F5, 
F6, F8, and F9: a novel IL-1 family signaling system that is active in 
psoriasis and promotes keratinocyte antimicrobial peptide expression. 
Journal of immunology (Baltimore, Md. : 1950), 186, 2613-2622. 
JORDAN, C. T., CAO, L., ROBERSON, E. D., PIERSON, K. C., YANG, C. F., 
JOYCE, C. E., RYAN, C., DUAN, S., HELMS, C. A., LIU, Y., CHEN, Y., 
MCBRIDE, A. A., HWU, W. L., WU, J. Y., CHEN, Y. T., MENTER, A., 
GOLDBACH-MANSKY, R., LOWES, M. A. & BOWCOCK, A. M. 2012a. 
PSORS2 is due to mutations in CARD14. Am J Hum Genet, 90, 784-95. 
JORDAN, CATHERINE T., CAO, L., ROBERSON, ELISHA D. O., DUAN, S., 
HELMS, CYNTHIA A., NAIR, RAJAN P., DUFFIN, KRISTINA C., 
STUART, PHILIP E., GOLDGAR, D., HAYASHI, G., OLFSON, EMILY H., 
FENG, B.-J., PULLINGER, CLIVE R., KANE, JOHN P., WISE, C. A., 
GOLDBACH-MANSKY, R., LOWES, MICHELLE A., PEDDLE, L., 
CHANDRAN, V., LIAO, W., RAHMAN, P., KRUEGER, GERALD G., 
GLADMAN, D., ELDER, JAMES T., MENTER, A. & BOWCOCK, ANNE M. 
2012b. Rare and Common Variants in CARD14, Encoding an Epidermal 
Regulator of NF-kappaB, in Psoriasis. The American Journal of Human 
Genetics, 90, 796-808. 
JUNG, K., LEE, D., LIM, H. S., LEE, S. I., KIM, Y. J., LEE, G. M., KIM, S. C. & 
KOH, G. Y. 2011. Double anti-angiogenic and anti-inflammatory protein 
  
138 
Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J 
Biol Chem, 286, 14410-8. 
KARADAG, A. S., YAVUZ, B., ERTUGRUL, D. T., AKIN, K. O., YALCIN, A. A., 
DEVECI, O. S., ATA, N., KUCUKAZMAN, M. & DAL, K. 2010. Is psoriasis 
a pre-atherosclerotic disease? Increased insulin resistance and impaired 
endothelial function in patients with psoriasis. International Journal of 
Dermatology, 49, 642-646. 
KECK, P. J., HAUSER, S. D., KRIVI, G., SANZO, K., WARREN, T., FEDER, J. & 
CONNOLLY, D. T. 1989. Vascular permeability factor, an endothelial cell 
mitogen related to PDGF. Science, 246, 1309-12. 
KEERMANN, M., KOKS, S., REIMANN, E., ABRAM, K., ERM, T., SILM, H. & 
KINGO, K. 2015. Expression of IL-36 family cytokines and IL-37 but not 
IL-38 is altered in psoriatic skin. J Dermatol Sci, 80, 150-2. 
KESHTGARPOUR, M. & DUDEK, A. Z. 2007. SU-011248, a vascular endothelial 
growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. 
Transl Res, 149, 103-6. 
KIM, J. & KRUEGER, J. G. 2015. The immunopathogenesis of psoriasis. 
Dermatol Clin, 33, 13-23. 
KIM, S. J., KIM, N. S. & LEE, J. L. 1993. Effect of cytokines on the expression of 
cell adhesion molecule and on the adhesion of melanoma cells to 
endothelial cells. Journal of Korean Medical Science, 8, 41-52. 
KIMBALL, A. B., SZAPARY, P., MROWIETZ, U., REICH, K., LANGLEY, R. G., 
YOU, Y., HSU, M. C., YEILDING, N., RADER, D. J. & MEHTA, N. N. 2012. 
Underdiagnosis and undertreatment of cardiovascular risk factors in 
patients with moderate to severe psoriasis. J Am Acad Dermatol, 67, 76-
85. 
KLEINBONGARD, P., HEUSCH, G. & SCHULZ, R. 2010. TNFalpha in 
atherosclerosis, myocardial ischemia/reperfusion and heart failure. 
Pharmacol Ther, 127, 295-314. 
KOBA, S. & HIRANO, T. 2011. [Dyslipidemia and atherosclerosis]. Nihon Rinsho, 
69, 138-43. 
KOCH, S., KUCHARZIK, T., HEIDEMANN, J., NUSRAT, A. & LUEGERING, A. 
2010. Investigating the role of proinflammatory CD16(+) monocytes in the 
  
139 
pathogenesis of inflammatory bowel disease. Clinical and Experimental 
Immunology, 161, 332-341. 
KOIKE, Y., OKUBO, M., KIYOHARA, T., FUKUCHI, R., SATO, Y., KUWATSUKA, 
S., TAKEICHI, T., AKIYAMA, M., SUGIURA, K. & UTANI, A. 2017. 
Granulocyte and monocyte apheresis can control juvenile generalised 
pustular psoriasis with mutation of the IL36RN gene. British Journal of 
Dermatology, n/a-n/a. 
KOVACH, M. A., NEWSTEAD, M. W., ZENG, X., PETERS-GOLDEN, M. & 
STANDIFORD, T. J. 2015. IL-36γ Is a potent inducer of type I and IL-17 
cytokine induction during lung infection. D102. ADVANCES IN LUNG 
IMMUNOLOGY AND SARCOIDOSIS. Am Thoracic Soc. 
KOVACH, M. A., SINGER, B., MARTINEZ-COLON, G., NEWSTEAD, M. W., 
ZENG, X., MANCUSO, P., MOORE, T. A., KUNKEL, S. L., PETERS-
GOLDEN, M., MOORE, B. B. & STANDIFORD, T. J. 2017. IL-36gamma 
is a crucial proximal component of protective type-1-mediated lung 
mucosal immunity in Gram-positive and -negative bacterial pneumonia. 
Mucosal Immunol, 10, 1320-1334. 
KOVACH, M. A., SINGER, B. H., NEWSTEAD, M. W., ZENG, X., MOORE, T. A., 
WHITE, E. S., KUNKEL, S. L., PETERS-GOLDEN, M. & STANDIFORD, 
T. J. 2016. IL-36gamma is secreted in microparticles and exosomes by 
lung macrophages in response to bacteria and bacterial components. J 
Leukoc Biol, 100, 413-21. 
KRAKAUER, T. 1995. IL-10 inhibits the adhesion of leukocytic cells to IL-1-
activated human endothelial cells. Immunology Letters, 45, 61-65. 
KRAUSE, C. D., HE, W., KOTENKO, S. & PESTKA, S. 2006. Modulation of the 
activation of Stat1 by the interferon-gamma receptor complex. Cell Res, 
16, 113-23. 
KRUEGER, G., KOO, J., LEBWOHL, M., MENTER, A., STERN, R. S. & 
ROLSTAD, T. 2001. The impact of psoriasis on quality of life: results of a 
1998 National Psoriasis Foundation patient-membership survey. Archives 
of Dermatology, 137, 280-284. 
KUBOKI, K., JIANG, Z. Y., TAKAHARA, N., HA, S. W., IGARASHI, M., 
YAMAUCHI, T., FEENER, E. P., HERBERT, T. P., RHODES, C. J. & 
KING, G. L. 2000. Regulation of Endothelial Constitutive Nitric Oxide 
  
140 
Synthase Gene Expression in Endothelial Cells and In Vivo: A Specific 
Vascular Action of Insulin. Circulation, 101, 676-681. 
KULKA, J. P. 1964. MICROCIRCULATORY IMPAIRMENT AS A FACTOR IN 
INFLAMMATORY TISSUE DAMAGE. Ann N Y Acad Sci, 116, 1018-44. 
KURODA, K., SAPADIN, A., SHOJI, T., FLEISCHMAJER, R. & LEBWOHL, M. 
2001. Altered expression of angiopoietins and Tie2 endothelium receptor 
in psoriasis. J Invest Dermatol, 116, 713-20. 
KURSUNLU, S. F., OZTURK, V. O., HAN, B., ATMACA, H. & EMINGIL, G. 2015. 
Gingival crevicular fluid interleukin-36beta (-1F8), interleukin-36gamma (-
1F9) and interleukin-33 (-1F11) levels in different periodontal disease. 
Arch Oral Biol, 60, 77-83. 
KURŞUNLU, S. F., ÖZTÜRK, V. Ö., HAN, B., ATMACA, H. & EMINGIL, G. 2015. 
Gingival crevicular fluid interleukin-36β (-1F8), interleukin-36γ (-1F9) and 
interleukin-33 (-1F11) levels in different periodontal disease. Archives of 
oral biology, 60, 77-83. 
KUSTERS, B., DE WAAL, R. M., WESSELING, P., VERRIJP, K., MAASS, C., 
HEERSCHAP, A., BARENTSZ, J. O., SWEEP, F., RUITER, D. J. & 
LEENDERS, W. P. 2003. Differential effects of vascular endothelial growth 
factor A isoforms in a mouse brain metastasis model of human melanoma. 
Cancer Res, 63, 5408-13. 
LANGLEY, R. G., ELEWSKI, B. E., LEBWOHL, M., REICH, K., GRIFFITHS, C. 
E., PAPP, K., PUIG, L., NAKAGAWA, H., SPELMAN, L. & 
SIGURGEIRSSON, B. 2014. Secukinumab in plaque psoriasis—results of 
two phase 3 trials. New England Journal of Medicine, 371, 326-338. 
LEBWOHL, M., TYRING, S. K., HAMILTON, T. K., TOTH, D., GLAZER, S., 
TAWFIK, N. H., WALICKE, P., DUMMER, W., WANG, X., GAROVOY, M. 
R. & PARISER, D. 2003. A novel targeted T-cell modulator, efalizumab, 
for plaque psoriasis. N Engl J Med, 349, 2004-13. 
LEMBO, S., CAPASSO, R., BALATO, A., CIRILLO, T., FLORA, F., ZAPPIA, V., 
BALATO, N., INGROSSO, D. & AYALA, F. 2014. MCP-1 in psoriatic 
patients: effect of biological therapy. J Dermatolog Treat, 25, 83-6. 
LI, A., DUBEY, S., VARNEY, M. L., DAVE, B. J. & SINGH, R. K. 2003. IL-8 directly 
enhanced endothelial cell survival, proliferation, and matrix 
  
141 
metalloproteinases production and regulated angiogenesis. J Immunol, 
170, 3369-76. 
LI, H.-H., LIN, Y. C., CHEN, P. J., HSIAO, C. H., LEE, J. Y. Y., CHEN, W. C., 
TZUNG, T. Y., WU, J. C. & CHANG, M.-S. 2005. Interleukin-19 
upregulates keratinocyte growth factor and is associated with psoriasis. 
British Journal of Dermatology, 153, 591-595. 
LI, J., JIN, C., AO, L., ZENG, Q., DINARELLO, C. & MENG, X. NOVEL 
CYTOKINE IL-37 SUPPRESSES TLR2/4-MEDIATED ICAM-1 
EXPRESSION IN ENDOTHELIAL CELLS VIA REGULATION OF NF-
KAPPAB ACTIVATION.  SHOCK, 2011. LIPPINCOTT WILLIAMS & 
WILKINS 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA, 17-
17. 
LI, N., MCLAREN, J. E., MICHAEL, D. R., CLEMENT, M., FIELDING, C. A. & 
RAMJI, D. P. 2010. ERK is integral to the IFN-gamma-mediated activation 
of STAT1, the expression of key genes implicated in atherosclerosis, and 
the uptake of modified lipoproteins by human macrophages. J Immunol, 
185, 3041-8. 
LI, N., YAMASAKI, K., SAITO, R., FUKUSHI-TAKAHASHI, S., SHIMADA-
OMORI, R., ASANO, M. & AIBA, S. 2014. Alarmin Function of Cathelicidin 
Antimicrobial Peptide LL37 through IL-36γ Induction in Human Epidermal 
Keratinocytes. The Journal of Immunology, 193, 5140-5148. 
LI, X., KONG, L., LI, F., CHEN, C., XU, R., WANG, H., PENG, S., ZHOU, M. & 
LI, B. 2015. Association between psoriasis and chronic obstructive 
pulmonary disease: a systematic review and meta-analysis. PloS one, 10, 
e0145221. 
LIEVENS, D. & VON HUNDELSHAUSEN, P. 2011. Platelets in atherosclerosis. 
Thromb Haemost, 106, 827-38. 
LISINSKI, T. J. & FURIE, M. B. 2002. Interleukin-10 inhibits proinflammatory 
activation of endothelium in response to Borrelia burgdorferi or 
lipopolysaccharide but not interleukin-1β or tumor necrosis factor α. 
Journal of Leukocyte Biology, 72, 503-511. 
LIU, L., ZHOU, Z., HUANG, S., GUO, Y., FAN, Y., ZHANG, J., ZHANG, J., FU, 
M. & CHEN, Y. E. 2013. Zc3h12c inhibits vascular inflammation by 
  
142 
repressing NF-kappaB activation and pro-inflammatory gene expression 
in endothelial cells. Biochem J, 451, 55-60. 
LIU, X. L., ZHANG, P. F., DING, S. F., WANG, Y., ZHANG, M., ZHAO, Y. X., NI, 
M. & ZHANG, Y. 2012. Local Gene Silencing of Monocyte 
Chemoattractant Protein-1 Prevents Vulnerable Plaque Disruption in 
Apolipoprotein E-Knockout Mice. PLoS ONE, 7, e33497. 
LOWES, M. A., BOWCOCK, A. M. & KRUEGER, J. G. 2007. Pathogenesis and 
therapy of psoriasis. Nature, 445, 866-873. 
LOWES, M. A., KIKUCHI, T., FUENTES-DUCULAN, J., CARDINALE, I., ZABA, 
L. C., HAIDER, A. S., BOWMAN, E. P. & KRUEGER, J. G. 2008. Psoriasis 
vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J 
Invest Dermatol, 128, 1207-11. 
LOWES, M. A., SUÁREZ-FARIÑAS, M. & KRUEGER, J. G. 2014. Immunology 
of Psoriasis. Annual review of immunology, 32, 227-255. 
LUBBERTS, E. 2015. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev 
Rheumatol, 11, 415-429. 
LUCAS, A. D., BURSILL, C., GUZIK, T. J., SADOWSKI, J., CHANNON, K. M. & 
GREAVES, D. R. 2003. Smooth Muscle Cells in Human Atherosclerotic 
Plaques Express the Fractalkine Receptor CX<sub>3</sub>CR1 and 
Undergo Chemotaxis to the CX<sub>3</sub>C Chemokine Fractalkine 
(CX<sub>3</sub>CL1). Circulation, 108, 2498-2504. 
MA, H.-L., LIANG, S., LI, J., NAPIERATA, L., BROWN, T., BENOIT, S., 
SENICES, M., GILL, D., DUNUSSI-JOANNOPOULOS, K. & COLLINS, M. 
2008. IL-22 is required for Th17 cell–mediated pathology in a mouse 
model of psoriasis-like skin inflammation. The Journal of clinical 
investigation, 118, 597-607. 
MA, T., GAO, Q., ZHU, F., GUO, C., WANG, Q., GAO, F. & ZHANG, L. 2013. 
Th17 cells and IL-17 are involved in the disruption of vulnerable plaques 
triggered by short-term combination stimulation in apolipoprotein E-
knockout mice. Cellular and Molecular Immunology, 10, 338-348. 
MACLEOD, T., DOBLE, R., MCGONAGLE, D., WASSON, C. W., ALASE, A., 
STACEY, M. & WITTMANN, M. 2016. Neutrophil Elastase-mediated 
proteolysis activates the anti-inflammatory cytokine IL-36 Receptor 
antagonist. Scientific Reports, 6, 24880. 
  
143 
MAGNE, D., PALMER, G., BARTON, J. L., MEZIN, F., TALABOT-AYER, D., 
BAS, S., DUFFY, T., NOGER, M., GUERNE, P. A., NICKLIN, M. J. & 
GABAY, C. 2006. The new IL-1 family member IL-1F8 stimulates 
production of inflammatory mediators by synovial fibroblasts and articular 
chondrocytes. Arthritis Res Ther, 8, R80. 
MAHIL, S. K., CATAPANO, M., DI MEGLIO, P., DAND, N., AHLFORS, H., CARR, 
I. M., SMITH, C. H., TREMBATH, R. C., PEAKMAN, M., WRIGHT, J., 
CICCARELLI, F. D., BARKER, J. N. & CAPON, F. 2017. An analysis of IL-
36 signature genes and individuals with IL1RL2 knockout mutations 
validates IL-36 as a psoriasis therapeutic target. Sci Transl Med, 9. 
MAISONPIERRE, P. C., SURI, C., JONES, P. F., BARTUNKOVA, S., WIEGAND, 
S. J., RADZIEJEWSKI, C., COMPTON, D., MCCLAIN, J., ALDRICH, T. 
H., PAPADOPOULOS, N., DALY, T. J., DAVIS, S., SATO, T. N. & 
YANCOPOULOS, G. D. 1997. Angiopoietin-2, a natural antagonist for 
Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60. 
MAJNO, G. 1964. Mechanisms of abnormal vascular permeability in acute 
inflammation. Injury, inflammation and immunity, 58-93. 
MANDL, M., SCHMITZ, S., WEBER, C. & HRISTOV, M. 2014. Characterization 
of the CD14(++)CD16(+) Monocyte Population in Human Bone Marrow. 
PLoS ONE, 9, e112140. 
MANGAN, P. R., HARRINGTON, L. E., O'QUINN, D. B., HELMS, W. S., 
BULLARD, D. C., ELSON, C. O., HATTON, R. D., WAHL, S. M., SCHOEB, 
T. R. & WEAVER, C. T. 2006. Transforming growth factor-beta induces 
development of the T(H)17 lineage. Nature, 441, 231-4. 
MARRAKCHI, S., GUIGUE, P., RENSHAW, B. R., PUEL, A., PEI, X. Y., 
FRAITAG, S., ZRIBI, J., BAL, E., CLUZEAU, C., CHRABIEH, M., TOWNE, 
J. E., DOUANGPANYA, J., PONS, C., MANSOUR, S., SERRE, V., 
MAKNI, H., MAHFOUDH, N., FAKHFAKH, F., BODEMER, C., 
FEINGOLD, J., HADJ-RABIA, S., FAVRE, M., GENIN, E., SAHBATOU, 
M., MUNNICH, A., CASANOVA, J. L., SIMS, J. E., TURKI, H., 
BACHELEZ, H. & SMAHI, A. 2011. Interleukin-36-receptor antagonist 
deficiency and generalized pustular psoriasis. N Engl J Med, 365, 620-8. 
MARTIN, J. C. J., BÉRIOU, G., HESLAN, M., CHAUVIN, C., UTRIAINEN, L., 
AUMEUNIER, A., SCOTT, C. L., MOWAT, A., CEROVIC, V., HOUSTON, 
  
144 
S. A., LEBOEUF, M., HUBERT, F. X., HÉMONT, C., MERAD, M., 
MILLING, S. & JOSIEN, R. 2014. Interleukin-22 binding protein (IL-22BP) 
is constitutively expressed by a subset of conventional dendritic cells and 
is strongly induced by retinoic acid. Mucosal immunology, 7, 101-113. 
MARTIN, P., PALMER, G., RODRIGUEZ, E., WOLDT, E., MEAN, I., JAMES, R. 
W., SMITH, D. E., KWAK, B. R. & GABAY, C. 2015. Atherosclerosis 
severity is not affected by a deficiency in IL-33/ST2 signaling. Immunity, 
Inflammation and Disease, 3, 239-246. 
MATARESE, A. & SANTULLI, G. 2012. Angiogenesis in Chronic Obstructive 
Pulmonary Disease: A Translational Appraisal. Translational Medicine @ 
UniSa, 3, 49-56. 
MCCURDY, S., BAUMER, Y., TOULMIN, E. & BOISVERT, W. 2014. Abstract 
13453: Macrophage-driven Expression of IL-37 Protects Against 
Atherosclerosis. Circulation, 130, A13453. 
MCDERMOTT, D. H., FONG, A. M., YANG, Q., SECHLER, J. M., CUPPLES, L. 
A., MERRELL, M. N., WILSON, P. W. F., D’AGOSTINO, R. B., 
O’DONNELL, C. J., PATEL, D. D. & MURPHY, P. M. 2003. Chemokine 
receptor mutant CX3CR1-M280 has impaired adhesive function and 
correlates with protection from cardiovascular disease in humans. Journal 
of Clinical Investigation, 111, 1241-1250. 
MCDERMOTT, D. H., HALCOX, J. P., SCHENKE, W. H., WACLAWIW, M. A., 
MERRELL, M. N., EPSTEIN, N., QUYYUMI, A. A. & MURPHY, P. M. 2001. 
Association between polymorphism in the chemokine receptor CX3CR1 
and coronary vascular endothelial dysfunction and atherosclerosis. Circ 
Res, 89, 401-7. 
MCDONALD, C. J. & CALABRESI, P. 1978. Psoriasis and occlusive vascular 
disease. Br J Dermatol, 99, 469-75. 
MCLAREN, J. E. & RAMJI, D. P. 2009. Interferon gamma: a master regulator of 
atherosclerosis. Cytokine Growth Factor Rev, 20, 125-35. 
MCNAB, F., MAYER-BARBER, K., SHER, A., WACK, A. & O'GARRA, A. 2015. 
Type I interferons in infectious disease. Nat Rev Immunol, 15, 87-103. 
MEASE, P. J., GOFFE, B. S., METZ, J., VANDERSTOEP, A., FINCK, B. & 
BURGE, D. J. 2000. Etanercept in the treatment of psoriatic arthritis and 
psoriasis: a randomised trial. The Lancet, 356, 385-390. 
  
145 
MEEKINS, J. W., MCLAUGHLIN, P. J., WEST, D. C., MCFADYEN, I. R. & 
JOHNSON, P. M. 1994. Endothelial cell activation by tumour necrosis 
factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clinical 
and Experimental Immunology, 98, 110-114. 
MEGLIO, P. D. & NESTLE, F. O. 2010. The role of IL-23 in the 
immunopathogenesis of psoriasis. F1000 Biology Reports, 2, 40. 
MEHTA, N. N., LI, K., SZAPARY, P., KRUEGER, J. & BRODMERKEL, C. 2013. 
Modulation of cardiometabolic pathways in skin and serum from patients 
with psoriasis. J Transl Med, 11, 194. 
MEHTA, N. N., LI, R., KRISHNAMOORTHY, P., YU, Y., FARVER, W., 
RODRIGUES, A., RAPER, A., WILCOX, M., BAER, A., 
DEROHANNESIAN, S., WOLFE, M., REILLY, M. P., RADER, D. J., 
VANVOORHEES, A. & GELFAND, J. M. 2012. Abnormal lipoprotein 
particles and cholesterol efflux capacity in patients with psoriasis. 
Atherosclerosis, 224, 218-21. 
MELERO-MARTIN, J. M., KHAN, Z. A., PICARD, A., WU, X., PARUCHURI, S. & 
BISCHOFF, J. 2007. In vivo vasculogenic potential of human blood-
derived endothelial progenitor cells. Blood, 109, 4761-8. 
MENTER, A. & GRIFFITHS, C. E. 2007. Current and future management of 
psoriasis. Lancet, 370, 272-84. 
MENTER, A., TYRING, S. K., GORDON, K., KIMBALL, A. B., LEONARDI, C. L., 
LANGLEY, R. G., STROBER, B. E., KAUL, M., GU, Y. & OKUN, M. 2008. 
Adalimumab therapy for moderate to severe psoriasis: a randomized, 
controlled phase III trial. Journal of the American Academy of 
Dermatology, 58, 106-115. 
MICHALAK-STOMA, A., BARTOSIŃSKA, J., KOWAL, M., JUSZKIEWICZ-
BOROWIEC, M., GERKOWICZ, A. & CHODOROWSKA, G. 2013. Serum 
Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients. 
Disease markers, 35, 625-631. 
MILLER, A. M., XU, D., ASQUITH, D. L., DENBY, L., LI, Y., SATTAR, N., BAKER, 
A. H., MCINNES, I. B. & LIEW, F. Y. 2008. IL-33 reduces the development 
of atherosclerosis. The Journal of Experimental Medicine, 205, 339-346. 
  
146 
MILLER, I. M., ELLERVIK, C., YAZDANYAR, S. & JEMEC, G. B. 2013. Meta-
analysis of psoriasis, cardiovascular disease, and associated risk factors. 
Journal of the American Academy of Dermatology, 69, 1014-1024. 
MIOSSEC, P. 2009. IL-17 and Th17 cells in human inflammatory diseases. 
Microbes Infect, 11, 625-30. 
MITSUI, A., TADA, Y., TAKAHASHI, T., SHIBATA, S., KAMATA, M., MIYAGAKI, 
T., FUJITA, H., SUGAYA, M., KADONO, T., SATO, S. & ASANO, Y. 2016. 
Serum IL-33 levels are increased in patients with psoriasis. Clin Exp 
Dermatol, 41, 183-9. 
MOATTI, D., FAURE, S., FUMERON, F., AMARA MEL, W., SEKNADJI, P., 
MCDERMOTT, D. H., DEBRE, P., AUMONT, M. C., MURPHY, P. M., DE 
PROST, D. & COMBADIERE, C. 2001. Polymorphism in the fractalkine 
receptor CX3CR1 as a genetic risk factor for coronary artery disease. 
Blood, 97, 1925-8. 
MOORE, K. J., SHEEDY, F. J. & FISHER, E. A. 2013. Macrophages in 
atherosclerosis: a dynamic balance. Nat Rev Immunol, 13, 709-721. 
MORIMURA, S., OKA, T., SUGAYA, M. & SATO, S. 2016. CX3CR1 deficiency 
attenuates imiquimod-induced psoriasis-like skin inflammation with 
decreased M1 macrophages. J Dermatol Sci, 82, 175-88. 
MULLER, W. A. 2013. Getting Leukocytes to the Site of Inflammation. Veterinary 
pathology, 50, 7-22. 
MUNIYAPPA, R., MONTAGNANI, M., KOH, K. K. & QUON, M. J. 2007. 
Cardiovascular actions of insulin. Endocr Rev, 28, 463-91. 
MUTAMBA, S., ALLISON, A., MAHIDA, Y., BARROW, P. & FOSTER, N. 2012. 
Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs 
and facilitates DC maturation by IL-1F8 and IL-1F9. European Journal of 
Immunology, 42, 607-617. 
NADEEM, A., AL-HARBI, N. O., ANSARI, M. A., AL-HARBI, M. M., EL-
SHERBEENY, A. M., ZOHEIR, K. M., ATTIA, S. M., HAFEZ, M. M., AL-
SHABANAH, O. A. & AHMAD, S. F. 2017. Psoriatic inflammation 
enhances allergic airway inflammation through IL-23/STAT3 signaling in a 
murine model. Biochem Pharmacol, 124, 69-82. 
  
147 
NAGALAKSHMI, M. L., RASCLE, A., ZURAWSKI, S., MENON, S. & DE WAAL 
MALEFYT, R. 2004. Interleukin-22 activates STAT3 and induces IL-10 by 
colon epithelial cells. International Immunopharmacology, 4, 679-691. 
NAIK, H. B., NATARAJAN, B., STANSKY, E., AHLMAN, M. A., TEAGUE, H., 
SALAHUDDIN, T., NG, Q., JOSHI, A. A., KRISHNAMOORTHY, P., DAVE, 
J., ROSE, S. M., DOVEIKIS, J., PLAYFORD, M. P., PRUSSICK, R. B., 
EHRLICH, A., KAPLAN, M. J., LOCKSHIN, B. N., GELFAND, J. M. & 
MEHTA, N. N. 2015. Severity of Psoriasis Associates With Aortic Vascular 
Inflammation Detected by FDG PET/CT and Neutrophil Activation in a 
Prospective Observational Study. Arterioscler Thromb Vasc Biol, 35, 
2667-76. 
NAIR, R. P., DUFFIN, K. C., HELMS, C., DING, J., STUART, P. E., GOLDGAR, 
D., GUDJONSSON, J. E., LI, Y., TEJASVI, T., FENG, B. J., RUETHER, 
A., SCHREIBER, S., WEICHENTHAL, M., GLADMAN, D., RAHMAN, P., 
SCHRODI, S. J., PRAHALAD, S., GUTHERY, S. L., FISCHER, J., LIAO, 
W., KWOK, P. Y., MENTER, A., LATHROP, G. M., WISE, C. A., 
BEGOVICH, A. B., VOORHEES, J. J., ELDER, J. T., KRUEGER, G. G., 
BOWCOCK, A. M. & ABECASIS, G. R. 2009. Genome-wide scan reveals 
association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet, 
41, 199-204. 
NAIR, R. P., RUETHER, A., STUART, P. E., JENISCH, S., TEJASVI, T., 
HIREMAGALORE, R., SCHREIBER, S., KABELITZ, D., LIM, H. W., 
VOORHEES, J. J., CHRISTOPHERS, E., ELDER, J. T. & 
WEICHENTHAL, M. 2008. Polymorphisms of the IL12B and IL23R genes 
are associated with psoriasis. J Invest Dermatol, 128, 1653-61. 
NARAYANAN, S., CALLIS-DUFFIN, K., BATTEN, J. & AGARWAL, N. 2010. 
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. 
Am J Med Sci, 339, 580-1. 
NATHAN, C. F., MURRAY, H. W., WIEBE, M. & RUBIN, B. Y. 1983. Identification 
of interferon-gamma as the lymphokine that activates human macrophage 
oxidative metabolism and antimicrobial activity. Journal of Experimental 
Medicine, 158, 670-689. 
  
148 
NEIMANN, A. L., SHIN, D. B., WANG, X., MARGOLIS, D. J., TROXEL, A. B. & 
GELFAND, J. M. 2006. Prevalence of cardiovascular risk factors in 
patients with psoriasis. J Am Acad Dermatol, 55, 829-35. 
NESTLE, F. O., KAPLAN, D. H. & BARKER, J. 2009. Psoriasis. N Engl J Med, 
361, 496-509. 
NGUYEN, T. & WU, J. J. 2014. Relationship between tumor necrosis factor-alpha 
inhibitors and cardiovascular disease in psoriasis: a review. Perm J, 18, 
49-54. 
NISHIBU, A., HAN, G. W., IWATSUKI, K., MATSUI, T., INOUE, M., AKIBA, H., 
KANEKO, R. & KANEKO, F. 1999. Overexpression of monocyte-derived 
cytokines in active psoriasis: a relation to coexistent arthropathy. J 
Dermatol Sci, 21, 63-70. 
NOFAL, A., AL-MAKHZANGY, I., ATTWA, E., NASSAR, A. & ABDALMOATI, A. 
2009. Vascular endothelial growth factor in psoriasis: an indicator of 
disease severity and control. J Eur Acad Dermatol Venereol, 23, 803-6. 
NOLD-PETRY, C. A., LO, C. Y., RUDLOFF, I., ELGASS, K. D., LI, S., GANTIER, 
M. P., LOTZ-HAVLA, A. S., GERSTING, S. W., CHO, S. X., LAO, J. C., 
ELLISDON, A. M., ROTTER, B., AZAM, T., MANGAN, N. E., ROSSELLO, 
F. J., WHISSTOCK, J. C., BUFLER, P., GARLANDA, C., MANTOVANI, 
A., DINARELLO, C. A. & NOLD, M. F. 2015. IL-37 requires the receptors 
IL-18R[alpha] and IL-1R8 (SIGIRR) to carry out its multifaceted anti-
inflammatory program upon innate signal transduction. Nat Immunol, 16, 
354-365. 
NOLD, M. F., NOLD-PETRY, C. A., ZEPP, J. A., PALMER, B. E., BUFLER, P. & 
DINARELLO, C. A. 2010. IL-37 is a fundamental inhibitor of innate 
immunity. Nat Immunol, 11, 1014-22. 
NOWAK, D. G., WOOLARD, J., AMIN, E. M., KONOPATSKAYA, O., SALEEM, 
M. A., CHURCHILL, A. J., LADOMERY, M. R., HARPER, S. J. & BATES, 
D. O. 2008. Expression of pro- and anti-angiogenic isoforms of VEGF is 
differentially regulated by splicing and growth factors. J Cell Sci, 121, 
3487-95. 
OGAWA, Y., KIM, J.-C., MORASSO, M. & UDEY, M. 2016. Macrophages 
regulate IL-17-associated skin inflammation in mice with Dlx3-deficient 
keratinocytes. Journal of Dermatological Science, 84, e2. 
  
149 
OGDIE, A., YU, Y., HAYNES, K., LOVE, T. J., MALIHA, S., JIANG, Y., TROXEL, 
A. B., HENNESSY, S., KIMMEL, S. E. & MARGOLIS, D. J. 2014. Risk of 
major cardiovascular events in patients with psoriatic arthritis, psoriasis 
and rheumatoid arthritis: a population-based cohort study. Annals of the 
rheumatic diseases, annrheumdis-2014-205675. 
OHYAMA, H., KATO-KOGOE, N., KUHARA, A., NISHIMURA, F., NAKASHO, K., 
YAMANEGI, K., YAMADA, N., HATA, M., YAMANE, J. & TERADA, N. 
2009. The involvement of IL-23 and the Th17 pathway in periodontitis. 
Journal of Dental Research, 88, 633-638. 
OKUBO, Y. & KOGA, M. 1998. Peripheral blood monocytes in psoriatic patients 
overproduce cytokines. Journal of Dermatological Science, 17, 223-232. 
OSBORN, L. 1990. Leukocyte adhesion to endothelium in inflammation. Cell, 62, 
3-6. 
PAMUK, G. E., NURI PAMUK, O., ORUM, H., ARICAN, O., TURGUT, B. & 
DEMIR, M. 2009. Elevated platelet-monocyte complexes in patients with 
psoriatic arthritis. Platelets, 20, 493-7. 
PAPP, K. A., LANGLEY, R. G., LEBWOHL, M., KRUEGER, G. G., SZAPARY, 
P., YEILDING, N., GUZZO, C., HSU, M.-C., WANG, Y. & LI, S. 2008. 
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal 
antibody, in patients with psoriasis: 52-week results from a randomised, 
double-blind, placebo-controlled trial (PHOENIX 2). The Lancet, 371, 
1675-1684. 
PARISI, R., RUTTER, M. K., LUNT, M., YOUNG, H. S., SYMMONS, D. P. M., 
GRIFFITHS, C. E. M. & ASHCROFT, D. M. 2015. Psoriasis and the Risk 
of Major Cardiovascular Events: Cohort Study Using the Clinical Practice 
Research Datalink. J Invest Dermatol, 135, 2189-2197. 
PARSANEJAD, R., FIELDS, W. R., STEICHEN, T. J., BOMBICK, B. R. & 
DOOLITTLE, D. J. 2008. Distinct regulatory profiles of interleukins and 
chemokines in response to cigarette smoke condensate in normal human 
bronchial epithelial (NHBE) cells. Journal of Interferon and Cytokine 
Research, 28, 703-712. 
PARSI, K. K., BREZINSKI, E. A., LIN, T. C., LI, C. S. & ARMSTRONG, A. W. 
2012. Are patients with psoriasis being screened for cardiovascular risk 
  
150 
factors? A study of screening practices and awareness among primary 
care physicians and cardiologists. J Am Acad Dermatol, 67, 357-62. 
PASSACQUALE, G., VAMADEVAN, P., PEREIRA, L., HAMID, C., CORRIGALL, 
V. & FERRO, A. 2011. Monocyte-Platelet Interaction Induces a Pro-
Inflammatory Phenotype in Circulating Monocytes. PLOS ONE, 6, e25595. 
PASSERINI, A. G., POLACEK, D. C., SHI, C., FRANCESCO, N. M., MANDUCHI, 
E., GRANT, G. R., PRITCHARD, W. F., POWELL, S., CHANG, G. Y., 
STOECKERT, C. J. & DAVIES, P. F. 2004. Coexisting proinflammatory 
and antioxidative endothelial transcription profiles in a disturbed flow 
region of the adult porcine aorta. Proceedings of the National Academy of 
Sciences of the United States of America, 101, 2482-2487. 
PASTAR, I., STOJADINOVIC, O., YIN, N. C., RAMIREZ, H., NUSBAUM, A. G., 
SAWAYA, A., PATEL, S. B., KHALID, L., ISSEROFF, R. R. & TOMIC-
CANIC, M. 2014. Epithelialization in Wound Healing: A Comprehensive 
Review. Advances in Wound Care, 3, 445-464. 
PEICHEV, M., NAIYER, A. J., PEREIRA, D., ZHU, Z., LANE, W. J., WILLIAMS, 
M., OZ, M. C., HICKLIN, D. J., WITTE, L., MOORE, M. A. & RAFII, S. 
2000. Expression of VEGFR-2 and AC133 by circulating human CD34(+) 
cells identifies a population of functional endothelial precursors. Blood, 95, 
952-8. 
PERKINS, N. D. 2007. Integrating cell-signalling pathways with NF-kappaB and 
IKK function. Nat Rev Mol Cell Biol, 8, 49-62. 
PLANT, D., YOUNG, H. S., WATSON, R. E., WORTHINGTON, J. & GRIFFITHS, 
C. E. 2006. The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol, 
15, 900-3. 
POLLHEIMER, J., BODIN, J., SUNDNES, O., EDELMANN, R. J., SKANLAND, 
S. S., SPONHEIM, J., BROX, M. J., SUNDLISAETER, E., LOOS, T., 
VATN, M., KASPRZYCKA, M., WANG, J., KUCHLER, A. M., TASKEN, K., 
HARALDSEN, G. & HOL, J. 2013. Interleukin-33 drives a proinflammatory 
endothelial activation that selectively targets nonquiescent cells. 
Arterioscler Thromb Vasc Biol, 33, e47-55. 
POTTEAUX, S., DELEUZE, V., MERVAL, R., BUREAU, M. F., ESPOSITO, B., 
SCHERMAN, D., TEDGUI, A. & MALLAT, Z. 2006. In vivo electrotransfer 
of interleukin-10 cDNA prevents endothelial upregulation of activated NF-
  
151 
kappaB and adhesion molecules following an atherogenic diet. Eur 
Cytokine Netw, 17, 13-8. 
PROKOPI, M., PULA, G., MAYR, U., DEVUE, C., GALLAGHER, J., XIAO, Q., 
BOULANGER, C. M., WESTWOOD, N., URBICH, C., WILLEIT, J., 
STEINER, M., BREUSS, J., XU, Q., KIECHL, S. & MAYR, M. 2009. 
Proteomic analysis reveals presence of platelet microparticles in 
endothelial progenitor cell cultures. Blood, 114, 723-32. 
RADAEVA, S., SUN, R., PAN, H. N., HONG, F. & GAO, B. 2004. Interleukin 22 
(IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is 
a survival factor for hepatocytes via STAT3 activation. Hepatology, 39, 
1332-42. 
RADWAN, W. M., KHALIFA, K. A., ESAILY, H. A. & LASHIN, N. A. 2016. 
CD14++CD16+ monocyte subset expansion in rheumatoid arthritis 
patients: Relation to disease activity and interleukin-17. The Egyptian 
Rheumatologist, 38, 161-169. 
RAUT, A. S., PRABHU, R. H. & PATRAVALE, V. B. 2013. Psoriasis clinical 
implications and treatment: a review. Crit Rev Ther Drug Carrier Syst, 30, 
183-216. 
RAY, M., RICHARDS, J., GABUNIA, K., KELEMEN, S. & AUTIERI, M. 2015. 
Abstract 579: Lack of Interleukin-19 Exacerbates Experimental 
Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 
A579. 
REHMAN, J., LI, J., ORSCHELL, C. M. & MARCH, K. L. 2003. Peripheral blood 
"endothelial progenitor cells" are derived from monocyte/macrophages 
and secrete angiogenic growth factors. Circulation, 107, 1164-9. 
REICH, K., NESTLE, F. O., PAPP, K., ORTONNE, J.-P., EVANS, R., GUZZO, 
C., LI, S., DOOLEY, L. T., GRIFFITHS, C. E. & INVESTIGATORS, E. S. 
2005. Infliximab induction and maintenance therapy for moderate-to-
severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet, 
366, 1367-1374. 
RENNERT, K., HEISIG, K., GROEGER, M., WALLERT, M., FUNKE, H., 
LORKOWSKI, S., HUBER, O. & MOSIG, A. S. 2016. Recruitment of 
CD16+ monocytes to endothelial cells in response to LPS-treatment and 
  
152 
concomitant TNF release is regulated by CX3CR1 and interfered by 
soluble fractalkine. Cytokine, 83, 41-52. 
ROGACEV, K. S., CREMERS, B., ZAWADA, A. M., SEILER, S., BINDER, N., 
EGE, P., GROSSE-DUNKER, G., HEISEL, I., HORNOF, F., JEKEN, J., 
REBLING, N. M., ULRICH, C., SCHELLER, B., BOHM, M., FLISER, D. & 
HEINE, G. H. 2012. CD14++CD16+ monocytes independently predict 
cardiovascular events: a cohort study of 951 patients referred for elective 
coronary angiography. J Am Coll Cardiol, 60, 1512-20. 
ROGER, V. L., GO, A. S., LLOYD-JONES, D. M., BENJAMIN, E. J., BERRY, J. 
D., BORDEN, W. B., BRAVATA, D. M., DAI, S., FORD, E. S., FOX, C. S., 
FULLERTON, H. J., GILLESPIE, C., HAILPERN, S. M., HEIT, J. A., 
HOWARD, V. J., KISSELA, B. M., KITTNER, S. J., LACKLAND, D. T., 
LICHTMAN, J. H., LISABETH, L. D., MAKUC, D. M., MARCUS, G. M., 
MARELLI, A., MATCHAR, D. B., MOY, C. S., MOZAFFARIAN, D., 
MUSSOLINO, M. E., NICHOL, G., PAYNTER, N. P., SOLIMAN, E. Z., 
SORLIE, P. D., SOTOODEHNIA, N., TURAN, T. N., VIRANI, S. S., 
WONG, N. D., WOO, D. & TURNER, M. B. 2012. Heart disease and stroke 
statistics--2012 update: a report from the American Heart Association. 
Circulation, 125, e2-e220. 
ROSINA, P., GIOVANNINI, A., GISONDI, P. & GIROLOMONI, G. 2009. 
Microcirculatory modifications of psoriatic lesions during topical therapy. 
Skin Res Technol, 15, 135-8. 
ROSSOL, M., KRAUS, S., PIERER, M., BAERWALD, C. & WAGNER, U. 2012. 
The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid 
arthritis and promotes expansion of the Th17 cell population. Arthritis 
Rheum, 64, 671-7. 
ROUSSAKI-SCHULZE, A. V., KOUSKOUKIS, C., PETINAKI, E., KLIMI, E., 
ZAFIRIOU, E., GALANOS, A. & RALLIS, E. 2005. Evaluation of cytokine 
serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol 
Res, 25, 169-73. 
SAIAG, P., COULOMB, B., LEBRETON, C., BELL, E. & DUBERTRET, L. 1985. 
Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a 
skin equivalent model in vitro. Science, 230, 669-672. 
  
153 
SAMUEL, C. E. 1988. Mechanisms of the antiviral action of interferons. Prog 
Nucleic Acid Res Mol Biol, 35, 27-72. 
SANDQVIST, M., NYBERG, G., HAMMARSTEDT, A., KLINTLAND, N., GOGG, 
S., CAIDAHL, K., AHREN, B., SMITH, U. & JANSSON, P. A. 2005. Low 
adipocyte IRS-1 protein expression is associated with an increased arterial 
stiffness in non-diabetic males. Atherosclerosis, 180, 119-25. 
SATO, T. N., TOZAWA, Y., DEUTSCH, U., WOLBURG-BUCHHOLZ, K., 
FUJIWARA, Y., GENDRON-MAGUIRE, M., GRIDLEY, T., WOLBURG, H., 
RISAU, W. & QIN, Y. 1995. Distinct roles of the receptor tyrosine kinases 
Tie-1 and Tie-2 in blood vessel formation. Nature, 376, 70-4. 
SCHEIERMANN, P., BACHMANN, M., HARDLE, L., PLELI, T., PIIPER, A., 
ZWISSLER, B., PFEILSCHIFTER, J. & MUHL, H. 2015. Application of IL-
36 receptor antagonist weakens CCL20 expression and impairs recovery 
in the late phase of murine acetaminophen-induced liver injury. Sci Rep, 
5, 8521. 
SCHLAAK, J. F., BUSLAU, M., JOCHUM, W., HERMANN, E., GIRNDT, M., 
GALLATI, H., ZUM BÜSCHENFELDE, K.-H. M. & FLEISCHER, B. 1994. 
T cells involved in psoriasis vulgaris belong to the Th1 subset. Journal of 
Investigative Dermatology, 102, 145-149. 
SCHLUTER, K., DIEHL, S., LANG, V., KAUFMANN, R., BOEHNCKE, W. H. & 
BURGER, C. 2016. Insulin Resistance May Contribute to Upregulation of 
Adhesion Molecules on Endothelial Cells in Psoriatic Plaques. Acta Derm 
Venereol, 96, 162-8. 
SCHMEISSER, A., GRAFFY, C., DANIEL, W. G. & STRASSER, R. H. 2003. 
Phenotypic overlap between monocytes and vascular endothelial cells. 
Adv Exp Med Biol, 522, 59-74. 
SCHMITZ, J., OWYANG, A., OLDHAM, E., SONG, Y., MURPHY, E., 
MCCLANAHAN, T. K., ZURAWSKI, G., MOSHREFI, M., QIN, J., LI, X., 
GORMAN, D. M., BAZAN, J. F. & KASTELEIN, R. A. 2005. IL-33, an 
Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related 
Protein ST2 and Induces T Helper Type 2-Associated Cytokines. 
Immunity, 23, 479-490. 
SCHONTHALER, H. B., HUGGENBERGER, R., WCULEK, S. K., DETMAR, M. 
& WAGNER, E. F. 2009. Systemic anti-VEGF treatment strongly reduces 
  
154 
skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci U S 
A, 106, 21264-9. 
SCHRODER, K., HERTZOG, P. J., RAVASI, T. & HUME, D. A. 2004. Interferon-
gamma: an overview of signals, mechanisms and functions. J Leukoc Biol, 
75, 163-89. 
SCUDIERO, I., ZOTTI, T., FERRAVANTE, A., VESSICHELLI, M., VITO, P. & 
STILO, R. 2011. Alternative splicing of CARMA2/CARD14 transcripts 
generates protein variants with differential effect on NF-kappaB activation 
and endoplasmic reticulum stress-induced cell death. J Cell Physiol, 226, 
3121-31. 
SCULL, C. M., HAYS, W. D. & FISCHER, T. H. 2010. Macrophage pro-
inflammatory cytokine secretion is enhanced following interaction with 
autologous platelets. Journal of Inflammation (London, England), 7, 53-53. 
SERTORIO, M., HOU, X., CARMO, R. F., DESSEIN, H., CABANTOUS, S., 
ABDELWAHED, M., ROMANO, A., ALBUQUERQUE, F., 
VASCONCELOS, L., CARMO, T., LI, J., VAROQUAUX, A., ARNAUD, V., 
OLIVEIRA, P., HAMDOUN, A., HE, H., ADBELMABOUD, S., MERGANI, 
A., ZHOU, J., MONIS, A., PEREIRA, L. B., HALFON, P., BOURLIERE, M., 
PARANA, R., DOS REIS, M., GONNELLI, D., MOURA, P., ELWALI, N. E., 
ARGIRO, L., LI, Y. & DESSEIN, A. 2015. IL-22 and IL-22 binding protein 
(IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and 
schistosome infections. Hepatology, 61, 1321-31. 
SHANG, W. Q., YU, J. J., ZHU, L., ZHOU, W. J., CHANG, K. K., WANG, Q. & LI, 
M. Q. 2015. Blocking IL-22, a potential treatment strategy for adenomyosis 
by inhibiting crosstalk between vascular endothelial and endometrial 
stromal cells. Am J Transl Res, 7, 1782-97. 
SHEN, F., HU, Z., GOSWAMI, J. & GAFFEN, S. L. 2006. Identification of common 
transcriptional regulatory elements in interleukin-17 target genes. J Biol 
Chem, 281, 24138-48. 
SIAFAKAS, N. M., ANTONIOU, K. M. & TZORTZAKI, E. G. 2007. Role of 
angiogenesis and vascular remodeling in chronic obstructive pulmonary 
disease. International Journal of Chronic Obstructive Pulmonary Disease, 
2, 453-462. 
  
155 
SIAKAVELLAS, S. I. & BAMIAS, G. 2012. Role of the IL-23/IL-17 axis in Crohn's 
disease. Discov Med, 14, 253-62. 
SINGH, T. P., ZHANG, H. H., BOREK, I., WOLF, P., HEDRICK, M. N., SINGH, 
S. P., KELSALL, B. L., CLAUSEN, B. E. & FARBER, J. M. 2016. 
Monocyte-derived inflammatory Langerhans cells and dermal dendritic 
cells mediate psoriasis-like inflammation. Nature Communications, 7, 
13581. 
SITIA, S., TOMASONI, L., ATZENI, F., AMBROSIO, G., CORDIANO, C., 
CATAPANO, A., TRAMONTANA, S., PERTICONE, F., NACCARATO, P., 
CAMICI, P., PICANO, E., CORTIGIANI, L., BEVILACQUA, M., MILAZZO, 
L., CUSI, D., BARLASSINA, C., SARZI-PUTTINI, P. & TURIEL, M. 2010. 
From endothelial dysfunction to atherosclerosis. Autoimmun Rev, 9, 830-
4. 
SOMMER, D. M., JENISCH, S., SUCHAN, M., CHRISTOPHERS, E. & 
WEICHENTHAL, M. 2006. Increased prevalence of the metabolic 
syndrome in patients with moderate to severe psoriasis. Arch Dermatol 
Res, 298, 321-8. 
SONNENBERG, G. F., FOUSER, L. A. & ARTIS, D. 2011. Border patrol: 
regulation of immunity, inflammation and tissue homeostasis at barrier 
surfaces by IL-22. Nat Immunol, 12, 383-90. 
STARY, H. C., CHANDLER, A. B., GLAGOV, S., GUYTON, J. R., INSULL, W., 
JR., ROSENFELD, M. E., SCHAFFER, S. A., SCHWARTZ, C. J., 
WAGNER, W. D. & WISSLER, R. W. 1994. A definition of initial, fatty 
streak, and intermediate lesions of atherosclerosis. A report from the 
Committee on Vascular Lesions of the Council on Arteriosclerosis, 
American Heart Association. Circulation, 89, 2462-78. 
STEINBERG, D. 1997. Lewis A. Conner Memorial Lecture: Oxidative 
Modification of LDL and Atherogenesis. Circulation, 95, 1062-1071. 
STEINBERG, D., PARTHASARATHY, S., CAREW, T. E., KHOO, J. C. & 
WITZTUM, J. L. 1989. Beyond cholesterol. Modifications of low-density 
lipoprotein that increase its atherogenicity. N Engl J Med, 320, 915-24. 
STERN, R. S. & HUIBREGTSE, A. 2011. Very severe psoriasis is associated with 
increased noncardiovascular mortality but not with increased 
cardiovascular risk. J Invest Dermatol, 131, 1159-66. 
  
156 
STICHERLING, M., SAUTIER, W., SCHRODER, J. M. & CHRISTOPHERS, E. 
1999. Interleukin-8 plays its role at local level in psoriasis vulgaris. Acta 
Derm Venereol, 79, 4-8. 
STRATIS, A., PASPARAKIS, M., RUPEC, R. A., MARKUR, D., HARTMANN, K., 
SCHARFFETTER-KOCHANEK, K., PETERS, T., VAN ROOIJEN, N., 
KRIEG, T. & HAASE, I. 2006. Pathogenic role for skin macrophages in a 
mouse model of keratinocyte-induced psoriasis-like skin inflammation. J 
Clin Invest, 116, 2094-104. 
SUGIURA, K., HARUNA, K., SUGA, Y. & AKIYAMA, M. 2014. Generalized 
pustular psoriasis caused by deficiency of interleukin-36 receptor 
antagonist successfully treated with granulocyte and monocyte adsorption 
apheresis. J Eur Acad Dermatol Venereol, 28, 1835-6. 
SUN, Y., MOZAFFARIAN, A., ARNETT, H. A., DINH, H., TRUEBLOOD, E. S. & 
TOWNE, J. E. 2013. 253 : IL-36 induces inflammation and collagen 
deposition in the lung. Cytokine, 63, 303. 
SWERLICK, R. A. 1997. The structure and function of the cutaneous vasculature. 
J Dermatol, 24, 734-8. 
SWERLICK, R. A., LEE, K. H., LI, L. J., SEPP, N. T., CAUGHMAN, S. W. & 
LAWLEY, T. J. 1992. Regulation of vascular cell adhesion molecule 1 on 
human dermal microvascular endothelial cells. J Immunol, 149, 698-705. 
TABIT, C. E., CHUNG, W. B., HAMBURG, N. M. & VITA, J. A. 2010. Endothelial 
dysfunction in diabetes mellitus: Molecular mechanisms and clinical 
implications. Reviews in endocrine & metabolic disorders, 11, 61-74. 
TAKATORI, H., KANNO, Y., WATFORD, W. T., TATO, C. M., WEISS, G., 
IVANOV, II, LITTMAN, D. R. & O'SHEA, J. J. 2009. Lymphoid tissue 
inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med, 206, 
35-41. 
TAKEO, M., LEE, W. & ITO, M. 2015. Wound Healing and Skin Regeneration. 
Cold Spring Harbor Perspectives in Medicine, 5, a023267. 
TAKESHITA, J., GREWAL, S., LANGAN, S. M., MEHTA, N. N., OGDIE, A., VAN 
VOORHEES, A. S. & GELFAND, J. M. 2017. Psoriasis and comorbid 
diseases: Implications for management. Journal of the American Academy 
of Dermatology, 76, 393-403. 
  
157 
TALEB, S. & TEDGUI, A. 2017. IL-17 in atherosclerosis: the good and the bad. 
Oxford University Press. 
TALEB, S., TEDGUI, A. & MALLAT, Z. 2015. IL-17 and Th17 cells in 
atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc 
Biol, 35, 258-64. 
TAM, L. S., KITAS, G. D. & GONZALEZ-GAY, M. A. 2014. Can suppression of 
inflammation by anti-TNF prevent progression of subclinical 
atherosclerosis in inflammatory arthritis? Rheumatology (Oxford), 53, 
1108-19. 
TELNER, P. & FEKETE, Z. 1961. The capillary responses in psoriatic skin. J 
Invest Dermatol, 36, 225-30. 
TENG, X., HU, Z., WEI, X., WANG, Z., GUAN, T., LIU, N., LIU, X., YE, N., DENG, 
G., LUO, C., HUANG, N., SUN, C., XU, M., ZHOU, X., DENG, H., 
EDWARDS, C. K., 3RD, CHEN, X., WANG, X., CUI, K., WEI, Y. & LI, J. 
2014. IL-37 ameliorates the inflammatory process in psoriasis by 
suppressing proinflammatory cytokine production. J Immunol, 192, 1815-
23. 
TERAJIMA, S., HIGAKI, M., IGARASHI, Y., NOGITA, T. & KAWASHIMA, M. 
1998. An important role of tumor necrosis factor-α in the induction of 
adhesion molecules in psoriasis. Archives of Dermatological Research, 
290, 246-252. 
TERAKI, Y., MIYAKE, A., TAKEBAYASHI, R. & SHIOHARA, T. 2004. Homing 
receptor and chemokine receptor on intraepidermal T cells in psoriasis 
vulgaris. Clin Exp Dermatol, 29, 658-63. 
TEUPSER, D., PAVLIDES, S., TAN, M., GUTIERREZ-RAMOS, J.-C., 
KOLBECK, R. & BRESLOW, J. L. 2004. Major reduction of atherosclerosis 
in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not 
the aortic root. Proceedings of the National Academy of Sciences of the 
United States of America, 101, 17795-17800. 
TIILIKAINEN, A., LASSUS, A., KARVONEN, J., VARTIAINEN, P. & JULIN, M. 
1980. Psoriasis and HLA‐Cw6. British Journal of Dermatology, 102, 179-
184. 
TORTOLA, L., ROSENWALD, E., ABEL, B., BLUMBERG, H., SCHAFER, M., 
COYLE, A. J., RENAULD, J. C., WERNER, S., KISIELOW, J. & KOPF, M. 
  
158 
2012. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte 
crosstalk. J Clin Invest, 122, 3965-76. 
TOWNE, J. E., GARKA, K. E., RENSHAW, B. R., VIRCA, G. D. & SIMS, J. E. 
2004. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and 
IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J 
Biol Chem, 279, 13677-88. 
TOWNE, J. E., RENSHAW, B. R., DOUANGPANYA, J., LIPSKY, B. P., SHEN, 
M., GABEL, C. A. & SIMS, J. E. 2011. Interleukin-36 (IL-36) ligands require 
processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or 
antagonist (IL-36Ra) activity. J Biol Chem, 286, 42594-602. 
TRACZEWSKI, P. & RUDNICKA, L. 2012. Briakinumab for the treatment of 
plaque psoriasis. BioDrugs, 26, 9-20. 
TREMBATH, R. C., CLOUGH, R. L., ROSBOTHAM, J. L., JONES, A. B., CAMP, 
R. D., FRODSHAM, A., BROWNE, J., BARBER, R., TERWILLIGER, J., 
LATHROP, G. M. & BARKER, J. N. 1997. Identification of a major 
susceptibility locus on chromosome 6p and evidence for further disease 
loci revealed by a two stage genome-wide search in psoriasis. Hum Mol 
Genet, 6, 813-20. 
TSOI, L. C., SPAIN, S. L., KNIGHT, J., ELLINGHAUS, E., STUART, P. E., 
CAPON, F., DING, J., LI, Y., TEJASVI, T., GUDJONSSON, J. E., KANG, 
H. M., ALLEN, M. H., MCMANUS, R., NOVELLI, G., SAMUELSSON, L., 
SCHALKWIJK, J., STAHLE, M., BURDEN, A. D., SMITH, C. H., CORK, 
M. J., ESTIVILL, X., BOWCOCK, A. M., KRUEGER, G. G., WEGER, W., 
WORTHINGTON, J., TAZI-AHNINI, R., NESTLE, F. O., HAYDAY, A., 
HOFFMANN, P., WINKELMANN, J., WIJMENGA, C., LANGFORD, C., 
EDKINS, S., ANDREWS, R., BLACKBURN, H., STRANGE, A., BAND, G., 
PEARSON, R. D., VUKCEVIC, D., SPENCER, C. C., DELOUKAS, P., 
MROWIETZ, U., SCHREIBER, S., WEIDINGER, S., KOKS, S., KINGO, 
K., ESKO, T., METSPALU, A., LIM, H. W., VOORHEES, J. J., 
WEICHENTHAL, M., WICHMANN, H. E., CHANDRAN, V., ROSEN, C. F., 
RAHMAN, P., GLADMAN, D. D., GRIFFITHS, C. E., REIS, A., KERE, J., 
NAIR, R. P., FRANKE, A., BARKER, J. N., ABECASIS, G. R., ELDER, J. 
T. & TREMBATH, R. C. 2012. Identification of 15 new psoriasis 
  
159 
susceptibility loci highlights the role of innate immunity. Nat Genet, 44, 
1341-8. 
ULUSOY, R. E., KARABUDAK, O., YOKUSOGLU, M., KILICASLAN, F., 
KIRILMAZ, A. & CEBECI, B. S. 2010. Noninvasive assessment of impaired 
endothelial function in psoriasis. Rheumatol Int, 30, 479-83. 
UMEHARA, H., GODA, S., IMAI, T., NAGANO, Y., MINAMI, Y., TANAKA, Y., 
OKAZAKI, T., BLOOM, E. T. & DOMAE, N. 2001. Fractalkine, a CX3C-
chemokine, functions predominantly as an adhesion molecule in 
monocytic cell line THP-1. Immunol Cell Biol, 79, 298-302. 
VAN DE KERKHOF, P. C. M., GRIFFITHS, C. E. M., REICH, K., LEONARDI, C. 
L., BLAUVELT, A., TSAI, T.-F., GONG, Y., HUANG, J., PAPAVASSILIS, 
C. & FOX, T. 2016. Secukinumab long-term safety experience: A pooled 
analysis of 10 phase II and III clinical studies in patients with moderate to 
severe plaque psoriasis. Journal of the American Academy of 
Dermatology, 75, 83-98.e4. 
VAN DE WETERING, D., DE PAUS, R. A., VAN DISSEL, J. T. & VAN DE 
VOSSE, E. 2009. Salmonella Induced IL-23 and IL-1β Allow for IL-12 
Production by Monocytes and Mφ1 through Induction of IFN-γ in CD56+ 
NK/NK-Like T Cells. PLOS ONE, 4, e8396. 
VAN DER MEER, P., DE BOER, R. A., WHITE, H. L., VAN DER STEEGE, G., 
HALL, A. S., VOORS, A. A. & VAN VELDHUISEN, D. J. 2005. The VEGF 
+405 CC Promoter Polymorphism is Associated With an Impaired 
Prognosis in Patients With Chronic Heart Failure: A MERIT-HF Substudy. 
Journal of Cardiac Failure, 11, 279-284. 
VAN DER WAL, A. C., BECKER, A. E., VAN DER LOOS, C. M. & DAS, P. K. 
1994. Site of intimal rupture or erosion of thrombosed coronary 
atherosclerotic plaques is characterized by an inflammatory process 
irrespective of the dominant plaque morphology. Circulation, 89, 36-44. 
VANHOUTTE, P. M. & SCOTT-BURDEN, T. 1994. The endothelium in health 
and disease. Texas Heart Institute Journal, 21, 62-67. 
VIGNE, S., PALMER, G., LAMACCHIA, C., MARTIN, P., TALABOT-AYER, D., 
RODRIGUEZ, E., RONCHI, F., SALLUSTO, F., DINH, H., SIMS, J. E. & 
GABAY, C. 2011. IL-36R ligands are potent regulators of dendritic and T 
cells. Blood, 118, 5813-23. 
  
160 
VIGNE, S., PALMER, G., MARTIN, P., LAMACCHIA, C., STREBEL, D. & 
RODRIGUEZ, E. 2012. IL-36 signaling amplifies Th1 responses by 
enhancing prolifera-tion and Th1 polarization of naive CD4+ T cells. Blood, 
120. 
VOS, J. B., VAN STERKENBURG, M. A., RABE, K. F., SCHALKWIJK, J., 
HIEMSTRA, P. S. & DATSON, N. A. 2005. Transcriptional response of 
bronchial epithelial cells to Pseudomonas aeruginosa: identification of 
early mediators of host defense. Physiol Genomics, 21, 324-36. 
VOSKAS, D., JONES, N., VAN SLYKE, P., STURK, C., CHANG, W., HANINEC, 
A., BABICHEV, Y. O., TRAN, J., MASTER, Z., CHEN, S., WARD, N., 
CRUZ, M., JONES, J., KERBEL, R. S., JOTHY, S., DAGNINO, L., 
ARBISER, J., KLEMENT, G. & DUMONT, D. J. 2005. A cyclosporine-
sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J 
Pathol, 166, 843-55. 
WANG, H., PETERS, T., KESS, D., SINDRILARU, A., ORESHKOVA, T., VAN 
ROOIJEN, N., STRATIS, A., RENKL, A. C., SUNDERKÖTTER, C., 
WLASCHEK, M., HAASE, I. & SCHARFFETTER-KOCHANEK, K. 2006. 
Activated macrophages are essential in a murine model for T cell–
mediated chronic psoriasiform skin inflammation. The Journal of Clinical 
Investigation, 116, 2105-2114. 
WANG, Y., GAO, H., LOYD, C. M., FU, W., DIACONU, D., LIU, S., COOPER, K. 
D., MCCORMICK, T. S., SIMON, D. I. & WARD, N. L. 2012. Chronic Skin-
Specific Inflammation Promotes Vascular Inflammation and Thrombosis. 
The Journal of investigative dermatology, 132, 2067-2075. 
WARA, A. K., CROCE, K., FOO, S., SUN, X., ICLI, B., TESMENITSKY, Y., 
ESEN, F., ROSENZWEIG, A. & FEINBERG, M. W. 2011. Bone marrow-
derived CMPs and GMPs represent highly functional proangiogenic cells: 
implications for ischemic cardiovascular disease. Blood, 118, 6461-4. 
WARBOYS, C. M., AMINI, N., DE LUCA, A. & EVANS, P. C. 2011. The role of 
blood flow in determining the sites of atherosclerotic plaques. F1000 Med 
Rep, 3, 5. 
WASILEWSKA, A., WINIARSKA, M., OLSZEWSKA, M. & RUDNICKA, L. 2016. 
Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin 
  
161 
diseases. Advances in Dermatology and Allergology/Postȩpy 
Dermatologii i Alergologii, 33, 247-252. 
WEIDEMANN, A. K., CRAWSHAW, A. A., BYRNE, E. & YOUNG, H. S. 2013. 
Vascular endothelial growth factor inhibitors: investigational therapies for 
the treatment of psoriasis. Clinical, Cosmetic and Investigational 
Dermatology, 6, 233-244. 
WEITZ-SCHMIDT, G., WELZENBACH, K., BRINKMANN, V., KAMATA, T., 
KALLEN, J., BRUNS, C., COTTENS, S., TAKADA, Y. & HOMMEL, U. 
2001. Statins selectively inhibit leukocyte function antigen-1 by binding to 
a novel regulatory integrin site. Nat Med, 7, 687-92. 
WHITMAN, S. C., RAVISANKAR, P., ELAM, H. & DAUGHERTY, A. 2000. 
Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein 
E-/- mice. Am J Pathol, 157, 1819-24. 
WILLIAMS, K. J. & TABAS, I. 1995. The Response-to-Retention Hypothesis of 
Early Atherogenesis. Arteriosclerosis, thrombosis, and vascular biology, 
15, 551-561. 
WITTE, E., KOKOLAKIS, G., WITTE, K., PHILIPP, S., DOECKE, W. D., BABEL, 
N., WITTIG, B. M., WARSZAWSKA, K., KUREK, A., ERDMANN-KEDING, 
M., KUNZ, S., ASADULLAH, K., KADIN, M. E., VOLK, H. D., STERRY, 
W., WOLK, K. & SABAT, R. 2014. IL-19 is a component of the 
pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol, 134, 
2757-2767. 
WOLF, J. & FERRIS, L. K. 2014. Anti-IL-36R antibodies, potentially useful for the 
treatment of psoriasis: a patent evaluation of WO2013074569. Expert 
Opin Ther Pat, 24, 477-9. 
WONGPIYABOVORN, J., YOOYONGSATIT, S., RUCHUSATSAWAT, K., 
AVIHINGSANON, Y. & HIRANKARN, N. 2008. Association of the CTG (-
2578/-460/+405) haplotype within the vascular endothelial growth factor 
gene with early-onset psoriasis. Tissue Antigens, 72, 458-63. 
WRIGHT, H. L., MOOTS, R. J., BUCKNALL, R. C. & EDWARDS, S. W. 2010. 
Neutrophil function in inflammation and inflammatory diseases. 
Rheumatology (Oxford), 49, 1618-31. 
  
162 
WRIGLEY, B. J., SHANTSILA, E., TAPP, L. D. & LIP, G. Y. 2013. CD14++CD16+ 
monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest, 
43, 121-30. 
WU, B. W., ZENG, Q. T., MENG, K. & JI, Q. W. 2013. The potential role of IL-37 
in atherosclerosis. Pharmazie, 68, 857-60. 
XIA, Y. P., LI, B., HYLTON, D., DETMAR, M., YANCOPOULOS, G. D. & RUDGE, 
J. S. 2003. Transgenic delivery of VEGF to mouse skin leads to an 
inflammatory condition resembling human psoriasis. Blood, 102, 161-8. 
XIAO, C., ZHU, Z., SUN, S., GAO, J., FU, M., LIU, Y., WANG, G., YAO, X. & LI, 
W. 2017. Activation of Langerhans cells promotes the inflammation in 
imiquimod-induced psoriasis-like dermatitis. J Dermatol Sci, 85, 170-177. 
XING, X., YANG, J., YANG, X., WEI, Y., ZHU, L., GAO, D. & LI, M. 2013. IL-17A 
induces endothelial inflammation in systemic sclerosis via the ERK 
signaling pathway. PLoS One, 8, e85032. 
YAMASAKI, E., SOMA, Y., KAWA, Y. & MIZOGUCHI, M. 2003. Methotrexate 
inhibits proliferation and regulation of the expression of intercellular 
adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured 
human umbilical vein endothelial cells. Br J Dermatol, 149, 30-8. 
YANG, J., ZHANG, L., YU, C., YANG, X.-F. & WANG, H. 2014. Monocyte and 
macrophage differentiation: circulation inflammatory monocyte as 
biomarker for inflammatory diseases. Biomarker Research, 2, 1-1. 
YANG, Z.-S., LIN, N.-N., LI, L. & LI, Y. 2016. The Effect of TNF Inhibitors on 
Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated 
Meta-Analysis. Clinical Reviews in Allergy & Immunology, 51, 240-247. 
YAWALKAR, N., TSCHARNER, G. G., HUNGER, R. E. & HASSAN, A. S. 2009. 
Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and 
macrophage subsets in plaque psoriasis. Journal of Dermatological 
Science, 54, 99-105. 
YEN, D., CHEUNG, J., SCHEERENS, H., POULET, F., MCCLANAHAN, T., 
MCKENZIE, B., KLEINSCHEK, M. A., OWYANG, A., MATTSON, J. & 
BLUMENSCHEIN, W. 2006. IL-23 is essential for T cell–mediated colitis 
and promotes inflammation via IL-17 and IL-6. The Journal of clinical 
investigation, 116, 1310-1316. 
  
163 
YIN, D., NAJI, D. H., XIA, Y., LI, S., BAI, Y., JIANG, G., ZHAO, Y., WANG, X., 
HUANG, Y., CHEN, S., FA, J., TAN, C., ZHOU, M., ZHOU, Y., WANG, L., 
LIU, Y., CHEN, F., LIU, J., CHEN, Q., TU, X., XU, C. & WANG, Q. K. 2017. 
Genomic Variant in IL-37 Confers A Significant Risk of Coronary Artery 
Disease. Scientific Reports, 7, 42175. 
YLÄ-HERTTUALA, S., LIPTON, B. A., ROSENFELD, M. E., SÄRKIOJA, T., 
YOSHIMURA, T., LEONARD, E. J., WITZTUM, J. L. & STEINBERG, D. 
1991. Expression of monocyte chemoattractant protein 1 in macrophage-
rich areas of human and rabbit atherosclerotic lesions. Proceedings of the 
National Academy of Sciences of the United States of America, 88, 5252-
5256. 
YODER, M. C. 2012. Human Endothelial Progenitor Cells. Cold Spring Harbor 
Perspectives in Medicine, 2, a006692. 
YODER, M. C., MEAD, L. E., PRATER, D., KRIER, T. R., MROUEH, K. N., LI, 
F., KRASICH, R., TEMM, C. J., PRCHAL, J. T. & INGRAM, D. A. 2007. 
Redefining endothelial progenitor cells via clonal analysis and 
hematopoietic stem/progenitor cell principals. Blood, 109, 1801-9. 
YOST, J. & GUDJONSSON, J. E. 2009. The role of TNF inhibitors in psoriasis 
therapy: new implications for associated comorbidities. F1000 Medicine 
Reports, 1, 30. 
YOUNG, H. S., SUMMERS, A. M., BHUSHAN, M., BRENCHLEY, P. E. & 
GRIFFITHS, C. E. 2004. Single-nucleotide polymorphisms of vascular 
endothelial growth factor in psoriasis of early onset. J Invest Dermatol, 
122, 209-15. 
YOUNG, H. S., SUMMERS, A. M., READ, I. R., FAIRHURST, D. A., PLANT, D. 
J., CAMPALANI, E., SMITH, C. H., BARKER, J. N., DETMAR, M. J., 
BRENCHLEY, P. E. & GRIFFITHS, C. E. 2006. Interaction between 
genetic control of vascular endothelial growth factor production and 
retinoid responsiveness in psoriasis. J Invest Dermatol, 126, 453-9. 
YU, Y., SHETH, N., KRISHNAMOORTHY, P., SABOURY, B., RAPER, A., BAER, 
A., OCHOTONY, R., DOVEIKIS, J., DEROHANNESSIAN, S., 
VOORHEES, A. S. V., TORIGIAN, D. A., ALAVI, A., GELFAND, J. M. & 
MEHTA, N. N. 2012. Aortic vascular inflammation in psoriasis is 
  
164 
associated with HDL particle size and concentration: a pilot study. 
American Journal of Cardiovascular Disease, 2, 285-292. 
ZABA, L. C., FUENTES-DUCULAN, J., EUNGDAMRONG, N. J., ABELLO, M. V., 
NOVITSKAYA, I., PIERSON, K. C., GONZALEZ, J., KRUEGER, J. G. & 
LOWES, M. A. 2009. Psoriasis is characterized by accumulation of 
immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J 
Invest Dermatol, 129, 79-88. 
ZANGENEH, F. & SHOOSHTARY, F. 2013. Psoriasis—types, causes and 
medication. Psoriasis-Types, Causes and Medication. InTech. 
ZEBROWSKA, A., WOZNIACKA, A., JUCZYNSKA, K., OCIEPA, K., 
WASZCZYKOWSKA, E., SZYMCZAK, I. & PAWLICZAK, R. 2017. 
Correlation between IL36alpha and IL17 and Activity of the Disease in 
Selected Autoimmune Blistering Diseases. Mediators Inflamm, 2017, 
8980534. 
ZHANG, J., ALCAIDE, P., LIU, L., SUN, J., HE, A., LUSCINSKAS, F. W. & SHI, 
G. P. 2011. Regulation of endothelial cell adhesion molecule expression 
by mast cells, macrophages, and neutrophils. PLoS One, 6, e14525. 
ZHANG, Y., CLIFF, W. J., SCHOEFL, G. I. & HIGGINS, G. 1993. 
Immunohistochemical study of intimal microvessels in coronary 
atherosclerosis. Am J Pathol, 143, 164-72. 
ZHANG, Y., MATSUO, H. & MORITA, E. 2005. Vascular endothelial growth factor 
121 is the predominant isoform in psoriatic scales. Exp Dermatol, 14, 758-
64. 
ZIATS, N. P. & ROBERTSON, A. L., JR. 1981. Effects of peripheral blood 
monocytes on human vascular cell proliferation. Atherosclerosis, 38, 401-
10. 
ZIEGLER-HEITBROCK, L. 2007. The CD14+ CD16+ blood monocytes: their role 
in infection and inflammation. J Leukoc Biol, 81, 584-92. 
 
